

Colorado Department of Health Care Policy and Financing Preferred Drug List (PDL)

Effective January 1, 2026

Prior Authorization Forms: Available online at <https://hcpf.colorado.gov/pharmacy-resources>

Prior Authorization (PA) Requests: Colorado Pharmacy Call Center Phone Number: 800-424-5725 | Fax Number: 800-424-5881

Electronic Prior Authorization (ePA): Electronic Prior Authorization Requests are supported by CoverMyMeds and may be submitted via Electronic Health Record (EHR) systems or through the CoverMyMeds provider portal.

The PDL applies to Medicaid fee-for-service members. It does not apply to members enrolled in Rocky Mountain Health HMO or Denver Health Medicaid Choice.

Initiation of pharmaceutical product subject to Prior Authorization: Please note that starting the requested drug, including a non-preferred drug, prior to a PA request being reviewed and approved, through either inpatient use, by using office "samples," or by any other means, does not necessitate Medicaid approval of the PA request.

Health First Colorado, at section 25.5-5-501, C.R.S., requires the generic of a brand name drug be prescribed if the generic is therapeutically equivalent to the brand name drug. Exceptions to this rule are: 1) If the brand name drug is more cost effective than the generic as determined by the Department, 2) If the patient has been stabilized on a brand name drug and the prescriber believes that transition to a generic would disrupt care, and 3) If the drug is being used for treatment of mental illness, cancer, epilepsy, or human immunodeficiency virus and acquired immune deficiency syndrome.

Please see the [Brand Favored Product List](#) for a list of medications where the brand name drug is more cost effective than the generic drug.

A provider may request a step therapy exception for the treatment of a serious or complex medical condition pursuant to section 25.5-4-428, C.R.S. Serious or complex medical condition means the following medical conditions: serious mental illness, cancer, epilepsy, multiple sclerosis, or human immunodeficiency virus (HIV)/ acquired immune deficiency syndrome (AIDS), or a condition requiring medical treatment to avoid death, hospitalization, or a worsening or advancing of disease progression resulting in significant harm or disability. The step therapy exception request form is available by visiting <https://hcpf.colorado.gov/pharmacy-resources>

Brand Name Required = BNR, Prior Authorization = PA, AutoPA = authorization can be automated at the point-of-sale transaction if criteria are met
Preferred drug list applies only to prescription (RX) products, unless specified.

| Preferred Agents | Non-preferred Agents | Prior Authorization Criteria (All Non-preferred products will be approved for one year unless otherwise stated.) |
|------------------|----------------------|---|
|------------------|----------------------|---|

I. Analgesics

Therapeutic Drug Class: NON-OPIOID ANALGESIA AGENTS - Oral – Effective 4/1/2025

| No PA Required | PA Required | <p>JOURNAVX (suzetrigine) may be approved if the following criteria are met:</p> <ul style="list-style-type: none"> • Member is \geq 18 years of age AND • Member is being prescribed suzetrigine for up to 14 days of treatment for moderate-to- severe acute pain AND • Prescriber attests that the member's pain is unable to be managed with an NSAID, acetaminophen, or other non-opioid analgesic AND • Journavx (suzetrigine) is not being prescribed to treat chronic pain AND • The medication is not being prescribed to treat pain associated with migraine AND • Member does not have severe hepatic impairment (Child-Pugh Class C) AND • Member has been counseled to avoid food or drink containing grapefruit during treatment with Journavx (suzetrigine) AND • Member is not concurrently taking a strong CYP3A inhibitor (such as ketoconazole, itraconazole, posaconazole, ritonavir, indinavir, saquinavir, clarithromycin, fluvoxamine) AND • Member is not concurrently taking a strong or moderate CYP3A inducer (such as carbamazepine, phenytoin, rifampin, efavirenz, rifabutin, St. John's Wort) · Members using hormonal contraceptives containing progestins other than levonorgestrel and norethindrone have been counseled regarding alternative or additional contraception, if appropriate, per product labeling. <p><u>Duration of Approval:</u> 3 months <u>Dosing Limit:</u> One 14-day course per approval on file <u>Quantity limit:</u> 29 tablets/14 days</p> <p>All other non-preferred oral non-opioid analgesic agents may be approved if member meets all of the following criteria:</p> <ul style="list-style-type: none"> • Member has trialed and failed duloxetine (20mg, 30mg, or 60mg) AND has trialed and failed gabapentin OR pregabalin capsule (Failure is defined as lack of efficacy with 8-week trial, allergy, intolerable side effects, or significant drug-drug interaction) <p>Prior authorization will be required for Lyrica (pregabalin) capsule dosages $>$ 600mg per day (maximum of 3 capsules daily) and gabapentin dosages $>$ 3600mg per day.</p> |
|--|-------------|---|
| Therapeutic Drug Class: NON-OPIOID ANALGESIA AGENTS - Topical – Effective 4/1/2025 | | |

| No PA Required | PA Required | Non-preferred topical products require a trial/failure with an adequate 8-week trial of gabapentin AND pregabalin AND duloxetine AND a preferred lidocaine 5% patch. Failure is defined as lack of efficacy with an 8-week trial, allergy, intolerable side effects, or significant drug-drug interaction. |
|-----------------|---------------------------|--|
| Lidocaine patch | Lidocaine patch (Puretek) | |

| | | |
|----------------------------|-----------------------------------|--|
| LIDODERM (lidocaine) patch | ZTLIDO (lidocaine) topical system | <p>Lidocaine 5% patch (Puretek manufacturer only) may be approved if the following criteria are met:</p> <ul style="list-style-type: none"> • Member is \geq 18 years of age AND • Member has had an adequate 8-week trial and failure of: gabapentin AND pregabalin AND duloxetine AND a preferred lidocaine 5% patch. Failure is defined as lack of efficacy with an 8-week trial, allergy, intolerable side effects, or significant drug-drug interaction AND • Prescriber has provided a justification of clinical necessity indicating that an alternative generic lidocaine 5% patch formulation cannot be used. |
|----------------------------|-----------------------------------|--|

Therapeutic Drug Class: NON-STEROIDAL ANTI-INFLAMMATORIES (NSAIDS) - Oral – Effective 4/1/2025

| No PA Required | PA Required | |
|-----------------------------------|---|--|
| Celecoxib capsule | ARTHROTEC (diclofenac sodium/ misoprostol) tablet | <p>DUEXIS (ibuprofen/famotidine) or VIMOVO (naproxen/esomeprazole) may be approved if the member meets the following criteria:</p> <ul style="list-style-type: none"> • Trial and failure[‡] of all preferred NSAIDs at maximally tolerated doses AND • Trial and failure[‡] of three preferred proton pump inhibitors in combination with NSAID within the last 6 months AND • Has a documented history of gastrointestinal bleeding |
| Diclofenac potassium 50 mg tablet | CELEBREX (celecoxib) capsule | |
| Diclofenac sodium EC/DR tablet | COMBOGESIC (Ibuprofen/Acetaminophen) tablet | |
| Ibuprofen suspension, tablet (RX) | DAYPRO (oxaprozin) caplet | <p>Diclofenac potassium 25 mg immediate-release tablets may be approved if the following criteria are met:</p> <ul style="list-style-type: none"> • Member is \geq 18 years of age AND • Member does not have any of the following medical conditions: <ul style="list-style-type: none"> ○ History of recent coronary artery bypass graft (CABG) surgery ○ History of myocardial infarction ○ Severe heart failure ○ Advanced renal disease ○ History of gastrointestinal bleeding |
| Indomethacin capsule, ER capsule | Diclofenac potassium capsule, powder pack | |
| Ketorolac tablet* | Diclofenac potassium 25 mg tablet | |
| Meloxicam tablet | Diclofenac sodium ER/SR tablet | |
| Nabumetone tablet | Diclofenac sodium/misoprostol tablet | |
| Naproxen DR/ER, tablet (RX) | Diflunisal tablet | |
| Naproxen suspension | DUEXIS (ibuprofen/famotidine) tablet | |
| Sulindac tablet | ELYXYB (celecoxib) solution | <p>ELYXYB (celecoxib) oral solution may be approved if the following criteria are met:</p> <ul style="list-style-type: none"> • Member is \geq 18 years of age AND • Requested medication is being prescribed for acute treatment of migraine (with or without aura) AND • Member does <u>not</u> have any of the following medical conditions: <ul style="list-style-type: none"> ○ History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs ○ History of recent coronary artery bypass graft (CABG) surgery ○ History of allergic-type reactions to sulfonamides ○ Severe heart failure ○ History of myocardial infarction ○ History of gastrointestinal bleeding ○ Advanced renal disease |

| | | |
|--|--|--|
| | <p>Ketoprofen IR, ER capsule</p> <p>LOFENA (diclofenac) tablet</p> <p>Meclofenamate capsule</p> <p>Mefenamic acid capsule</p> <p>Meloxicam submicronized capsule, suspension</p> <p>NALFON (fenoprofen) capsule, tablet</p> <p>NAPRELAN (naproxen CR) tablet</p> <p>Naproxen sodium CR, ER, IR tablet</p> <p>Naproxen/esomeprazole DR tablet</p> <p>Oxaprozin tablet</p> <p>Piroxicam capsule</p> <p>RELAFEN DS (nabumetone) tablet</p> <p>Tolmetin tablet</p> <p>VIMOVO (naproxen/esomeprazole) DR tablet</p> | <ul style="list-style-type: none"> ○ Pregnancy past 30 weeks gestation <p>AND</p> <ul style="list-style-type: none"> ● Member is unable to take an alternative NSAID in a solid oral dosage form AND ● Member has tried and failed[†] one preferred NSAID oral liquid AND ● Member is unable to use celecoxib capsules, opened and sprinkled into applesauce or other soft food <p>[†]Failure is defined as lack of efficacy, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interactions.</p> <p><u>Maximum dose:</u> 120 mg/day</p> <p>All other non-preferred oral agents may be approved following trial and failure[‡] of four preferred agents. [‡]Failure is defined as lack of efficacy, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interactions.</p> <p>*Ketorolac tablets quantity limit: 5-day supply per 30 days and 20 tablets per 30 days</p> |
|--|--|--|

Therapeutic Drug Class: NON-STEROIDAL ANTI-INFLAMMATORIES (NSAIDS) - Non-Oral – Effective 4/1/2025

| No PA Required | PA Required | <p>SPRIX (ketorolac) may be approved if meeting the following criteria:</p> <ul style="list-style-type: none"> ● Member is unable to tolerate, swallow or absorb oral NSAID formulations OR ● Member has trialed and failed three preferred oral or topical NSAID agents (failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions) ● Quantity limit: 5-single day nasal spray bottles per 30 days <p>All other non-preferred topical agents may be approved for members who have trialed and failed one preferred agent. Failure is defined as lack of efficacy with 14-day trial, allergy, intolerable side effects, or significant drug-drug interaction.</p> <p>Diclofenac topical patch quantity limit: 2 patches per day</p> <p>Diclofenac 3% gel (generic Solaraze) prior authorization criteria can be found in the Antineoplastic agents, topical, section of the PDL.</p> |
|--|---|--|
| Diclofenac 1.5% topical solution | Diclofenac 1.3% topical patch, 2% pump | |
| Diclofenac sodium 1% gel (OTC/Rx) | <p>FLECTOR (diclofenac) 1.3% topical patch</p> <p>Ketorolac nasal spray</p> <p>LICART (diclofenac) 1.3% topical patch</p> <p>PENNSAID (diclofenac solution) 2% pump, 2% solution packet</p> | |
| Opioid Utilization Policy (long-acting and short-acting opioids): | | |

It is highly encouraged that the healthcare team utilize the Prescription Drug Monitoring Program (PDMP) to aid in ensuring safe and efficacious therapy for members using controlled substances.

Total Morphine Milligram Equivalent Policy Effective 10/1/17:

- The maximum allowable morphine milligram equivalent (MME) is 200 MME. Prescriptions for short-acting (SA) and long-acting (LA) opioids are cumulatively included in this calculation. The prescription that exceeds the cumulative MME limit of 200 MME for a member will require prior authorization and may require a provider-to-provider telephone consultation with the pain management physician (free of charge and provided by Health First Colorado).
- Prior authorization will be granted to allow for tapering
- Prior authorization for 1 year will be granted for diagnosis of sickle cell anemia
- Prior authorization for 1 year will be granted for admission to or diagnosis of hospice or end of life care
- Prior authorization for 1 year will be granted for pain associated with cancer

MME calculation is conducted using conversion factors from the following link: <https://pharmacypmp.az.gov/resources/mme-calculator>

Only one long-acting opioid agent (including different strengths) and one short-acting opioid agent (including different strengths) will be considered for a prior authorization.

Medicaid provides guidance on the treatment of pain, including tapering, on our webpage under the heading Pain Management Resources and Opioid Use at: <https://www.colorado.gov/pacific/hcpf/pain-management-resources-and-opioid-use>

Opioid Naïve Policy Effective 8/1/17 (Update effective 04/01/23 in Italics):

Members who have not filled a prescription for an opioid within the past 180 days will be identified as “opioid treatment naïve” and have the following limitations placed on the initial prescription(s):

- The prescription is limited to short-acting opioid agents *or Butrans (buprenorphine)*. Use of other long-acting opioid agents will require prior authorization approval for members identified as opioid treatment naïve.
- The days’ supply of the first, second, and third prescription for an opioid will be limited to 7 days, the quantity will be limited to 8 dosage forms per day (tablets, capsules), maximum #56 tablets/capsules for a 7-day supply
- The fourth prescription for an opioid will require prior authorization, filling further opioid prescriptions may require a clinical pharmacist review or provider to provider telephone consultation with a pain management physician (free of charge and provided by Health First Colorado).
- If a member has had an opioid prescription filled within the past 180 days, then this policy would not apply to that member and other opioid policies would apply as applicable.

Dental Prescriptions Opioid Policy Effective 11/15/18 (implemented in the claims system 01/07/19):

Members who receive an opioid prescribed by a dental provider will be subject to day supply limits and quantity per day limits for short acting opioids.

- The prescription is limited to short-acting opioid agents only. Use of long-acting opioid agents and short acting fentanyl agents will require prior authorization approval for members’ prescriptions written by a dental provider.
- The days’ supply of the first, second, and third prescription for an opioid will be limited to 4 days, the quantity will be limited to 6 dosage forms per day (tablets, capsules), maximum #24 tablets/capsules for a 4-day supply
- The fourth prescription for an opioid will require prior authorization. A prior authorization for the fourth fill may be approved for up to a 7-day supply and the quantity will be limited to 8 dosage forms per day (#56 tablets/capsules) for members with any of the following diagnoses/undergoing any of the following procedures:
 - Traumatic oro-facial tissue injury with major mandibular/maxillary surgical procedures
 - Severe cellulitis of facial planes
 - Severely impacted teeth with facial space infection necessitating surgical management
- Other potential exemptions that exceed the first 3 fill limits (day supply and quantity) may be evaluated with a provider-to-provider telephone consult with a pain management specialist (free of charge and provided by Health First Colorado)

If a member has had an opioid prescription prescribed by a non-dental provider, then this policy would not apply to that member and other opioid policies would apply as applicable. Dental prescriptions do not impact the opioid treatment naïve policy, but the prescriptions will be counted towards the Morphine Milligram Equivalent (MME) daily dose.

Opioid and Benzodiazepine Combination Effective 9/15/19:

Prior authorization will be required for members receiving long-term therapy with an opioid medication who are newly started on a benzodiazepine medication **OR** for members receiving long-term therapy with a benzodiazepine medication who are newly started on an opioid medication. Prior authorization may be approved if meeting the following:

- The member discontinued or is no longer taking either the opioid or benzodiazepine medication and will not be using these in combination **OR**
- The member will not be taking the prescribed opioid and benzodiazepine medications at the same time based on prescribed dosing interval (such as prn administration) for the regimen **AND** the prescriber attests that the member has received appropriate counseling* regarding the risks associated with combining opioid and benzodiazepine medications including increased risk for sedation, respiratory depression, overdose, and overdose-related death and counseling regarding the FDA Boxed Warning for combining these medications **OR**
- The prescriber has evaluated the regimen and attests that it is appropriate for the member to continue use of the concomitant opioid and benzodiazepine medication regimen as prescribed **AND** the prescriber attests that the member has received appropriate counseling* regarding the risks associated with combining opioid and benzodiazepine medications including increased risk for sedation, respiratory depression, overdose, and overdose-related death and counseling regarding the FDA Boxed Warning for combining these medications **OR**
- Prior authorization may be approved for members receiving palliative or hospice care **OR**
- For benzodiazepine prior authorizations, approval may be granted if the benzodiazepine is being prescribed for seizure disorder or convulsions.

**If counseling has not been provided, the prescriber attests that a reasonable effort will be made to contact the member or the member's pharmacy to ensure that counseling is provided.*

Opioid and Quetiapine Combination Effective 9/15/19:

Pharmacy claims for members receiving opioid and quetiapine medications in combination will require entry of point-of-sale DUR service codes (Reason for Service, Professional Service, Result of Service) for override of drug-drug interaction (DD) related to risk of increased sedation from concomitant use of this drug combination.

Opioid and Buprenorphine-Containing substance use disorder (SUD) Product Combination Effective 06/01/21:

Opioid claims submitted for members currently receiving buprenorphine-containing SUD medications will require entry of point-of-sale DUR service codes (Reason for Service, Professional Service, Result of Service) for override of drug-drug interaction (DD) with use of this drug combination.

| Therapeutic Drug Class: PIOIDS, Short Acting – Effective 4/1/2025 | | |
|---|--|---|
| Preferred No PA Required* (If criteria and quantity limit are met) | Non-Preferred PA Required | |
| *Acetaminophen/codeine tablets | Acetaminophen / codeine elixir | *Preferred codeine and tramadol products do not require prior authorization for adult members (18 years of age or greater) if meeting all other opioid policy criteria. |
| Hydrocodone/acetaminophen solution, tablet | ASCOMP WITH CODEINE (codeine/butalbital/aspirin/caffeine) | Preferred codeine or tramadol products prescribed for members < 18 years of age must meet the following criteria: |
| Hydromorphone tablet | *Butalbital/caffeine/acetaminophen/codeine capsule | <ul style="list-style-type: none"> • Preferred tramadol and tramadol-containing products may be approved for members < 18 years of age if meeting the following: <ul style="list-style-type: none"> ○ Member is 12 years to 17 years of age AND ○ Tramadol is NOT being prescribed for post-surgical pain following tonsil or adenoid procedure AND ○ Member's BMI-for-age is not > 95th percentile per CDC guidelines AND ○ Member does not have obstructive sleep apnea or severe lung disease OR ○ For members < 12 years of age with complex conditions or life-limiting illness who are receiving care under a pediatric specialist, tramadol and tramadol-containing products may be approved on a case-by-case basis |
| Morphine IR solution, tablet | Butalbital/caffeine/aspirin/codeine capsules | <ul style="list-style-type: none"> • Preferred Codeine and codeine-containing products will receive prior authorization approval for members meeting the following criteria may be approved for members < 18 years of age if meeting the following: <ul style="list-style-type: none"> ○ Member is 12 years to 17 years of age AND ○ Codeine is NOT being prescribed for post-surgical pain following tonsil or adenoid procedure AND ○ Member's BMI-for-age is not > 95th percentile per CDC guidelines AND |
| Oxycodone solution, tablet | Butalbital compound/codeine | |
| Oxycodone/acetaminophen tablet | Butorphanol tartrate (nasal) spray | |
| *Tramadol 25mg, 50mg | Carisoprodol/aspirin/codeine | |
| *Tramadol/acetaminophen tablet | Codeine tablet | |

| | |
|---|--|
| <p>Dihydrocodeine/acetaminophen/caffeine tablet</p> <p>DILAUDID (hydromorphone) solution, tablet</p> <p>FIORICET/CODEINE (codeine/butalbital/acetaminophen/caffeine) capsule</p> <p>Hydrocodone/ibuprofen tablet</p> <p>Hydromorphone solution</p> <p>Levorphanol tablet</p> <p>Meperidine solution, tablet</p> <p>Morphine concentrated solution, oral syringe</p> <p>NALOCET (oxycodone/acetaminophen) tablet</p> <p>Oxycodone capsule, syringe, concentrated solution</p> <p>Oxycodone/acetaminophen solution</p> <p>Oxycodone/acetaminophen tablet (generic PROLATE)</p> <p>Oxymorphone tablet</p> <p>Pentazocine/naloxone tablet</p> <p>PERCOCET (oxycodone/acetaminophen) tablet</p> <p>ROXICODONE (oxycodone) tablet</p> <p>ROXYBOND (oxycodone) tablet</p> <p>SEGLENTIS (tramadol/celecoxib) tablet</p> <p>Tramadol 100mg tablet</p> <p>Tramadol solution</p> | <ul style="list-style-type: none"> ○ Member does not have obstructive sleep apnea or severe lung disease AND ○ Member is not pregnant, or breastfeeding AND ○ Renal function is not impaired (GFR > 50 ml/min) AND ○ Member is not receiving strong inhibitors of CYP3A4 (such as erythromycin, clarithromycin, itraconazole, ketoconazole, posaconazole, fluconazole [≥ 200mg daily], voriconazole, delavirdine, and milk thistle) AND ○ Member meets <u>one</u> of the following: <ul style="list-style-type: none"> ● Member has trialed codeine or codeine-containing products in the past with no history of allergy or adverse drug reaction to codeine ● Member has not trialed codeine or codeine-containing products in the past and the prescriber acknowledges reading the following statement: “Approximately 1-2% of the population metabolizes codeine in a manner that exposes them to a much higher potential for toxicity. Another notable proportion of the population may not clinically respond to codeine. We ask that you please have close follow-up with members newly starting codeine and codeine-containing products to monitor for safety and efficacy.” <p>Non-preferred tramadol products may be approved following trial and failure of generic tramadol 50mg tablet AND generic tramadol/acetaminophen tablet.</p> <p>All other non-preferred short-acting opioid products may be approved following trial and failure of three preferred products. Failure is defined as allergy[‡], lack of efficacy, intolerable side effects, or significant drug-drug interaction.</p> <p>[‡]Allergy: hives, maculopapular rash, erythema multiforme, pustular rash, severe hypotension, bronchospasm, and angioedema</p> <p><u>Quantity Limits:</u> Short-acting opioids will be limited to a total of 120 tablets per 30 days (4/day) per member for members who are not included in the opioid treatment naive policy.</p> <ul style="list-style-type: none"> ● Exceptions will be made for members with a diagnosis of a terminal illness (hospice or palliative care) or sickle cell anemia. ● For members who are receiving more than 120 tablets currently and who do not have a qualifying exemption diagnosis, a 6-month prior authorization can be granted via the prior authorization process for providers to taper members. ● Please note that if more than one agent is used, the combined total utilization may not exceed 120 units in 30 days. There may be allowed certain exceptions to this limit for acute situations (for example: post-operative surgery, fractures, shingles, car accident). <p><u>Maximum Doses:</u></p> <p>Tramadol: 400mg/day</p> <p>Codeine: 360mg/day</p> <p>Butorphanol intranasal: 10ml per 30 days (four 2.5ml 10mg/ml package units per 30 days)</p> |
|---|--|

| | | |
|---|---|--|
| | | |
| Therapeutic Drug Class: FENTANYL PREPARATIONS (buccal, transmucosal, sublingual) – Effective 4/1/2025 | | |
| | PA Required | |
| <p>ACTIQ (fentanyl citrate) lozenge</p> <p>Fentanyl citrate lozenge, buccal tablet</p> <p>FENTORA (fentanyl citrate) buccal tablet</p> <p>Fentanyl buccal, intranasal, transmucosal, and sublingual products: Prior authorization approval may be granted for members experiencing breakthrough cancer pain and those that have already received and are tolerant to opioid drugs for the cancer pain AND are currently being treated with a long-acting opioid drug. The prior authorization may be granted for up to 4 doses per day. For patients in hospice or palliative care, prior authorization will be automatically granted regardless of the number of doses prescribed.</p> | | |
| Therapeutic Drug Class: OPIOIDS, Long Acting – Effective 4/1/2025 | | |
| Preferred No PA Required (unless indicated by * criteria) | Non-Preferred PA Required | |
| <p>BELBUCA (buprenorphine) buccal film</p> <p>BUTRANS^{BNR} (buprenorphine) transdermal patch</p> <p>*Fentanyl 12mcg, 25mcg, 50mcg, 75mcg, 100mcg transdermal patch</p> <p>Morphine ER (generic MS Contin) tablet</p> <p>Tramadol ER (generic Ultram ER) tablet</p> | <p>**OXYCONTIN (oxycodone ER) tablet</p> <p>Buprenorphine transdermal patch</p> <p>CONZIP (tramadol ER) capsule</p> <p>Fentanyl 37mcg, 62mcg, 87mcg transdermal patch</p> <p>Hydrocodone ER capsule, tablet</p> <p>Hydromorphone ER tablet</p> <p>HYSINGLA (hydrocodone ER) tablet</p> <p>Methadone (all forms)</p> <p>Morphine ER capsule</p> <p>MS CONTIN (morphine ER) tablet</p> <p>Oxycodone ER tablet</p> <p>Oxymorphone ER tablet</p> <p>Tramadol ER capsule</p> | <p>*Belbuca (buprenorphine) buccal film may be approved for members who have trialed and failed‡ treatment with Butrans (buprenorphine) patch at a dose of 20 mcg/hr OR with prescriber confirmation that the maximum dose of Butrans 20 mcg/hr will not provide adequate analgesia. <u>Quantity limit:</u> 60 films/30 days.</p> <p>Oxycontin (oxycodone ER) may be approved for members who have trialed and failed‡ treatment with TWO preferred agents.</p> <p>All other non-preferred products may be approved for members who have trialed and failed‡ three preferred products.</p> <p>‡Failure is defined as lack of efficacy with 14-day trial, allergy (hives, maculopapular rash, erythema multiforme, pustular rash, intolerable application site skin reactions, severe hypotension, bronchospasm, and angioedema), intolerable side effects, or significant drug-drug interaction.</p> <p>Methadone: Members may receive 30-day approval when prescribed for neonatal abstinence syndrome without requiring trial and failure of preferred agents or opioid prescriber consultation.</p> <p>Methadone Continuation: Members who have been receiving methadone for pain indications do not have to meet non-preferred criteria. All new starts for methadone will require prior authorization under the non-preferred criteria listed above.</p> <p><i>If a prescriber would like to discuss strategies for tapering off methadone or transitioning to other pain management therapies for a Health First Colorado member, consultation with the Health First Colorado pain management physician is available free of charge by contacting the pharmacy call center helpdesk and requesting an opioid prescriber consult.</i></p> <p><u>Reauthorization:</u></p> |

| | | |
|--|--|--|
| | | <p>Reauthorization for a non-preferred agent may be approved if the following criteria are met:</p> <ul style="list-style-type: none"> • Provider attests to continued benefit outweighing risk of opioid medication use AND • Member met original prior authorization criteria for this drug class at time of original authorization <p><u>Quantity/Dosing Limits:</u></p> <ul style="list-style-type: none"> • Oxycontin and Hydrocodone ER (generic Zohydro ER) will only be approved for twice daily dosing. • Hysingla will only be approved for once daily dosing. • Fentanyl patches will require a PA for doses of more than 15 patches/30 days (if using one strength) or 30 patches for 30 days (if using two strengths). For fentanyl patch strengths of 37mcg/hr, 62mcg/hr, and 87mcg/hr, member must trial and fail two preferred strengths of separate patches that will provide the desired dose (such as 12mcg/hr + 50mcg/hr = 62mcg/hr). |
|--|--|--|

Therapeutic Drug Class: **BUPRENORPHINE, Injectable** – Effective 7/1/2025

| Preferred No PA Required (*Must meet eligibility criteria) | Non-Preferred PA Required | <p>Preferred agents may be approved if the following criteria are met:</p> <ul style="list-style-type: none"> • The requested medication is being dispensed directly to the healthcare professional (medication should not be dispensed directly to the member) AND • Provider attests to member's enrollment in a complete treatment program, including counseling and psychosocial support AND • Member has a documented diagnosis of moderate to severe opioid use disorder AND • For members newly started on therapy who are not currently using a transmucosal buprenorphine-containing product, prescriber attests that transmucosal buprenorphine induction therapy will be initiated in accordance with product labeling. <p><u>Maximum dose:</u></p> <ul style="list-style-type: none"> • Brixadi (buprenorphine) injection: 128 mg/month • Subloca (buprenorphine) injection: 600 mg/month during 1st month of induction therapy; 300 mg/month maintenance dose thereafter |
|---|------------------------------|---|
| Brixadi Weekly/Monthly (buprenorphine) syringe Subloca (buprenorphine) syringe | | |

II. Anti-Infectives

Therapeutic Drug Class: **ANTIBIOTICS, Inhaled** – Effective 1/1/2026

| Preferred No PA Required (*Must meet eligibility criteria) | Non-Preferred PA Required | <p>*CAYSTON (aztreonam) inhalation solution may be approved if the following criteria are met:</p> <ul style="list-style-type: none"> • Member has a history of trial and failure of preferred tobramycin solution for inhalation (failure is defined as lack of efficacy with a 4-week trial, intolerable side effects, or significant drug-drug interactions) OR provider attests that member cannot use preferred tobramycin solution for inhalation due to documented allergy or contraindication to therapy AND • The member has known colonization of <i>Pseudomonas aeruginosa</i> in the lungs AND • The member has been prescribed an inhaled beta agonist to use prior to nebulization of Cayston (aztreonam). |
|---|--|---|
| Tobramycin inhalation solution (generic TOBI) *CAYSTON (aztreonam) inhalation solution | ARIKAYCE (amikacin liposomal) inhalation vial BETHKIS (tobramycin) inhalation ampule KITABIS (tobramycin) nebulizer pak TOBI (tobramycin) inhalation solution | |

| Drug Name | Minimum Age | Maximum Dose | Quantity Limit (Based on day supply limitation for pack size dispensed) |
|--------------------------------|---------------|-------------------------|---|
| ARIKAYCE (amikacin) | ≥ 18 years | 590 mg once daily | Not applicable |
| BETHKIS (tobramycin) | Age ≥ 6 years | 300 mg twice daily | 28-day supply per 56-day period |
| CAYSTON (aztreonam) | ≥ 7 years | 75 mg three times daily | 28-day supply per 56-day period |
| KITABIS PAK (tobramycin) | Age ≥ 6 years | 300 mg twice daily | 28-day supply per 56-day period |
| TOBI [†] (tobramycin) | Age ≥ 6 years | 300 mg twice daily | 28-day supply per 56-day period |
| TOBI PODHALER (tobramycin) | Age ≥ 6 years | 112 mg twice daily | 28-day supply per 56-day period |

[†]Limitations apply to brand product formulation only

Members currently stabilized on any inhaled antibiotic agent in this class may receive approval to continue that agent.

| | | |
|---|---|--|
| Therapeutic Drug Class: ANTI-HERPETIC AGENTS - Oral – Effective 1/1/2026 | | |
| No PA Required Acyclovir tablet, capsule | PA Required Acyclovir suspension (<i>all other members</i>) | Non-preferred products may be approved for members who have failed an adequate trial with two preferred products with different active ingredients. Failure is defined as lack of efficacy with 14-day trial, allergy, intolerable side effects, or significant drug-drug interaction. |

| | | |
|--|-------------------------------|--|
| *Acyclovir suspension (<i>members under 18 years or cannot swallow a solid dosage form</i>) Famciclovir tablet Valacyclovir tablet | VALTREX (valacyclovir) tablet | Sitavig (acyclovir) buccal tablet may be approved for diagnosis of recurrent herpes labialis (cold sores) if member meets non-preferred criteria listed above AND has failed trial with oral acyclovir suspension. Failure is defined as lack of efficacy with 14-day trial, allergy, intolerable side effects, or significant drug-drug interaction. *Acyclovir suspension does not require prior authorization for members < 18 years of age and may be approved for members ≥ 18 years of age who cannot swallow an oral dosage form. |
|--|-------------------------------|--|

| Maximum Dose Table | | |
|--------------------|--------------|--|
| | Adult | Pediatric |
| Acyclovir | 4,000 mg/day | 3,200 mg/day |
| Famciclovir | 2,000 mg/day | |
| Valacyclovir | 4,000 mg/day | Age 2-11 years: 3,000 mg/day Age ≥ 12 years: 4,000 mg/day |

Therapeutic Drug Class: ANTI-HERPETIC AGENTS - Topical – Effective 1/1/2026

| No PA Required | PA Required | |
|--|---|---|
| Acyclovir cream (<i>Teva only</i>) | Acyclovir cream (<i>all other manufacturers</i>) | Non-Preferred Zovirax and acyclovir ointment/cream formulations may be approved for members who have failed an adequate trial with the preferred topical acyclovir ointment/cream product (diagnosis, dose and duration) as deemed by approved compendium. (Failure is defined as: lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction) |
| Acyclovir ointment | Penciclovir cream | |
| DENAVIR ^{BNR} (penciclovir) cream | XERESE (acyclovir/ hydrocortisone) cream ZOVIRAX (acyclovir) cream, ointment | Xereze (acyclovir/hydrocortisone) prior authorization may be approved for members that meet the following criteria: <ul style="list-style-type: none"> • Documented diagnosis of recurrent herpes labialis AND • Member is immunocompetent AND • Member has failed treatment of at least 10 days with acyclovir (Failure is defined as significant drug-drug interaction, lack of efficacy, contraindication to or intolerable side effects) AND • Member has failed treatment of at least one day with famciclovir 1500 mg OR valacyclovir 2 grams twice daily (Failure is defined as significant drug-drug interaction, lack of efficacy, contraindication to or intolerable side effects) |

Therapeutic Drug Class: FLUOROQUINOLONES – Oral – Effective 1/1/2026

| Preferred No PA Required (*if meeting eligibility criteria) | Non-Preferred PA Required | |
|---|--|--|
| *CIPRO (ciprofloxacin) oral suspension ^{BNR} Ciprofloxacin tablet Levofloxacin tablet Moxifloxacin tablet | BAXDELA (delafloxacin) tablet CIPRO (ciprofloxacin) tablet Ciprofloxacin oral suspension Levofloxacin oral solution Ofloxacin tablet | *CIPRO suspension does not require prior authorization for members < 18 years of age and may be approved for members ≥ 18 years of age Non-preferred products may be approved for members who have failed an adequate trial (7 days) with at least one preferred product. (Failure is defined as: lack of efficacy, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interaction). Levofloxacin solution may be approved for members with prescriber attestation that member: <ul style="list-style-type: none"> • is unable to take Cipro (ciprofloxacin) crushed tablet or suspension OR • is < 5 years of age and being treated for pneumonia OR • is ≥ 6 months old and being treated for fever in the setting of chemotherapy-induced neutropenia OR |

| | | |
|---|---|--|
| | | <ul style="list-style-type: none"> • has failed† an adequate trial (7 days) of ciprofloxacin suspension <p>†Failure is defined as lack of efficacy, allergy, intolerable side effects, significant drug-drug interaction, or contraindication to therapy.</p> |
| Therapeutic Drug Class: HEPATITIS C VIRUS TREATMENTS – Effective 1/1/2026 | | |
| Direct Acting Antivirals (DAAs) | | |
| <p>Preferred</p> <p>No PA Required for initial treatment (*must meet eligibility criteria)</p> <p>EPCLUSA (sofosbuvir/velpatasvir) 200 mg -50 mg, 150 mg-37.5 mg tablet, pellet pack</p> <p>HARVONI (ledipasvir/sofosbuvir) 45mg-200mg tablet, pellet pack</p> <p>Ledipasvir/Sofosbuvir 90 mg-400 mg tablet (<i>Asegua only</i>)</p> <p>MAVYRET (glecaprevir/pibrentasvir) tablet, pellet pack</p> <p>Sofosbuvir/Velpatasvir 400mg-100mg (<i>Asegua only</i>)</p> <p>*VOSEVI tablet (sofosbuvir/velpatasvir/voxilaprevir)</p> | <p>Non-Preferred</p> <p>PA Required</p> <p>EPCLUSA 400 mg-100 mg (sofosbuvir/velpatasvir) tablet</p> <p>HARVONI 90 mg-400 mg (ledipasvir/sofosbuvir) tablet</p> <p>SOVALDI (sofosbuvir) tablet, pellet packet</p> <p>ZEPATIER (elbasvir/grazoprevir) tablet</p> | <p>Pharmacy claims for preferred products prescribed for initial treatment will be eligible for up to a 90-day supply fill allowing for the appropriate days' duration for completing the initial treatment regimen (with no PA required). Subsequent fills will require prior authorization meeting re-treatment criteria below.</p> <p>*Second line preferred agents (Vosevi) may be approved for members 18 years of age or older with chronic HCV infection who are non-cirrhotic or have compensated cirrhosis (Child-Pugh A) AND meet the following criteria:</p> <ul style="list-style-type: none"> • GT 1-6 and has previously failed treatment with a regimen containing an NS5A inhibitor (such as ledipasvir, daclatasvir, or ombitasvir) OR • GT 1a or 3 and has previously failed treatment with a regimen containing sofosbuvir without an NS5A inhibitor AND • Request meets the applicable criteria below for re-treatment. <p>Re-treatment: All requests for HCV re-treatment for members who have failed therapy with a DAA will be reviewed on a case-by-case basis. Additional information may be requested for re-treatment requests including:</p> <ul style="list-style-type: none"> • Assessment of member readiness for re-treatment • Previous regimen medications and dates treated • Genotype of previous HCV infection • Any information regarding adherence to previously trialed regimen(s) and current chronic medications • Adverse effects experienced from previous treatment regimen • Concomitant therapies during previous treatment regimen • Vosevi regimens will require verification that member has been tested for evidence of active hepatitis B virus (HBV) infection and for evidence of prior HBV infection prior to initiating treatment. <p>Non-preferred agents may be approved if documentation is provided indicating an acceptable rationale for not prescribing a preferred treatment regimen (acceptable rationale may include patient-specific medical contraindications to a preferred treatment or cases where a member has initiated treatment on a non-preferred drug and needs to complete therapy).</p> |

| | | |
|--|--|---|
| | | Members currently receiving treatment with a non-preferred agent will receive approval to finish their treatment regimen, provided required documentation is sent via normal prior authorization request process. |
|--|--|---|

Ribavirin Products

| | | |
|-----------------------|--|---|
| No PA Required | | Preferred products are eligible for up to a 90-day supply fill. Non-preferred ribavirin products require prior authorizations which will be evaluated on a case-by-case basis. |
| Ribavirin capsule | | |
| Ribavirin tablet | | |

Therapeutic Drug Class: HUMAN IMMUNODEFICIENCY VIRUS (HIV) TREATMENTS, ORAL – Effective 1/1/2026

Oral products indicated for HIV pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP) are eligible for coverage with a written prescription by an enrolled pharmacist. Additional information regarding pharmacist enrollment can be found at <https://hcpf.colorado.gov/pharm-serv>.

Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

| | | |
|---|--|--|
| No PA Required | | All products are preferred and do not require prior authorization. |
| EDURANT (rilpivirine) tablet | | |
| Efavirenz capsule, tablet | | |
| Etravirine tablet | | |
| INTELENCE (etravirine) tablet | | |
| Nevirapine suspension, IR tablet, ER tablet | | |
| PIFELTRO (doravirine) tablet | | |

Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)

| | | |
|---|--|--|
| No PA Required | | All products are preferred and do not require prior authorization. |
| Abacavir solution, tablet | | |
| Didanosine DR capsule | | |
| Emtricitabine capsule | | |
| EMTRIVA (emtricitabine) capsule, solution | | |
| EPIVIR (lamivudine) solution, tablet | | |

| | | |
|---|--|--|
| Lamivudine solution, tablet | | |
| RETROVIR (zidovudine) capsule, syrup | | |
| Stavudine capsule | | |
| Tenofovir disoproxil fumarate (TDF) tablet | | |
| VIREAD (TDF) oral powder, tablet | | |
| ZIAGEN (abacavir) solution, tablet | | |
| Zidovudine capsule, syrup, tablet | | |
| Protease Inhibitors (PIs) | | |
| No PA Required | | All products are preferred and do not require prior authorization. |
| APTIVUS (tipranavir) capsule | | |
| Atazanavir capsule | | |
| Darunavir tablet | | |
| Fosamprenavir tablet | | |
| LEXIVA (fosamprenavir) suspension, tablet | | |
| NORVIR (ritonavir) powder packet, tablet | | |
| PREZISTA (darunavir) suspension, tablet | | |
| REYATAZ (atazanavir) capsule, powder pack | | |
| Ritonavir tablet | | |
| VIRACEPT (nelfinavir) tablet | | |
| Other Agents | | |
| No PA Required | | All products are preferred and do not require prior authorization. |
| ISENTRESS (raltegravir) chewable, powder pack, tablet | | |
| ISENTRESS HD (raltegravir) tablet | | |
| Maraviroc tablet | | |

| | | |
|---|--|---|
| <p>RUKOBIA (fostemsavir tromethamine ER) tablet</p> <p>SELZENTRY (maraviroc) solution, tablet</p> <p>SUNLENCA (lenacapavir) tablet</p> <p>TIVICAY (dolutegravir) tablet</p> <p>TIVICAY PD (dolutegravir) tablet for suspension</p> <p>TYBOST (cobicistat) tablet</p> <p>VOCABRIA (cabotegravir) tablet</p> <p>YEZTUGO (lenacapavir) tablet</p> | | |
| Combination Agents | | |
| <p>No PA Required</p> <p>Abacavir/Lamivudine tablet</p> <p>ATRIPLA (efavirenz/Emtricitabine/TDF) tablet</p> <p>BIKTARVY (bictegravir/emtricitabine/TAF) tablet</p> <p>CIMDUO (lamivudine/TDF) tablet</p> <p>COMBIVIR (lamivudine/zidovudine) tablet</p> <p>COMPLERA (emtricitabine/rilpivirine/TDF) tablet</p> <p>DELSTRIGO (doravirine/lamivudine/TDF) tablet</p> <p>DESCOVY (emtricitabine/TAF) tablet</p> <p>DOVATO (dolutegravir/lamivudine) tablet</p> <p>Efavirenz/Emtricitabine/TDF tablet</p> <p>Efavirenz/Lamivudine/TDF tablet</p> <p>Emtricitabine/rilpivirine/TDF tablet</p> <p>Emtricitabine/TDF tablet</p> <p>EPZICOM (abacavir/lamivudine) tablet</p> | | <p>All products are preferred and do not require prior authorization.</p> |

| | | |
|--|--|--|
| EVOTAZ (atazanavir/cobicistat) tablet | | |
| GENVOYA (elvitegravir/cobicistat/ emtricitabine/TAF) tablet | | |
| JULUCA (dolutegravir/rilpivirine) tablet | | |
| KALETRA (lopinavir/ritonavir) solution, tablet | | |
| Lamivudine/Zidovudine tablet | | |
| Lopinavir/Ritonavir solution, tablet | | |
| ODEFSEY (emtricitabine/rilpivirine/TAF) tablet | | |
| PREZCOBIX (darunavir/cobicistat) tablet | | |
| STRIBILD (elvitegravir/cobicistat/ emtricitabine/TDF) tablet | | |
| SYMPI/SYMPI LO (efavirenz/lamivudine/TDF) tablet | | |
| SYMTUZA (darunavir/cobicistat/ emtricitabine/TAF) tablet | | |
| TRIUMEQ (abacavir/dolutegravir/ lamivudine) tablet | | |
| TRIUMEQ PD (abacavir/dolutegravir) tablet for suspension | | |
| TRIZIVIR (abacavir/lamivudine/zidovudine) tablet | | |
| TRUVADA (emtricitabine/TDF) tablet | | |

Therapeutic Drug Class: TETRACYCLINES – Effective 7/1/2025

| No PA Required | PA Required | |
|---|---|---|
| Doxycycline hyclate capsules | Demeocycline tablet | Prior authorization for non-preferred tetracycline agents may be approved if member has trialed/failed a preferred doxycycline product AND preferred minocycline. Failure is defined as lack of efficacy, allergy, intolerable side effects, contraindication, or significant drug-drug interaction. |
| Doxycycline hyclate tablets | DORYX (doxycycline DR) tablet | Prior authorization for liquid oral tetracycline formulations may be approved if member is unable to take a solid oral dosage form. |
| Doxycycline monohydrate 50mg, 100mg capsule | Doxycycline hyclate DR tablet | |
| Doxycycline monohydrate tablets | Doxycycline monohydrate 75mg, 150mg capsule | Nuzyra (omadacycline) prior authorization may be approved if member meets all of the following criteria: the above “non-preferred” prior authorization criteria and the following: |
| Minocycline capsules | Doxycycline monohydrate suspension | <ul style="list-style-type: none"> • Member has trialed and failed[†] therapy with a preferred doxycycline product and preferred minocycline OR clinical rationale is provided describing why these medications cannot be trialed (including resistance and sensitivity) AND • Member has diagnosis of either Community Acquired Bacterial Pneumonia (CABP) or Acute Bacterial Skin and Skin Structure Infection (ABSSSI) or clinical rationale and supporting literature describing/supporting intended use AND one of the following: |
| | Minocycline IR, ER tablet | |
| | MINOLIRA (minocycline ER) tablet | |

| | | |
|--|---|---|
| | MORGIDOX (doxycycline/skin cleanser) kit NUZYRA (omadacycline) tablet SOLODYN ER (minocycline ER) tablet Tetracycline capsule XIMINO (minocycline ER) capsule | <ul style="list-style-type: none"> ○ If member diagnosis is ABSSSI, member must have trial and failure[†] of sulfamethoxazole/trimethoprim product in addition to preferred tetracyclines OR ○ If member diagnosis is CABP, member must have trial and failure[†] of either a beta-lactam antibiotic (amoxicillin/clavulanic acid) or a macrolide (azithromycin) <p>AND</p> <ul style="list-style-type: none"> ● Maximum duration of use is 14 days <p>[†]Failure is defined as lack of efficacy with 7-day trial, allergy, intolerable side effects, contraindication, or significant drug-drug interaction.</p> |
|--|---|---|

III. Cardiovascular

Therapeutic Drug Class: ALPHA-BLOCKERS – Effective 7/1/2025

| No PA Required | PA Required | |
|------------------|------------------------------|--|
| Prazosin capsule | MINIPRESS (prazosin) capsule | Non-preferred products may be approved following trial and failure of one preferred product (failure is defined as lack of efficacy with 4-week trial, allergy or intolerable side effects). |

Therapeutic Drug Class: BETA-BLOCKERS – Effective 7/1/2025

Beta-Blockers, Single Agent

| No PA Required (*Must meet eligibility criteria) | PA Required | |
|---|--|---|
| | Betaxolol tablet | *HEMANGEOL (propranolol) oral solution may be approved for members between 5 weeks and 1 year of age with proliferating infantile hemangioma requiring systemic therapy. Maximum dose: 1.7 mg/kg twice daily |
| Acebutolol capsule | BYSTOLIC (nebivolol) tablet | Non-preferred products may be approved following trial and failure with two preferred products (failure is defined as lack of efficacy with 4-week trial, allergy, intolerable side effects or significant drug-drug interactions). |
| Atenolol tablet | COREG (carvedilol) tablet | |
| Bisoprolol tablet | COREG CR (carvedilol ER) capsule | INNOPRAN XL (propranolol ER) capsule brand product formulation may be approved if meeting the following: |
| Carvedilol IR tablet | Carvedilol ER capsule | <ul style="list-style-type: none"> ● Request meets non-preferred criteria listed above AND ● Member has trialed and failed therapy with a generic propranolol ER capsule formulation OR prescriber provides clinical rationale supporting why generic propranolol ER capsule product formulations cannot be trialed. Failure is defined as lack of efficacy with 4-week trial, allergy, intolerable side effects or significant drug-drug interactions. |
| *HEMANGEOL (propranolol) solution | INDERAL LA/XL (propranolol ER) capsule | |
| Labetalol tablet | INNOPRAN XL (propranolol ER) capsule | |
| Metoprolol tartrate tablet | KASPARGO (metoprolol succinate) sprinkle capsule | KAPSPARGO SPRINKLE (metoprolol succinate) extended-release capsule may be approved for members \geq 6 years of age who are unable to take a solid oral dosage form. Maximum dose: 200mg/day (adult); 50mg/day (pediatric) |
| Metoprolol succinate ER tablet | LOPRESSOR (metoprolol tartrate) tablet | |
| Nadolol tablet | Pindolol tablet | Members currently stabilized on timolol oral tablet non-preferred products may receive approval to continue on that product. |
| Nebivolol tablet | TENORMIN (atenolol) tablet | |
| | Timolol tablet | |

| | | |
|---------------------------------|---|--|
| Propranolol IR tablet, solution | TOPROL XL (metoprolol succinate) tablet | Members currently stabilized on the non-preferred Bystolic (nebivolol) tablets may receive approval to continue on that product. |
| Propranolol ER capsule | | Members currently stabilized on the non-preferred carvedilol ER capsules may receive approval to continue on that product. |

Table 1: Receptor Selectivity and Other Properties of Preferred Beta Blockers

| | β_1 | β_2 | Alpha-1 receptor antagonist | Intrinsic sympathomimetic activity (ISA) |
|----------------------|-----------|-----------|-----------------------------|--|
| Acebutolol | X | | | X |
| Atenolol | X | | | |
| Betaxolol | X | | | |
| Bisoprolol | X | | | |
| Carvedilol | X | X | X | |
| Labetalol | X | X | X | |
| Metoprolol succinate | X | | | |
| Metoprolol tartrate | X | | | |
| Nadolol | X | X | | |
| Nebivolol | X | | | |
| Pindolol | X | X | | X |
| Propranolol | X | X | | |

Beta-Blockers, Anti-Arrhythmics

| No PA Required | PA Required | |
|----------------|---|--|
| Sotalol tablet | BETAPACE/AF (sotalol) tablet SOTYLIZE (sotalol) solution | SOTYLIZE (sotalol) oral solution may be approved for members 3 days to < 5 years of age. For members \geq 5 years of age, SOTYLIZE (sotalol) oral solution may be approved for members who are unable to take a solid oral dosage form OR members that have trialed and failed therapy with one preferred product. (Failure is defined as allergy or intolerable side effects.) Maximum dose: 320 mg/day |

Beta-Blockers, Combinations

| No PA Required | PA Required | |
|--------------------------------|--|---|
| Atenolol/Chlorthalidone tablet | TENORETIC (atenolol/chlorthalidone) tablet | Non-preferred products may be approved following trial and failure with two preferred products (failure is defined as lack of efficacy with 4-week trial, allergy, intolerable side effects or significant drug-drug interactions). |

| | | |
|------------------------|-------------------------------|--|
| Bisoprolol/HCTZ tablet | ZIAC (bisoprolol/HCTZ) tablet | |
| Metoprolol/HCTZ tablet | | |

Therapeutic Drug Class: CALCIUM CHANNEL-BLOCKERS – Effective 7/1/2025

Dihydropyridines (DHPs)

| No PA Required | PA Required | |
|-----------------------|--|--|
| Amlodipine tablet | ADALAT CC (nifedipine ER) tablet | Non-preferred products may be approved following trial and failure of two preferred agents. Failure is defined as lack of efficacy, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interactions. |
| Felodipine ER tablet | NORLIQVA (amlodipine) suspension | Nimodipine oral capsule may be approved for adult members (≥ 18 years of age) with subarachnoid hemorrhage |
| Nifedipine ER tablet | KATERZIA (amlodipine) suspension | NYMALIZE (nimodipine) oral syringe may be approved for adult members (≥ 18 years of age) with subarachnoid hemorrhage who also have a feeding tube or have difficulty swallowing solid dosage forms. Maximum dose: 360 mg/day for 21 days (6 syringes/day or 126 syringes/21 days) |
| Nifedipine IR capsule | Isradipine capsule | KATERZIA (amlodipine) suspension may be approved if meeting the following: |
| | Levamlodipine tablet | <ul style="list-style-type: none"> • The member has a feeding tube or confirmed difficulty swallowing solid oral dosage forms OR cannot obtain the required dose through crushed amlodipine tablets AND • For members < 6 years of age, the prescriber confirms that the member has already been receiving the medication following initiation in a hospital or other clinical setting |
| | Nicardipine capsule | |
| | Nimodipine capsule | |
| | Nisoldipine ER tablet | |
| | NORVASC (amlodipine) tablet | |
| | NYMALIZE (nimodipine) solution, oral syringe | |
| | PROCARDIA XL (nifedipine ER) tablet | |
| | SULAR (nisoldipine ER) tablet | |

Non-Dihydropyridines (Non-DHPs)

| No PA Required | PA Required | |
|---|--|--|
| Diltiazem IR tablet | CARDIZEM (diltiazem) tablet | Non-preferred products may be approved following trial and failure of three preferred agents. Failure is defined as lack of efficacy, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interactions. |
| Diltiazem CD/ER capsule | CARDIZEM CD/LA (diltiazem CD/ER) capsule, tablet | |
| Verapamil IR, ER tablet | Diltiazem ER/LA tablet | |
| Verapamil ER 120 mg, 180 mg, 240 mg capsule | TIAZAC ER (diltiazem ER) capsule | |

| | Verapamil ER 360 mg capsule Verapamil PM ER 100 mg, 200 mg, 300 mg capsule VERELAN/PM (verapamil ER) pellet capsule | |
|---|---|---|
| Therapeutic Drug Class: ANGIOTENSIN MODIFIERS – Effective 7/1/2025 | | |
| Angiotensin-converting enzyme inhibitors (ACE Inh) | | |
| No PA Required | PA Required | |
| Benazepril tablet | ACCUPRIL (quinapril) tablet | Non-preferred ACE inhibitors, ACE inhibitor combinations, ARBs, ARB combinations, renin inhibitors, and renin inhibitor combination products may be approved for members who have trialed and failed treatment with three preferred products (failure is defined as lack of efficacy with a 4-week trial, allergy, intolerable side effects, or significant drug-drug interaction). |
| Enalapril tablet | ALTACE (ramipril) capsule | |
| Fosinopril tablet | Captopril tablet | Enalapril solution may be approved without trial and failure of three preferred agents for members who are unable to take a solid oral dosage form. |
| Lisinopril tablet | Enalapril solution | QBRELIS (lisinopril) solution may be approved for members 6 years of age or older who are unable to take a solid oral dosage form and have trialed and failed Epaned (enalapril) solution. Failure is defined as lack of efficacy with a 4-week trial, allergy, intolerable side effects, or significant drug-drug interaction. |
| Quinapril tablet | EPANED (enalapril) solution | |
| Ramipril tablet | LOTENSIN (benazepril) tablet Moexipril tablet Perindopril tablet PRINIVIL (lisinopril) tablet QBRELIS (lisinopril) solution Trandolapril tablet VASOTEC (enalapril) tablet ZESTRIL (lisinopril) tablet | |
| ACE Inhibitor Combinations | | |
| No PA Required | PA Required | |
| Amlodipine/Benazepril capsule | ACCURETIC (quinapril/HCTZ) tablet | Non-preferred ACE inhibitors, ACE inhibitor combinations, ARBs, ARB combinations, renin inhibitors, and renin inhibitor combination products may be approved for members who have trialed and failed treatment with three preferred products (failure is defined as lack of efficacy with a 4-week trial, allergy, intolerable side effects, or significant drug-drug interaction). |
| Benazepril/HCTZ tablet | Captopril/HCTZ tablet | |
| Enalapril/HCTZ tablet | Fosinopril/HCTZ tablet | |

| | | |
|--|---|--|
| Lisinopril/HCTZ tablet | LOTENSIN HCT (benazepril/HCTZ) tablet | |
| Quinapril/HCTZ tablet | LOTREL (amlodipine/benazepril) capsule | |
| | VASERETIC (enalapril/HCTZ) tablet | |
| | ZESTORETIC (lisinopril/HCTZ) tablet | |
| Angiotensin II receptor blockers (ARBs) | | |
| No PA Required | PA Required | |
| Irbesartan tablet | ARBELI (losartan) oral suspension | Non-preferred ACE inhibitors, ACE inhibitor combinations, ARBs, ARB combinations, renin inhibitors, and renin inhibitor combination products may be approved for members who have trialed and failed treatment with three preferred products (failure is defined as lack of efficacy with a 4-week trial, allergy, intolerable side effects, or significant drug-drug interaction). |
| Losartan tablet | ATACAND (candesartan) tablet | |
| Olmesartan tablet | AVAPRO (irbesartan) tablet | |
| Telmisartan tablet | BENICAR (olmesartan) tablet | |
| Valsartan tablet | Candesartan tablet COZAAR (losartan) tablet DIOVAN (valsartan) tablet EDARBI (azilsartan) tablet Eprosartan tablet MICARDIS (telmisartan) tablet Valsartan solution | |
| ARB Combinations | | |
| Preferred No PA Required (Unless indicated*) *ENTRESTO (sacubitriil/valsartan) tablet ^{BNR} | Non-Preferred PA Required ATACAND HCT (candesartan/HCTZ) tablet AVALIDE (irbesartan/HCTZ) tablet AZOR (olmesartan/amlodipine) tablet BENICAR HCT (olmesartan/HCTZ) tablet Candesartan/HCTZ tablet | Non-preferred ACE inhibitors, ACE inhibitor combinations, ARBs, ARB combinations, renin inhibitors, and renin inhibitor combination products may be approved for members who have trialed and failed treatment with three preferred products (failure is defined as lack of efficacy with a 4-week trial, allergy, intolerable side effects, or significant drug-drug interaction). *ENTRESTO (sacubitriil/valsartan) may be approved for members if the following criteria are met: <ul style="list-style-type: none"> • Member is 1 to 17 years of age and has a diagnosis of symptomatic heart failure with systemic left ventricular systolic dysfunction (LVSD) and/or has chronic heart failure with a below-normal left ventricular ejection fraction (LVEF) OR • Member is \geq 18 years of age and has a diagnosis of chronic heart failure. |

| | | |
|-----------------------------|--|--|
| Olmesartan/HCTZ tablet | DIOVAN HCT (valsartan/HCTZ) tablet | <ul style="list-style-type: none"> Diagnosis will be verified through automated verification (AutoPA) of the appropriate corresponding ICD-10 diagnosis codes related to the indicated use of the medication. |
| Telmisartan/HCTZ tablet | EDARBYCLOR (azilsartan/chlorthalidone) tablet | |
| Valsartan/Amlodipine tablet | ENTRESTO (sacubitriol/valsartan) sprinkles | |
| Valsartan/HCTZ tablet | EXFORGE (valsartan/amlodipine) tablet | |
| | EXFORGE HCT (valsartan/amlodipine/HCTZ) tablet | |
| | HYZAAR (losartan/HCTZ) tablet | |
| | MICARDIS HCT (telmisartan/HCTZ) tablet | |
| | Olmesartan/amlodipine/HCTZ tablet | |
| | Sacubitriol/valsartan tablet | |
| | Telmisartan/amlodipine tablet | |
| | TRIBENZOR (olmesartan/amlodipine/HCTZ) tablet | |
| | Valsartan/Amlodipine/HCTZ tablet | |

Renin Inhibitors & Renin Inhibitor Combinations

PA Required

Aliskiren tablet

TEKTURNA (aliskiren) tablet

TEKTURNA HCT (aliskiren/HCTZ) tablet

Non-preferred renin inhibitors and renin inhibitor combination products may be approved for members who have failed treatment with three preferred products from the angiotensin modifier class (failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction).

Renin inhibitors and combinations will not be approved in patients with diabetes. Renin inhibitors are contraindicated when used in combination with an ACE inhibitor, ACE inhibitor combination, ARB, or ARB combination.

Therapeutic Drug Class: PULMONARY ARTERIAL HYPERTENSION THERAPIES – Effective 7/1/2025

Phosphodiesterase Inhibitors

Preferred

***Must meet eligibility criteria**

*Sildenafil oral suspension, tablet

Non-Preferred

PA Required

ADCIRCA (tadalafil) tablet

*Eligibility criteria for preferred products:

Preferred sildenafil and tadalafil tablet formulations may be approved for a diagnosis of pulmonary hypertension or right-sided heart failure.

| | | |
|------------------------|---|---|
| *Tadalafil 20mg tablet | ALYQ (tadalafil) tablet LIQREV (sildenafil) suspension REVATIO (sildenafil) suspension, tablet TADLIQ suspension | Sildenafil suspension may be approved for a diagnosis of pulmonary hypertension for members < 5 years of age who cannot take a solid oral dosage form. Non-preferred oral tablet products may be approved if meeting the following: <ul style="list-style-type: none">• Member has a diagnosis of pulmonary hypertension AND• Member has trialed and failed treatment with preferred sildenafil tablet AND preferred tadalafil tablet. Failure is defined as lack of efficacy with 4-week trial, allergy, intolerable side effects, or significant drug-drug interaction. Members who have been previously stabilized on a non-preferred product may receive approval to continue on the medication. Non-preferred oral liquid products may be approved if meeting the following: <ul style="list-style-type: none">• Member has a diagnosis of pulmonary hypertension AND• Request meets one of the following:<ul style="list-style-type: none">◦ Member has trialed and failed treatment with one preferred oral liquid formulation (failure is defined as lack of efficacy with a 4-week trial, allergy, intolerable side effects, contraindication, or significant drug-drug interaction) OR◦ Prescriber verifies that the member is unable to take a solid oral dosage form and that there is clinical necessity for use of a regimen with a less frequent dosing interval. |
|------------------------|---|---|

| Endothelin Receptor Antagonists | | |
|---|---|---|
| Preferred *Must meet eligibility criteria *Ambrisentan tablet *Bosentan 62.5mg, 125mg tablet | Non-Preferred PA Required *Must meet eligibility criteria Bosentan tablet for suspension LETAIRIS (ambrisentan) tablet OPSUMIT (macitentan) tablet OPSYNVI (macitentan/tadalafil) tablet TRACLEER (bosentan) 32mg tablet for suspension TRACLEER (bosentan) 62.5mg, 125mg tablet | *Eligibility Criteria for all agents in the class Approval may be granted for a diagnosis of pulmonary hypertension. Member and prescriber should be enrolled in applicable REMS program for prescribed medication. Non-preferred agents may be approved for members who have trialed and failed two preferred agents. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction. TRACLEER (bosentan) tablet for suspension may be approved if meeting one of the following: <ul style="list-style-type: none">• The member cannot swallow a solid oral dosage form OR• The request meets eligibility criteria and non-preferred criteria listed above. Members who have been previously stabilized on a non-preferred product may receive approval to continue the medication. |

| Prostacyclin Analogues and Receptor Agonists | | |
|--|--|---|
| Preferred (*Must meet eligibility criteria) | Non-Preferred PA Required | *Eligibility Criteria for all agents in the class Approval will be granted for a diagnosis of pulmonary hypertension. |

| | | |
|--|--|---|
| *FLOLAN (epoprostenol) vial | Epoprostenol vial | Non-preferred products may be approved for members who have failed treatment with a Preferred Product. (Failure is defined as: lack of efficacy, allergy, intolerable side effects, contraindication to IV therapy or significant drug-drug interaction). |
| *ORENITRAM (treprostinil ER) tablet, titration kit | Treprostinil vial | |
| *REMODULIN (treprostinil) vial | TYVASO (treprostinil) inhaler, inhalation solution | Members who have been previously stabilized on a non-preferred product may receive approval to continue on the medication. |
| *VENTAVIS (iloprost) inhalation solution | UPTRAVI (selexipag) tablet, dose pack, vial | |
| | VELETRI (epoprostenol) vial | |
| | YUTREPIA (treprostinil) capsule for inhalation | |

Guanylate Cyclase (sGC) Stimulator

| | | |
|--|--|--|
| | Non-Preferred PA Required ADEMPAS (riociguat) tablet | ADEMPAS (riociguat) may be approved for members who meet the following criteria: <ul style="list-style-type: none"> For members of childbearing potential: <ul style="list-style-type: none"> Member is not pregnant and is able to receive monthly pregnancy tests while taking ADEMPAS and one month after stopping therapy AND Member and their partners are utilizing one of the following contraceptive methods during treatment and for one month after stopping treatment (IUD, contraceptive implants, tubal sterilization, a hormone method with a barrier method, two barrier methods, vasectomy with a hormone method, or vasectomy with a barrier method) <p>AND</p> <ul style="list-style-type: none"> Member has a CrCl \geq 15 mL/min and is not on dialysis AND Member does not have severe liver impairment (Child Pugh C) AND Member has a diagnosis of persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO Group 4) after surgical treatment or has inoperable CTEPH OR Member has a diagnosis of pulmonary hypertension and has failed treatment with a preferred product for pulmonary hypertension. (Failure is defined as a lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction). |
|--|--|--|

Therapeutic Drug Class: LIPOTROPICS – Effective 7/1/2025

Bile Acid Sequestrants

| No PA Required | PA Required | |
|---|---|---|
| Colesevelam tablet | Colesevelam packet | Non-preferred bile acid sequestrants may be approved if the member has failed treatment with 2 preferred products in the last 12 months (failure is defined as lack of efficacy with 4-week trial, allergy, intolerable side effects or significant drug-drug interactions). |
| Colestipol tablet | COLESTID (colestipol) tablet, granules | Non-preferred lipotropic agents with a preferred product with same strength, dosage form, and active ingredient may be approved with adequate trial and/or failure of the preferred product with the same ingredient (such as preferred ezetimibe and Zetia) and 2 additional agents. (Failure is defined as: lack of efficacy with 4-week trial, allergy, intolerable side effects or significant drug-drug interactions). |
| Cholestyramine packet, light packet, powder | Colestipol granules | |
| | QUESTRAN (cholestyramine/sugar) packet, powder | |
| | QUESTRAN LIGHT (cholestyramine/ aspartame) packet, powder | |

| | | |
|---|--|---|
| | WELCHOL (colesevelam) packet, tablet | |
| Fibrates | | |
| No PA Required | PA Required | |
| Fenofibric acid DR (generic Trilipix) capsule Fenofibrate capsule, tablet (generic Lofibra/Tricor) Gemfibrozil tablet | ANTARA (fenofibrate) capsule Fenofibric acid tablet Fenofibrate capsule (generic Antara/Fenoglide/Lipofen) FENOGLIDE (fenofibrate) tablet LIPOFEN (fenofibrate) capsule LOPID (gemfibrozil) tablet TRICOR (fenofibrate nano) tablet TRILIPIX (fenofibric acid) capsule | Non-preferred fibrates may be approved if the member has failed treatment with generic gemfibrozil or generic fenofibrate and niacin ER in the last 12 months (failure is defined as lack of efficacy with 4-week trial of each drug, allergy, intolerable side effects or significant drug-drug interactions). Non-preferred lipotropic agents with a preferred product with same strength, dosage form, and active ingredient may be approved with adequate trial and/or failure of the preferred product with the same ingredient (such as preferred ezetimibe and Zetia) and 2 additional agents. (Failure is defined as: lack of efficacy with 4-week trial, allergy, intolerable side effects or significant drug-drug interactions). |
| Other Lipotropics | | |
| No PA Required (*Must meet eligibility criteria) | PA Required | |
| Ezetimibe tablet Niacin ER tablet *Omega-3 ethyl esters capsule (generic Lovaza) | Icosapent ethyl capsule LOVAZA (omega-3 ethyl esters) capsule NEXLETOL (bempedoic acid) tablet NEXLIZET (bempedoic acid/ezetimibe) tablet ZETIA (ezetimibe) tablet | Non-preferred lipotropic agents with a preferred product with same strength, dosage form, and active ingredient may be approved with adequate trial and/or failure of the preferred product with the same ingredient and 2 additional agents. (Failure is defined as: lack of efficacy with 4-week trial, contraindication, allergy, intolerable side effects or significant drug-drug interactions). *Omega-3 ethyl esters (generic Lovaza) may be approved for members who have a baseline triglyceride level ≥ 500 mg/dL Lovaza (brand name) may be approved if meeting the following: <ul style="list-style-type: none"> • Member has a baseline triglyceride level ≥ 500 mg/dL AND • Member has failed an adequate trial of omega-3 Ethyl Esters AND an adequate trial of gemfibrozil or fenofibrate (failure is defined as lack of efficacy with 4-week trial, allergy, intolerable side effects or significant drug-drug interactions) Nexletol (bempedoic acid) or Nexlizet (bempedoic acid/ezetimibe) may be approved if meeting the following criteria: <ul style="list-style-type: none"> • Member is ≥ 18 years of age AND • Member is not pregnant AND • Member is not receiving concurrent simvastatin > 20 mg daily or pravastatin > 40 mg daily AND |

| | | | | |
|--|--|--|---|--|
| | | <ul style="list-style-type: none"> Member has a diagnosis of either heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease (see definition below), AND <table border="1" data-bbox="1607 159 2440 409"> <tr> <td data-bbox="1607 159 2440 192">Conditions Which Define Clinical Atherosclerotic Cardiovascular Disease</td> </tr> <tr> <td data-bbox="1607 192 2440 409"> <ul style="list-style-type: none"> Acute Coronary Syndrome History of Myocardial Infarction Stable or Unstable Angina Coronary or other Arterial Revascularization Stroke Transient Ischemic Attack Peripheral Arterial Disease of Atherosclerotic Origin </td> </tr> </table> Member is concurrently adherent (> 80% of the past 180 days) on a maximally tolerated dose of a high intensity statin therapy (atorvastatin \geq 40 mg daily OR rosuvastatin \geq 20 mg daily [as a single-entity or as a combination product]) AND ezetimibe (as a single-entity or as a combination product) concomitantly for \geq 8 continuous weeks), AND If intolerant to a statin due to side effects, member must have a one month documented trial with at least two other maximally dosed statins in addition to ezetimibe. For members with a past or current incidence of rhabdomyolysis, a one-month trial and failure of a statin is not required, AND Member has a treated LDL $>$ 70 mg/dL for a clinical history of ASCVD OR LDL $>$ 100 mg/dL if familial hypercholesterolemia <p><u>Initial Approval:</u> 1 year</p> <p><u>Reauthorization:</u> Reauthorization may be approved for 1 year with provider attestation of medication safety and efficacy during the initial treatment period</p> | Conditions Which Define Clinical Atherosclerotic Cardiovascular Disease | <ul style="list-style-type: none"> Acute Coronary Syndrome History of Myocardial Infarction Stable or Unstable Angina Coronary or other Arterial Revascularization Stroke Transient Ischemic Attack Peripheral Arterial Disease of Atherosclerotic Origin |
| Conditions Which Define Clinical Atherosclerotic Cardiovascular Disease | | | | |
| <ul style="list-style-type: none"> Acute Coronary Syndrome History of Myocardial Infarction Stable or Unstable Angina Coronary or other Arterial Revascularization Stroke Transient Ischemic Attack Peripheral Arterial Disease of Atherosclerotic Origin | | | | |

Therapeutic Drug Class: STATINS – Effective 7/1/2025

| No PA Required | PA Required | |
|---------------------|---|--|
| Atorvastatin tablet | ALTOPREV (lovastatin ER) tablet | |
| Lovastatin tablet | ATORVALIQ (atorvastatin) suspension | Non-preferred products may be approved following trial and failure of treatment with two preferred products (failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions). For members who are unable to take a solid oral dosage form, non-preferred liquid product formulations may be approved without requiring trial and failure of preferred products. |
| Pravastatin tablet | CRESTOR (rosuvastatin) tablet | |
| Rosuvastatin tablet | EZALLOR (rosuvastatin) sprinkle capsule | Age Limitations: Altorev (lovastatin ER) will not be approved for members $<$ 10 years of age. Fluvastatin will not be approved for members $<$ 10 years of age. Livalo (pitavastatin) will not be approved for members $<$ 8 years of age. |
| Simvastatin tablet | FLOLIPID (simvastatin) suspension | |
| | Fluvastatin capsule, ER tablet | |
| | LESCOL XL (fluvastatin ER) tablet | |
| | LIPITOR (atorvastatin) tablet | |
| | LIVALO (pitavastatin) tablet | |

| | | |
|---|---|---|
| | Pitavastatin tablet ZOCOR (simvastatin) tablet ZYPITAMAG (pitavastatin) tablet | |
| Therapeutic Drug Class: STATIN COMBINATIONS – Effective 7/1/2025 | | |
| No PA Required Simvastatin/Ezetimibe tablet | PA Required Atorvastatin/Amlodipine tablet CADUET (atorvastatin/amlodipine) tablet VYTORIN (simvastatin/ezetimibe) tablet | Non-preferred Statin combinations may be approved following trial and failure of treatment with two preferred products (failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions). <u>Age Limitations:</u> Vytorin and generic ezetimibe/simvastatin will not be approved for members < 18 years of age. Caduet and generic amlodipine/atorvastatin will not be approved for members < 10 years of age. |
| Therapeutic Drug Class: Movement Disorders – Effective 7/1/2025 | | |
| No PA Required (*Must meet eligibility criteria) *Austedo (deutetrabenazine) tablet *Austedo (deutetrabenazine) XR tablet, titration pack *Ingrezza (valbenazine) capsule, initiation pack * Tetrabenazine tablet | PA Required Xenazine (tetrabenazine) tablet | <p>*Eligibility Criteria for all agents in the class</p> <ul style="list-style-type: none"> • Member is \geq18 years of age AND • Member has been diagnosed with tardive dyskinesia or chorea associated with Huntington's disease AND • If the member has hepatic impairment, FDA labeling for use has been evaluated AND • <u>For chorea associated with Huntington's disease:</u> <ul style="list-style-type: none"> ○ Member has been evaluated for untreated or inadequately treated depression and member has been counseled regarding the risks of depression and suicidality associated with agents in this therapeutic class. <p>AND</p> <ul style="list-style-type: none"> • <u>For tardive dyskinesia:</u> <ul style="list-style-type: none"> ○ If applicable, the need for ongoing treatment with 1st and 2nd generation antipsychotics, metoclopramide, or prochlorperazine has been evaluated AND ○ A baseline Abnormal Involuntary Movement Scale (AIMS) has been performed. <p>Xenazine (tetrabenazine) Maximum dose 50 mg/day (PA available for extensive metabolizers of CYP2D6)</p> <p>Ingrezza (valbenazine) Quantity limits:</p> <ul style="list-style-type: none"> • 40 mg: 1.767 capsules/day • 60 mg: 1 capsule/day • 80 mg: 1 capsule/day <p>Austedo (deutetrabenazine)</p> |

| | | |
|--|--|---|
| | | Maximum dose: 48 mg/day Non-preferred Movement Disorder Agents may be approved for members ≥ 18 years of age after trial and failure of two preferred products. Failure is defined as lack of efficacy, contraindication, allergy, intolerable side effects or significant drug-drug interaction. |
|--|--|---|

IV. Central Nervous System

Therapeutic Drug Class: ANTICONVULSANTS -Oral – Effective 4/1/2025

| No PA Required | PA Required <i>Non-preferred brand name medications do not require a prior authorization when the equivalent generic is preferred and “dispense as written” is indicated on the prescription.</i> | Members currently stabilized (in outpatient or acute care settings) on any non-preferred medication in this class may receive prior authorization approval to continue on that medication. Non-preferred brand name medications do not require a prior authorization when the equivalent generic is preferred and “dispense as written” is indicated on the prescription. |
|--|--|--|
| Barbiturates | | |
| Phenobarbital elixir, solution, tablet | MY SOLINE (primidone) tablet | |
| Primidone tablet | | |
| Hydantoins | | |
| DILANTIN (phenytoin) 30 mg capsules, Infatab, suspension | DILANTIN (phenytoin ER), 100 mg capsules | |
| PHENYTEK (phenytoin ER) capsule | | |
| Phenytoin suspension, chewable, ER capsule | | |
| Succinamides | | |
| Ethosuximide capsule, solution | CELONTIN (methsuximide) Kapseal Methsuximide capsule | |
| | ZARONTIN (ethosuximide) capsule, solution | |
| Benzodiazepines | | |
| Clobazam oral syringe, tablet, suspension | KLONOPIN (clonazepam) tablet | |
| Clonazepam tablet, ODT | ONFI (clobazam) suspension, tablet | |

Members currently stabilized (in outpatient or acute care settings) on any non-preferred medication in this class may receive prior authorization approval to continue on that medication.

Non-preferred brand name medications do not require a prior authorization when the equivalent generic is preferred and “dispense as written” is indicated on the prescription.

Non-Preferred Products Newly Started for Treating Seizure Disorder or Convulsions:

Non-preferred medications newly started for members with a diagnosis of seizure disorder/convulsions may be approved if the following criteria are met:

- The requested medication is being prescribed by a practitioner who has sufficient education and experience to safely manage treatment **AND**
- The request meets minimum age and maximum dose limits listed in Table 1 **AND**
- For medications indicated for use as adjunctive therapy, the medication is being used in conjunction with another medication indicated for treatment of seizure disorder/convulsions **AND**
- The request meets additional criteria listed for any of the following:

APTIOM (eslicarbazepine)

- Member has history of trial and failure[‡] of any carbamazepine-containing product

BRIVIACT (brivaracetam)

- Member has history of trial and failure[‡] of any levetiracetam-containing product

DIACOMIT (stiripentol)

- Member is concomitantly taking clobazam **AND**
- Member has diagnosis of seizures associated with Dravet syndrome

ELEPSIA XR (levetiracetam ER) tablet

- Member has history of trial and failure[‡] of levetiracetam ER (KEPPRA XR)

EPIDIOLEX (cannabidiol)

- Member has diagnosis of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet Syndrome **OR**

| | | |
|--|---|--|
| | SYMPAZAN (clobazam) SL film | <ul style="list-style-type: none"> Member has a diagnosis of seizures associated with tuberous sclerosis complex (TSC). |
| Valproic Acid and Derivatives | | |
| DEPAKOTE (divalproex DR) sprinkle capsule | DEPAKOTE (divalproex DR) tablet | |
| Divalproex sprinkle capsule, DR tablet, ER tablet | DEPAKOTE ER (divalproex ER) tablet | |
| Valproic acid capsule, solution | | |
| Carbamazepine Derivatives | | |
| Carbamazepine IR tablet, ER tablet, chewable, ER capsule, suspension | APTIOM (eslicarbazepine) tablet | |
| CARBATROL ER (carbamazepine) capsule | Eslicarbazepine tablet | |
| Oxcarbazepine tablet | EQUETRO (carbamazepine) capsule | |
| TEGRETOL (carbamazepine) suspension, tablet | Oxcarbazepine suspension | |
| TEGRETOL XR (carbamazepine ER) tablet | Oxcarbazepine ER (generic Oxtellar XR) tablet | |
| TRILEPTAL ^{BNR} (oxcarbazepine) suspension | OXTELLAR XR (oxcarbazepine) tablet | |
| | TRILEPTAL (oxcarbazepine) tablet | |
| Lamotrigines | | |
| Lamotrigine IR tablet, ER tablet, chewable/dispersible tablet, ODT | LAMICTAL (lamotrigine) chewable/dispersible dose pack, tablet | |
| | LAMICTAL (lamotrigine) ODT, ODT dose pack | |
| | LAMICTAL XR (lamotrigine ER) tablet, dose pack | |
| <p>FINTEPLA (fenfluramine)</p> <ul style="list-style-type: none"> Member has a diagnosis of seizures associated with Dravet syndrome or Lennox-Gastaut syndrome <p>OXTELLAR XR (oxcarbazepine ER)</p> <ul style="list-style-type: none"> Member is being treated for partial-onset seizures AND Member has history of trial and failure[‡] of any carbamazepine or oxcarbazepine-containing product <p>SPRITAM (levetiracetam) tablet for suspension</p> <ul style="list-style-type: none"> Member has history of trial and failure[‡] of levetiracetam solution <p>SYMPAZAN (clobazam) film</p> <ul style="list-style-type: none"> Member has history of trial and failure[‡] of clobazam tablet or solution OR Provider attests that member cannot take clobazam tablet or solution <p><u>Non-Preferred Products Newly Started for Non-Seizure Disorder Diagnoses:</u> Non-preferred medications newly started for non-seizure disorder diagnoses may be approved if meeting the following criteria:</p> <ul style="list-style-type: none"> Member has history of trial and failure[‡] of two preferred agents AND The prescription meets minimum age and maximum dose limits listed in Table 1. <p>[‡]Failure is defined as lack of efficacy, allergy, intolerable side effects, significant drug-drug interaction, documented contraindication to therapy, or inability to take preferred formulation. Members identified as HLA-B*15:02 positive, carbamazepine and oxcarbazepine should be avoided per Clinical Pharmacogenetics Implementation Consortium Guideline. This may be considered a trial for prior authorization approvals of a non-preferred agent.</p> | | |
| Table 1: Non-preferred Product Minimum Age and Maximum Dose | | |
| | | Minimum Age** |
| | | Maximum Dose** |
| Barbiturates | | |
| primidone (MYSOLINE) | | 2,000 mg per day |
| Benzodiazepines | | |
| clobazam (ONFI) suspension, tablet | 2 years | 40 mg per day |
| clobazam film (SYMPAZAN) | 2 years | 40 mg per day |
| clonazepam (KLONOPIIN) | | 20 mg per day |
| Brivaracetam/Levetiracetam | | |
| brivaracetam (BRIVIACT) | 1 month | 200 mg per day |
| levetiracetam (KEPPRA) | 1 month | 3,000 mg per day |

| | | | | |
|--|---|---|---------------------------------|--|
| | Lamotrigine ER/IR/ODT dose packs | levetiracetam (SPRITAM) | 4 years | 3,000 mg per day |
| | Topiramates | levetiracetam ER (ELEPSIA XR) | 12 years | 3,000 mg per day |
| | | levetiracetam ER (KEPPRA XR) | 12 years | 3,000 mg per day |
| | | Carbamazepine Derivatives | | |
| | | carbamazepine (EPITOL) | | 1,600 mg per day |
| | | carbamazepine ER (EQUETRO) | | 1,600 mg per day |
| | | eslicarbazepine (APTIOM) | 4 years | 1,600 mg per day |
| | | oxcarbazepine ER (OXTELLAR XR) | 6 years | 2,400 mg per day |
| | | Hydantoins | | |
| | | phenytoin ER (DILANTIN) 100mg capsules, suspension, Infatab | | 1,000 mg loading dose 600 mg/day maintenance dose |
| | | Lamotrigines | | |
| | | lamotrigine IR (LAMICTAL) | 2 years | 500 mg per day |
| | | lamotrigine (LAMICTAL ODT) | 2 years | 500 mg per day |
| | | lamotrigine ER (LAMICTAL XR) | 13 years | 600 mg per day |
| | Brivaracetam/Levetiracetam | Succinamides | | |
| | | ethosuximide (ZARONTIN) | 3 years | 1,500 mg/day |
| | | methsuximide (CELONTIN) | | Not listed |
| | | Valproic Acid and Derivatives | | |
| | | divalproex ER (DEPAKOTE ER) | 10 years | 60 mg/kg/day |
| | | Topiramates | | |
| | | topiramate (TOPAMAX) | 2 years | 400 mg per day |
| | | topiramate ER (QUDEXY XR) | 2 years | 400 mg per day |
| | | topiramate ER (TROKENDI XR) | 6 years | 400 mg per day |
| | | Other | | |
| | | cannabidiol (EPIDIOLEX) | 1 year | 25 mg/kg/day |
| | | cenobamate (XCOPRI) | 18 years | 400 mg per day |
| | | felbamate tablet, suspension | 2 years | 3,600 mg per day |
| | | fenfluramine (FINTEPLA) | 2 years | 26 mg per day |
| | | lacosamide (VIMPAT) | 1 month | 400 mg per day |
| | | perampanel (FYCOMPA) | 4 years | 12 mg per day |
| | | rufinamide (BANZEL) tablet and suspension | 1 year | 3,200 mg per day |
| | | stiripentol (DIACOMIT) | 6 months (weighing \geq 7 kg) | 3,000 mg per day |
| | | tiagabine | 12 years | 56 mg per day |
| | | tiagabine (GABITRIL) | 12 years | 56 mg per day |
| | | vigabatrin | 1 month | 3,000 mg per day |
| | | vigabatrin (SABRIL) | 1 month | 3,000 mg per day |
| | | vigabatrin (VIGADRONE) powder packet | 1 month | 3,000 mg per day |
| | | zonisamide (ZONEGRAN) | 16 years | 600 mg per day |
| | Other | | | |
| *Felbamate suspension | BANZEL (rufinamide) suspension, tablet | | | |
| FELBATOL (felbamate) suspension | DIACOMIT (stiripentol) capsule, powder packet | | | |
| FELBATOL (felbamate) ^{BNR} tablet | EPIDIOLEX (cannabidiol) solution | | | |
| Lacosamide solution, tablet | Felbamate tablet | | | |
| Zonisamide capsule | FINTEPLA (fenfluramine) solution | | | |
| | FYCOMPA (perampanel) suspension, tablet | | | |
| | GABITRIL (tiagabine) tablet | | | |

| | |
|---|---|
| Lacosamide UD solution MOTPOLY XR (lacosamide) capsule Perampanel tablet Rufinamide suspension, tablet SABRIL (vigabatrin) powder packet, tablet Tiagabine tablet Vigabatrin tablet, powder packet VIGAFYDE (vigabatrin) solution VIMPAT (lacosamide) solution, kit, tablet XCOPRI (cenobamate) tablet, pack ZONISADE (zonisamide) suspension ZTALMY (ganaxolone) suspension | **Limits based on data from FDA package insert. Approval for age/dosing that falls outside of the indicated range may be evaluated on a case-by-case basis. |
|---|---|

Therapeutic Drug Class: NEWER GENERATION ANTI-DEPRESSANTS – Effective 4/1/2025

| No PA Required | PA Required | |
|--|---|---|
| Bupropion IR, SR, XL tablet | | |
| Citalopram solution, tablet | <i>Non-preferred brand name medications do not require a prior authorization when the equivalent generic is preferred and “dispense as written” is indicated on the prescription.</i> | Non-preferred products may be approved for members who have failed adequate trial with two preferred newer generation anti-depressant products. If two preferred newer generation anti-depressant products are not available for indication being treated, approval of prior authorization for non-preferred products will require adequate trial of all preferred products FDA approved for that indication (failure is defined as lack of efficacy with 6-week trial, allergy, intolerable side effects, or significant drug-drug interaction). |
| Desvenlafaxine succinate ER (generic Pristiq) tablet | APLENZIN (bupropion ER) tablet | |
| Duloxetine (generic Cymbalta) capsule | AUVELITY ER (dextromethorphan/bupropion) tablet | |
| Escitalopram tablet | Bupropion XL (generic Forfivo XL) tablet | |
| Fluoxetine capsule, solution, 60 mg tablet | CELEXA (citalopram) tablet | |
| Fluvoxamine tablet | Citalopram hydrobromide capsule | |
| Mirtazapine tablet, ODT | CYMBALTA (duloxetine) capsule | |
| Paroxetine IR tablet | Desvenlafaxine fumarate ER tablet | |
| Sertraline solution, tablet | DRIZALMA (duloxetine) sprinkle capsule | |
| | EFFEXOR XR (venlafaxine ER) capsule | |
| | Escitalopram solution | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

| | | |
|-------------------------|--|---|
| Trazodone tablet | FETZIMA (levomilnacipran ER) capsule, titration pack | <ul style="list-style-type: none"> ○ Consideration for the favorable long-term safety data associated with use of SSRIs as first-line, recommended therapies for perinatal depressive disorders by the American College of Obstetricians and Gynecologists (ACOG) or SNRIs as reasonable ACOG-recommended alternatives |
| Venlafaxine IR tablet | Fluoxetine IR tablet, DR capsule | |
| Venlafaxine ER capsules | Fluvoxamine ER capsule | |
| Vilazodone tablet | FORFIVO XL (bupropion ER) tablet | |
| | LEXAPRO (escitalopram) tablet | |
| | Nefazodone tablet | |
| | Paroxetine CR/ER tablet, suspension | |
| | Paroxetine mesylate capsule | |
| | PAXIL (paroxetine) tablet, suspension | |
| | PAXIL CR (paroxetine ER) tablet | |
| | PEXEVA (paroxetine mesylate) tablet | |
| | PRISTIQ (desvenlafaxine succinate ER) tablet | |
| | PROZAC (fluoxetine) Pulvule | |
| | RALDESY (trazodone) solution | |
| | REMERON (mirtazapine) Soltab (ODT), tablet | |
| | Sertraline capsule | |
| | TRINTELLIX (vortioxetine) tablet | |
| | Venlafaxine ER tablet | |
| | Venlafaxine besylate ER tablet | |
| | VIIBRYD (vilazodone) tablet, dose pack | |
| | WELLBUTRIN SR, XL (bupropion) tablet | |
| | ZOLOFT (sertraline) tablet, oral concentrate | |
| | ZURZUVAE (zuranolone) capsule | |

Therapeutic Drug Class: MONOAMINE OXIDASE INHIBITORS (MAOIs) – Effective 4/1/2025

| | | |
|--|--------------------------------|---|
| | PA Required | |
| | EMSAM (selegiline) patch | Non-preferred products may be approved for members who have failed adequate trial (8 weeks) with two preferred anti-depressant products. If two preferred anti-depressant products are not available for indication being treated, approval of prior authorization for non-preferred products will require adequate trial of all preferred anti-depressant products FDA approved for that indication. (Failure is defined as: lack of efficacy after 8-week trial, allergy, intolerable side effects, or significant drug-drug interaction) |
| | MARPLAN (isocarboxazid) tablet | |
| | NARDIL (phenelzine) tablet | |
| | Phenelzine tablet | |

| | | |
|--|------------------------|---|
| | Tranylcypromine tablet | Members currently stabilized on a Non-preferred MAOI antidepressant may receive approval to continue that agent for one year if medically necessary. Verification may be provided from the prescriber or the pharmacy. |
|--|------------------------|---|

Therapeutic Drug Class: TRICYCLIC ANTI-DEPRESSANTS (TCAs) – Effective 4/1/2025

| No PA Required | PA Required <i>Non-preferred brand name medications do not require a prior authorization when the equivalent generic is preferred and “dispense as written” is indicated on the prescription.</i> | |
|--|--|---|
| Amitriptyline tablet | Amoxapine tablet | Non-preferred products may be approved for members who have failed adequate trial (8 weeks) with three preferred tricyclic products. If three preferred products are not available for indication being treated, approval of prior authorization for non-preferred products will require adequate trial of all tricyclic preferred products FDA approved for that indication. (Failure is defined as: lack of efficacy after 8-week trial, allergy, intolerable side effects, or significant drug-drug interaction) |
| Clomipramine capsule | ANAFRANIL (clomipramine) capsule | Members currently stabilized on a non-preferred tricyclic antidepressant may receive approval to continue on that agent for one year if medically necessary. Verification may be provided from the prescriber or the pharmacy. |
| Desipramine tablet | Imipramine pamoate capsule | |
| Doxepin 10mg, 25mg, 50mg, 75mg, 100mg, 150mg capsule, oral concentrate | NORPRAMIN (desipramine) tablet | |
| Imipramine HCl tablet | Nortriptyline solution | |
| Nortriptyline capsule | PAMELOR (nortriptyline) capsule | |
| | Protriptyline tablet | |
| | Trimipramine capsule | |

Therapeutic Drug Class: ANTI-PARKINSON'S AGENTS – Effective 4/1/2025

| Dopa decarboxylase inhibitors, dopamine precursors and combinations | | |
|---|---|--|
| No PA Required | PA Required | |
| Carbidopa/Levodopa IR, ER tablet | Carbidopa IR | Non-preferred agents may be approved with adequate trial and failure of carbidopa-levodopa IR and ER formulations (failure is defined as lack of efficacy with a 4-week trial, allergy, intolerable side effects or significant drug-drug interactions). |
| Carbidopa/Levodopa/Entacapone tablet | Carbidopa/Levodopa ODT | Carbidopa or levodopa single agent products may be approved for members with diagnosis of Parkinson's Disease as add-on therapy to carbidopa-levodopa. |
| | CREXONT ER (carbidopa/levodopa) capsule | |
| | DHIVY (carbidopa/levodopa) tablet | Non-preferred medications that <u>are not</u> prescribed for Parkinson's Disease (or an indication related to Parkinson's Disease) may receive approval for other FDA-labeled indications without meeting trial and failure step therapy criteria. |
| | DUOPA (carbidopa/levodopa) suspension | |
| | INBRIJA (levodopa) capsule for inhalation | |

| | | |
|----------------------------|--|---|
| | <p>LODOSYN (carbidopa) tablet</p> <p>RYTARY ER (carbidopa/levodopa) capsule</p> <p>SINEMET (carbidopa/levodopa) IR tablet</p> <p>STALEVO (carbidopa/levodopa/ entacapone) tablet</p> | <p>Members with history of trial and failure of a non-preferred Parkinson's Disease agent that is the brand/generic equivalent of a preferred product (same strength, dosage form and active ingredient) may be considered as having met a trial and failure of the equivalent preferred.</p> <p>Members currently stabilized on a non-preferred product may receive approval to continue therapy with that product.</p> |
| MAO-B inhibitors | | |
| No PA Required | | PA Required |
| Rasagiline tablet | AZILECT (rasagiline) tablet | Non-preferred agents may be approved with adequate trial and failure of selegiline capsule or tablet (failure is defined as lack of efficacy with a 4-week trial, allergy, intolerable side effects or significant drug-drug interactions). |
| Selegiline capsule, tablet | XADAGO (safinamide) tablet ZELAPAR (selegiline) ODT | Non-preferred medications that are not prescribed for Parkinson's Disease (or an indication related to Parkinson's Disease) may receive approval for other FDA-labeled indications without meeting trial and failure step therapy criteria. Members with history of trial and failure of a non-preferred Parkinson's Disease agent that is the brand/generic equivalent of a preferred product (same strength, dosage form and active ingredient) may be considered as having met a trial and failure of the equivalent preferred. Members currently stabilized on a non-preferred product may receive approval to continue therapy with that product. |
| Dopamine Agonists | | |
| No PA Required | | PA Required |
| Pramipexole IR tablet | APOKYN (apomorphine) SC cartridge | Non-preferred agents may be approved with adequate trial and failure of ropinirole IR AND pramipexole IR (failure is defined as lack of efficacy with 4-week trial, documented contraindication to therapy, allergy, intolerable side effects or significant drug-drug interactions). |
| Ropinirole IR tablet | Apomorphine SC cartridge Bromocriptine capsule, tablet MIRAPEX (pramipexole) ER tablet NEUPRO (rotigotine) patch PARLODEL (bromocriptine) capsule, tablet Pramipexole ER tablet Ropinirole ER tablet | <p>APOKYN (apomorphine subcutaneous cartridge) may be approved if meeting the following:</p> <ul style="list-style-type: none"> • APOKYN (apomorphine) is being used as an adjunct to other medications for acute, intermittent treatment of hypomobility, "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) in patients with advanced Parkinson's disease AND • Due to the risk of profound hypotension and loss of consciousness, member is not concomitantly using a 5HT3 antagonist such as ondansetron, granisetron, dolasetron, palonosetron or alosetron. <p>Maximum dose: 6mg (0.6mL) three times per day</p> <p>KYNMOBI (apomorphine sublingual film) may be approved if meeting the following:</p> <ul style="list-style-type: none"> • KYNMOBI (apomorphine) is being used for the acute, intermittent treatment of "off" episodes in patients with Parkinson's disease AND • Due to the risk of profound hypotension and loss of consciousness, member must not be concomitantly using a 5HT3 antagonist such as ondansetron, granisetron, dolasetron, palonosetron or alosetron. <p>Maximum dose: 30mg five times per day</p> |

| | | |
|--|--|--|
| | | <p>Non-preferred medications that <u>are not</u> prescribed for Parkinson's Disease (or an indication related to Parkinson's Disease) may receive approval for other FDA-labeled indications without meeting trial and failure step therapy criteria.</p> <p>Members with history of trial and failure of a non-preferred Parkinson's Disease agent that is the brand/generic equivalent of a preferred product (same strength, dosage form and active ingredient) may be considered as having met a trial and failure of the equivalent preferred.</p> <p>Members currently stabilized on a non-preferred product may receive approval to continue therapy with that product.</p> |
|--|--|--|

| Other Parkinson's agents | | |
|------------------------------------|------------------------------------|--|
| No PA Required | PA Required | |
| Amantadine capsule, solution/syrup | Amantadine tablet | Non-preferred agents may be approved with adequate trial and failure of two preferred agents (failure is defined as lack of efficacy with 4-week trial, documented contraindication to therapy, allergy, intolerable side effects or significant drug-drug interactions). |
| Benztropine tablet | COMTAN (entacapone) tablet | Non-preferred medications that <u>are not</u> prescribed for Parkinson's Disease (or an indication related to Parkinson's Disease) may receive approval for other FDA-labeled indications without meeting trial and failure step therapy criteria. |
| Trihexyphenidyl tablet, elixir | Entacapone tablet | Members with history of trial and failure of a non-preferred Parkinson's Disease agent that is the brand/generic equivalent of a preferred product (same strength, dosage form and active ingredient) may be considered as having met a trial and failure of the equivalent preferred. |
| | GOCOVRI ER (amantadine ER) capsule | Members currently stabilized on a non-preferred product may receive approval to continue therapy with that product. |
| | NOURIANZ (istradefylline) tablet | |
| | ONGENTYS (opicapone) capsule | |
| | OSMOLEX ER (amantadine) tablet | |
| | TASMAR (tolcapone) tablet | |
| | Tolcapone tablet | |

| Therapeutic Drug Class: BENZODIAZEPINES (NON-SEDATIVE HYPNOTIC) – Effective 4/1/2025 | | |
|---|----------------------------------|--|
| No PA Required <i>(*may be subject to age limitations)</i> | PA Required | |
| Alprazolam IR, ER tablet* | Alprazolam ODT, oral concentrate | Non-preferred products may be approved following trial and failure of three preferred agents. Failure is defined as lack of efficacy, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interactions. |
| Chlordiazepoxide capsule* | ATIVAN (lorazepam) tablet | <u>Children:</u> Prior authorization will be required for all agents when prescribed for children <18 years of age (with the exception of oral solution products) and may be approved with prescriber verification of necessity of use for member age. |
| Clonazepam tablet, ODT | Diazepam Intensol | |
| Clorazepate tablet* | KLONOPIN (clonazepam) tablet | Diazepam Intensol may be approved following trial and failure of the preferred 5 mg/5 mL oral solution. Failure is defined as intolerable side effects, drug-drug interaction, or lack of efficacy. |
| Diazepam tablet*, solution | LOREEV (lorazepam ER) capsule | |
| Lorazepam tablet*, oral concentrate | XANAX (alprazolam) tablet | |

| Oxazepam capsule* | XANAX XR (alprazolam ER) tablet | <p>All benzodiazepine anxiolytics will require prior authorization for members ≥ 65 years of age when exceeding 90 days of therapy.</p> <p>Continuation of Therapy:</p> <ul style="list-style-type: none"> • Members < 65 years of age who are currently stabilized on a non-preferred benzodiazepine medication may receive approval to continue that medication. • Members < 18 years of age who are currently stabilized on a non-preferred oral solution product may receive authorization to continue that medication. <p>Prior authorization will be required for prescribed doses that exceed the maximum (Table 1).</p> <table border="1" data-bbox="1481 437 2333 1486"> <caption>Table 1 Maximum Doses</caption> <thead> <tr> <th data-bbox="1481 437 1669 507">Product</th><th data-bbox="1669 437 2045 507">Maximum Daily Dose</th><th data-bbox="2045 437 2333 507">Maximum Monthly Dose</th></tr> </thead> <tbody> <tr> <td data-bbox="1481 507 1669 561">Alprazolam tablet</td><td data-bbox="1669 507 2045 561" rowspan="6">Adults ≥ 18 years: 10 mg/day</td><td data-bbox="2045 507 2333 561" rowspan="6">Total of 300 mg from all dosage forms per 30 days</td></tr> <tr> <td data-bbox="1481 561 1669 615">Alprazolam ER tablet</td></tr> <tr> <td data-bbox="1481 615 1669 669">Alprazolam ODT</td></tr> <tr> <td data-bbox="1481 669 1669 722">XANAX (alprazolam) tablet</td></tr> <tr> <td data-bbox="1481 722 1669 776">XANAX XR (alprazolam ER) tablet</td></tr> <tr> <td data-bbox="1481 776 1669 847">Alprazolam Intensol oral concentrate 1 mg/mL</td></tr> <tr> <td data-bbox="1481 847 1669 964">Clorazepate tablet</td><td rowspan="2">>12 years: 90 mg/day $\underline{\text{Children 9-12 years: up to 60 mg/day}}$</td><td rowspan="2">Total of 2,700 mg (adults) and 1,800 mg (children) from all tablet strengths per 30 days</td></tr> <tr> <td data-bbox="1481 964 1669 1018">TRANXENE (clorazepate) T-Tab</td></tr> <tr> <td data-bbox="1481 1018 1669 1160">Chlordiazepoxide capsule</td><td rowspan="3">$\underline{\text{Adults \geq 18 years: 300 mg/day}}$ $\underline{\text{Children 6-17 years: up to 40 mg/day (pre-operative apprehension and anxiety)}}$</td><td rowspan="3">Total of 9,000 mg (adults) and 120 mg (children, pre-op therapy) from all tablet strengths per 30 days</td></tr> <tr> <td data-bbox="1481 1160 1669 1214">Diazepam Intensol oral concentrate 5 mg/mL</td></tr> <tr> <td data-bbox="1481 1214 1669 1268">Diazepam solution 5 mg/5 mL</td></tr> <tr> <td data-bbox="1481 1268 1669 1321">Diazepam tablet</td><td rowspan="2">$\underline{\text{Adults \geq 18 years: 40 mg/day}}$ $\underline{\text{Members age 6 months to 17 years: up to 10 mg/day}}$</td><td rowspan="2">Total of 1200 mg (adults) and 300 mg (pediatrics) from all dosage forms per 30 days</td></tr> <tr> <td data-bbox="1481 1321 1669 1375">ATIVAN (lorazepam) Intensol concentrate 2 mg/mL</td></tr> <tr> <td data-bbox="1481 1375 1669 1486">ATIVAN (lorazepam) tablet</td><td>$\underline{\text{Adults \geq 18 years: 10 mg/day}}$ $\underline{\text{Children: N/A}}$</td><td>Total of 300 mg from all dosage forms per 30 days</td></tr> </tbody> </table> | Product | Maximum Daily Dose | Maximum Monthly Dose | Alprazolam tablet | Adults ≥ 18 years: 10 mg/day | Total of 300 mg from all dosage forms per 30 days | Alprazolam ER tablet | Alprazolam ODT | XANAX (alprazolam) tablet | XANAX XR (alprazolam ER) tablet | Alprazolam Intensol oral concentrate 1 mg/mL | Clorazepate tablet | >12 years: 90 mg/day $\underline{\text{Children 9-12 years: up to 60 mg/day}}$ | Total of 2,700 mg (adults) and 1,800 mg (children) from all tablet strengths per 30 days | TRANXENE (clorazepate) T-Tab | Chlordiazepoxide capsule | $\underline{\text{Adults \geq 18 years: 300 mg/day}}$ $\underline{\text{Children 6-17 years: up to 40 mg/day (pre-operative apprehension and anxiety)}}$ | Total of 9,000 mg (adults) and 120 mg (children, pre-op therapy) from all tablet strengths per 30 days | Diazepam Intensol oral concentrate 5 mg/mL | Diazepam solution 5 mg/5 mL | Diazepam tablet | $\underline{\text{Adults \geq 18 years: 40 mg/day}}$ $\underline{\text{Members age 6 months to 17 years: up to 10 mg/day}}$ | Total of 1200 mg (adults) and 300 mg (pediatrics) from all dosage forms per 30 days | ATIVAN (lorazepam) Intensol concentrate 2 mg/mL | ATIVAN (lorazepam) tablet | $\underline{\text{Adults \geq 18 years: 10 mg/day}}$ $\underline{\text{Children: N/A}}$ | Total of 300 mg from all dosage forms per 30 days |
|---|---|--|---------|--------------------|----------------------|-------------------|--------------------------------------|---|----------------------|----------------|---------------------------|---------------------------------|--|--------------------|---|--|------------------------------|--------------------------|---|--|--|-----------------------------|-----------------|--|---|---|---------------------------|--|---|
| Product | Maximum Daily Dose | Maximum Monthly Dose | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Alprazolam tablet | Adults ≥ 18 years: 10 mg/day | Total of 300 mg from all dosage forms per 30 days | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Alprazolam ER tablet | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Alprazolam ODT | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| XANAX (alprazolam) tablet | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| XANAX XR (alprazolam ER) tablet | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Alprazolam Intensol oral concentrate 1 mg/mL | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Clorazepate tablet | >12 years: 90 mg/day $\underline{\text{Children 9-12 years: up to 60 mg/day}}$ | Total of 2,700 mg (adults) and 1,800 mg (children) from all tablet strengths per 30 days | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| TRANXENE (clorazepate) T-Tab | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Chlordiazepoxide capsule | $\underline{\text{Adults \geq 18 years: 300 mg/day}}$ $\underline{\text{Children 6-17 years: up to 40 mg/day (pre-operative apprehension and anxiety)}}$ | Total of 9,000 mg (adults) and 120 mg (children, pre-op therapy) from all tablet strengths per 30 days | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Diazepam Intensol oral concentrate 5 mg/mL | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Diazepam solution 5 mg/5 mL | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Diazepam tablet | $\underline{\text{Adults \geq 18 years: 40 mg/day}}$ $\underline{\text{Members age 6 months to 17 years: up to 10 mg/day}}$ | Total of 1200 mg (adults) and 300 mg (pediatrics) from all dosage forms per 30 days | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| ATIVAN (lorazepam) Intensol concentrate 2 mg/mL | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| ATIVAN (lorazepam) tablet | $\underline{\text{Adults \geq 18 years: 10 mg/day}}$ $\underline{\text{Children: N/A}}$ | Total of 300 mg from all dosage forms per 30 days | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | |
|--|---|--|---|--|--|--|------------------|--|--|--|------------------|--|--|--|
| | | <table border="1"> <tr> <td>Lorazepam oral concentrated soln 2 mg/mL</td><td></td><td></td><td></td></tr> <tr> <td>Lorazepam tablet</td><td></td><td></td><td></td></tr> <tr> <td>Oxazepam capsule</td><td> <u>Adults > 18 years:</u> 120 mg/day <u>Children 6-18 years:</u> absolute dosage not established </td><td>Total of 3600 mg from all dosage forms per 30 days</td><td></td></tr> </table> | Lorazepam oral concentrated soln 2 mg/mL | | | | Lorazepam tablet | | | | Oxazepam capsule | <u>Adults > 18 years:</u> 120 mg/day <u>Children 6-18 years:</u> absolute dosage not established | Total of 3600 mg from all dosage forms per 30 days | |
| Lorazepam oral concentrated soln 2 mg/mL | | | | | | | | | | | | | | |
| Lorazepam tablet | | | | | | | | | | | | | | |
| Oxazepam capsule | <u>Adults > 18 years:</u> 120 mg/day <u>Children 6-18 years:</u> absolute dosage not established | Total of 3600 mg from all dosage forms per 30 days | | | | | | | | | | | | |
| Therapeutic Drug Class: ANXIOLYTIC, NON- BENZODIAZEPINES – Effective 4/1/2025 | | | | | | | | | | | | | | |
| No PA Required Buspirone tablet | | Non-preferred products may be approved following trial and failure of buspirone. Failure is defined as lack of efficacy, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interactions. | | | | | | | | | | | | |
| Therapeutic Drug Class: ATYPICAL ANTI-PSYCHOTICS - Oral and Topical – Effective 4/1/2025 | | | | | | | | | | | | | | |
| No PA Required (unless indicated by * in criteria; all products subject to dose and age limitations) | PA Required <i>Non-preferred brand name medications do not require a prior authorization when the equivalent generic is preferred and “dispense as written” is indicated on the prescription.</i> | <p>*Vraylar (cariprazine) or Rexulti (brexpiprazole) may be approved for members after trial and failure of one preferred agent. Failure is defined as contraindication, lack of efficacy with 6-week trial, allergy, intolerable side effects, significant drug-drug interactions, or known interacting genetic polymorphism that prevents safe preferred product dosing.</p> <p>Non-preferred products may be approved for members meeting all of the following:</p> <ul style="list-style-type: none"> Medication is being prescribed for an FDA-Approved indication AND Prescription meets dose and age limitations (Table 1) AND Request meets one of the following: <ul style="list-style-type: none"> Member has history of trial and failure of two preferred products with FDA approval for use for the prescribed indication (failure defined as lack of efficacy with 6-week trial, allergy, intolerable side effects (including rapid weight gain), contraindication, significant drug-drug interactions, or known interacting genetic polymorphism that prevents safe preferred product dosing) OR Prescriber attests that within the last year (365 days) the member has trialed and failed (been unsuccessfully treated with) a preferred antipsychotic medication that was used to treat the member’s diagnosis (failure defined as lack of efficacy with 6-week trial, allergy, intolerable side effects (including rapid weight gain), significant drug-drug interactions, or known interacting genetic polymorphism that prevents safe preferred product dosing). Treatment must be under an FDA approved indication for a mental health condition or disorder. | | | | | | | | | | | | |
| Aripiprazole tablet | ABILIFY (aripiprazole) tablet, MyCite | | | | | | | | | | | | | |
| Asenapine SL tablet | Aripiprazole oral solution, ODT | | | | | | | | | | | | | |
| Clozapine tablet | CAPLYTA (lumateperone) capsule | | | | | | | | | | | | | |
| Lurasidone tablet | COBENFY (xanomeline/trospium) capsule, starter pack | | | | | | | | | | | | | |
| Olanzapine tablet, ODT | Clozapine ODT | | | | | | | | | | | | | |
| Paliperidone ER tablet | CLOZARIL (clozapine) tablet, ODT | | | | | | | | | | | | | |
| Quetiapine IR tablet** | FANAPT (iloperidone tablet, titration pack) | | | | | | | | | | | | | |
| Quetiapine ER tablet | GEODON (ziprasidone) capsule | | | | | | | | | | | | | |
| REXULTI (brexpiprazole) dose pack, tablet* | INVEGA ER (paliperidone) tablet | | | | | | | | | | | | | |
| Risperidone ODT, oral solution, tablet | LATUDA (lurasidone) tablet | | | | | | | | | | | | | |
| VRAYLAR (cariprazine) 1.5mg, 3mg, 4.5mg, 6mg capsule* | LYBALVI (olanzapine/samidorphan) tablet | | | | | | | | | | | | | |
| Ziprasidone capsule | | Age Limits: All products including preferred products will require a PA for members younger than the FDA approved age for the agent (Table 1). Members younger than the FDA approved age for the agent who are currently stabilized on an atypical antipsychotic will be eligible for approval. | | | | | | | | | | | | |

| | |
|---|---|
| NUPLAZID (pimavanserin) capsule, tablet Olanzapine/Fluoxetine capsule OPIPZA (aripiprazole) film RISPERDAL (risperidone) tablet, oral solution SAPHRIS (asenapine) SL tablet SECUADO (asenapine) patch SEROQUEL IR (quetiapine IR) tablet*** SEROQUEL XR (quetiapine ER) tablet SYMBYAX (olanzapine/fluoxetine) capsule VERSACLOZ (clozapine) suspension VRAYLAR (cariprazine) 0.5mg, 0.75mg capsule ZYPREXA (olanzapine) tablet ZYPREXA ZYDIS (olanzapine) ODT | <p>Atypical Antipsychotic prescriptions for members under 5 years of age may require a provider-provider telephone consult with a child and adolescent psychiatrist (provided at no cost to provider or member).</p> <p>**Quetiapine IR when given at subtherapeutic doses may be restricted for therapy. Low-dose quetiapine (<150mg/day) is only FDA approved as part of a drug titration schedule to aid patients in getting to the target quetiapine dose. PA will be required for quetiapine < 150mg per day except for utilization (when appropriate) in members 65 years or older. PA will be approved for members 10-17 years of age with approved diagnosis (Table 1) stabilized on <150mg quetiapine IR per day.</p> <p>Aripiprazole solution: Aripiprazole <u>tablet</u> quantity limit is 2 tablets/day for pediatric members to allow for incremental dose titration and use of the preferred tablet formulation should be considered for dose titrations when possible and clinically appropriate. If incremental dose cannot be achieved with titration of the aripiprazole tablet for members < 18 years of age OR for members unable to swallow solid tablet dosage form, aripiprazole solution may be approved. For all other cases, aripiprazole solution is subject to meeting non-preferred product approval criteria listed above.</p> <p>Nuplazid (pimavanserin tartrate) may be approved for the treatment of hallucinations and delusions associated with Parkinson's Disease psychosis AND following trial and failure of therapy with quetiapine or clozapine, or clinical rationale is provided supporting why these medications cannot be trialed. Failure will be defined as contraindication, intolerable side effects, drug-drug interaction, or lack of efficacy.</p> <p>Abilify MyCite may be approved if meeting all of the following:</p> <ul style="list-style-type: none"> Member has history of adequate trial and failure of 5 preferred agents (one trial must include aripiprazole tablet). Failure is defined as lack of efficacy with 6-week trial on maximally tolerated dose, allergy, intolerable side effects, significant drug-drug interactions AND Information is provided regarding adherence measures being recommended by provider and followed by member (such as medication organizer or digital medication reminders) AND Member has history of adequate trial and failure of 3 long-acting injectable formulations of atypical antipsychotics, one of which must contain aripiprazole (failure is defined as lack of efficacy with 8-week trial, contraindication, allergy, intolerable side effects, significant drug-drug interactions) AND Abilify MyCite is being used with a MyCite patch and member is using a compatible mobile application. AND Medication adherence information is being shared with their provider via a web portal or dashboard. <p>Quantity Limits: Quantity limits will be applied to all products (Table 1). In order to receive approval for off-label dosing, the member must have an FDA approved indication and must have tried and failed on the FDA approved dosing regimen.</p> <p>Members currently stabilized on a non-preferred atypical antipsychotic may receive approval to continue therapy with that agent for one year.</p> |
|---|---|

Therapeutic Drug Class: **ATYPICAL ANTI-PSYCHOTCS – Injectables** – Effective 10/1/2025

| No PA Required | PA Required | |
|--|---|--|
| ABILIFY ASIMTUFII (ariPIPrazole) syringe, vial | <i>Non-preferred brand name medications do not require a prior authorization when the equivalent generic is preferred and “dispense as written” is indicated on the prescription.</i> | Preferred products do not require prior authorization. All products are subject to meeting FDA-labeled dosing quantity limits listed in Table 1. |
| ABILIFY MAINTENA (ariPIPrazole) syringe, vial | GEODON (ziprasidone) vial | Non-preferred products may be approved for members meeting the following: |
| ARISTADA ER (ariPIPrazole lauroxil) syringe | Risperidone microspheres ER vial | <ul style="list-style-type: none"> Medication is being prescribed for an FDA-Approved indication AND Prescription meets dose limitations (Table 1) AND Member has history of trial and failure of one preferred product with FDA approval for use for the prescribed indication (failure is defined as lack of efficacy with 6-week trial, allergy, intolerable side effects, contraindication, significant drug-drug interactions, or known interacting genetic polymorphism that prevents safe preferred product dosing). |
| ARISTADA INITIO (ariPIPrazole lauroxil) syringe | RYKINDO (risperidone microspheres) vial, vial kit | |
| Chlorpromazine ampule, vial | ZYPREXA (olanzapine) vial | |
| Fluphenazine vial | | |
| Fluphenazine decanoate vial | | |
| HALDOL (haloperidol decanoate) ampule | | |
| Haloperidol decanoate ampule, vial | | |
| Haloperidol lactate syringe, vial | | |
| INVEGA HAFYERA (paliperidone palmitate) syringe | | |
| INVEGA SUSTENNA (paliperidone palmitate) syringe | | |
| INVEGA TRINZA (paliperidone palmitate) syringe | | |
| Olanzapine vial | | |
| PERSERIS ER (risperidone) syringe, syringe kit | | |
| RISPERDAL CONSTA ^{BNR} (risperidone microspheres) syringe, vial | | |
| UZEDY (risperidone) syringe | | |
| Ziprasidone | | |
| ZYPREXA RELPREVV (olanzapine pamoate) Vial kit | | |

Table 1: FDA-Labeled Dosing Quantity Limits

| Long-Acting injectable | Route | Quantity Limit |
|----------------------------------|--------------|---|
| ABILIFY ASIMTUFII (ariPIPrazole) | IM | 1 pack/2 months (56 days) |
| ABILIFY MAINTENA (ariPIPrazole) | IM | 1 pack/28 days |
| ARISTADA ER (ariPIPrazole) | IM | 1,064 mg: 1 pack/2 months (56 days) All other strengths: 1 pack/28 days |
| ARISTADA INITIO (ariPIPrazole) | IM | 1 pack/7 weeks (49 days) |
| INVEGA HAFYERA (paliperidone) | IM | 1 pack/6 months (168 days) |
| INVEGA SUSTENNA (paliperidone) | IM | 156 mg: 2 packs/5 weeks (35 days) All other strengths: 1 pack/28 days |
| INVEGA TRINZA (paliperidone) | IM | 1 pack/3 months (84 days) |
| PERSERIS ER (risperidone) | Subcutaneous | 1 pack/28 days |
| RISPERDAL CONSTA (risperidone) | IM | 2 packs/28 days |
| UZEDY ER (risperidone) | Subcutaneous | 150 mg, 200 mg and 250 mg: 1 pack/2 months (56 days) All other strengths: 1 pack/28 days |
| ZYPREXA RELPREVV (olanzapine) | IM | 405 mg: 1 pack/28 days All other strengths: 1 pack/14 days |

*Requests for dosing regimens exceeding maximum may be approved for one year with prescriber attestation that the member is stabilized on the requested dose and schedule.

Note: Effective January 14, 2022, no place of service prior authorization is required for extended-release injectable medications (LAIs) used for the treatment of mental health or substance use disorders (SUD), when administered by a healthcare professional and billed under the pharmacy benefit. In addition, LAIs may be administered in any setting (pharmacy, clinic, medical office or member home) and billed to the pharmacy or medical benefit as most appropriate and in accordance with all Health First Colorado billing policies.

| Table 1 Atypical Antipsychotics – FDA Approved Indication, Age Range, Quantity and Maximum Dose | | | | | |
|--|-------------------------|---|---|---|---|
| Brand | Generic | Approved Indications | Age Range | Maximum Daily Dose by Age/Indication | Quantity and Maximum Dose Limitations |
| ABILIFY | aripiprazole | Schizophrenia Bipolar I Disorder Bipolar I Disorder Irritability w/autistic disorder Tourette's disorder Adjunctive treatment of MDD | ≥ 13 years ≥ 18 years 10-17 years 6-17 years 6-18 years ≥ 18 years | 30 mg 30 mg 30 mg 15 mg 20 mg (weight-based) 15 mg | Maximum one tablet per day (maximum of two tablets per day allowable for members < 18 years of age to accommodate for incremental dose changes) |
| CAPLYTA | lumateperone | Schizophrenia Bipolar I Disorder Bipolar II Disorder | ≥ 18 years | 42 mg | Maximum dosage of 42mg per day |
| CLOZARIL | clozapine | Treatment-resistant schizophrenia Recurrent suicidal behavior in schizophrenia or schizoaffective disorder | ≥ 18 years | 900 mg | Maximum dosage of 900mg per day |
| COBENFY | xanomeline and trospium | Schizophrenia | ≥ 18 years | 250 mg xanomeline and 60 mg trospium | Maximum two capsules per day |
| FANAPT | iloperidone | Schizophrenia Bipolar I Disorder | ≥ 18 years | 24 mg | Maximum two tablets per day |

| | | | | | | |
|-------------|----------------------------|--|--|--|---|--|
| GEODON | ziprasidone | Schizophrenia Bipolar I Disorder | ≥ 18 years ≥ 18 years | 200 mg 160 mg | Maximum two capsules per day | |
| INVEGA ER | paliperidone | Schizophrenia & schizoaffective disorder | ≥ 12 years and weight ≥ 51 kg ≥ 12 years and weight < 51 kg | 12 mg 6 mg | Maximum two 6mg tablets per day; all other strengths 1 tablet per day | |
| LATUDA | lurasidone | Schizophrenia Schizophrenia Bipolar I disorder Bipolar I disorder | ≥ 18 years 13-17 years ≥ 18 years 10-17 years | 160 mg 80 mg 120 mg 80 mg | Maximum one tablet per day (If dosing 160mg for schizophrenia, then max of two tablets per day) | |
| LYBALVI | olanzapine and samidorphan | Schizophrenia in adults Bipolar I disorder in adults | ≥ 18 years ≥ 18 years | 20 mg olanzapine and 10 mg samidorphan | Maximum one tablet per day | |
| NUPLAZID | pimavanserin | Parkinson's disease psychosis | ≥ 18 years | 34 mg | Maximum dosage of 34mg per day | |
| RISPERDAL | risperidone | Schizophrenia Schizophrenia Bipolar mania Irritability w/autistic disorder | ≥ 18 years 13-17 years ≥ 10 years 5-17 years | 16 mg 6 mg 6 mg 3 mg | Maximum dosage of 16mg/day (4 tablet/day limitation applied in claims system to allow for dose escalation and tapering) | |
| REXULTI | brexpiprazole | Schizophrenia Adjunctive treatment of MDD Agitation associated with Alzheimer's disease (AD) | ≥ 13 years ≥ 18 years | 4 mg 3 mg | Maximum of 3mg/day for MDD adjunctive therapy, and agitation due to AD, Maximum of 4mg/day for schizophrenia | |
| SAPHRIS | asenapine | Schizophrenia Bipolar mania or mixed episodes | ≥ 18 years ≥ 10 years | 20 mg 20 mg | Maximum two tablets per day | |
| SECUADO | asenapine patch | Schizophrenia | ≥ 18 years | 7.6 mg/ 24 hours | Maximum 1 patch per day | |
| SEROQUEL | quetiapine | Schizophrenia Schizophrenia Bipolar I mania or mixed Bipolar I mania or mixed Bipolar I depression Bipolar I Disorder Maintenance | ≥ 18 years 13-17 years ≥ 18 years 10-17 years ≥ 18 years ≥ 18 years | 750 mg 800 mg 800 mg 600 mg 300 mg 800 mg | Maximum three tablets per day | |
| SEROQUEL XR | quetiapine ER | Schizophrenia Bipolar I mania Bipolar I mania Bipolar I depression Adjunctive treatment of MDD | ≥ 13 years ≥ 18 years 10-17 years ≥ 18 years ≥ 18 years | 800 mg 800 mg 600 mg 300 mg 300 mg | Maximum one tablet per day (for 300mg & 400mg tablets max 2 tablets per day) | |
| SYMBYAX | olanzapine/ fluoxetine | Acute depression in Bipolar I Disorder Treatment resistant depression (MDD) | ≥ 10 years | 12 mg olanzapine/ 50 mg fluoxetine | Maximum three capsules per day (18mg olanzapine/75mg fluoxetine) | |
| VERSACLOZ | clozapine | Treatment-resistant schizophrenia Recurrent suicidal behavior in schizophrenia or schizoaffective disorder | ≥ 18 years ≥ 18 years | 900 mg | Maximum dosage of 900 mg per day | |

| | | | | | | | |
|--|-----------------------------|-------------|--|--|------------------------------|----------------------------|--|
| | VRAYLAR | cariprazine | Schizophrenia Acute manic or mixed episodes with Bipolar I disorder Depressive episodes with Bipolar I disorder Adjunctive treatment of MDD | ≥ 18 years ≥ 18 years ≥ 18 years ≥ 18 years | 6 mg 6 mg 3 mg 3 mg | Maximum dosage of 6mg/day | |
| | ZYPREXA ZYPREXA ZYDIS | olanzapine | Schizophrenia Acute manic or mixed episodes with Bipolar I disorder | ≥ 13 years | 20 mg | Maximum one tablet per day | |

Therapeutic Drug Class: CALCITONIN GENE – RELATED PEPTIDE INHIBITORS (CGRPis) – Effective 4/1/2025

| PA Required for all agents | | *Preferred agents may be approved if meeting the following criteria: | | |
|--|---|---|--|--|
| Preferred <ul style="list-style-type: none"> * AIMOVID (erenumab-aooe) auto-injector * AJOVY (fremanezumab-vfrm) auto-injector, syringe * EMGALITY (galcanezumab-gnlm) pen, 120 mg syringe * NURTEC (rimegepant) ODT * UBRELVY (ubrogepant) tablet | Non-Preferred <ul style="list-style-type: none"> EMGALITY (galcanezumab-gnlm) 100 mg syringe QULIPTA (atogepant) tablet ZAVZPRET (zavegepant) nasal | <p>Preferred Medications for Migraine Prevention (must meet all of the following):</p> <ul style="list-style-type: none"> • The requested medication is being used as preventive therapy for episodic or chronic migraine AND • Member has diagnosis of migraine with or without aura AND • Member has tried and failed 2 oral preventive pharmacological agents listed as Level A per the most current American Headache Society/American Academy of Neurology guidelines (such as divalproex, topiramate, metoprolol, propranolol). Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction OR • If the prescribed medication is Nurtec, the member has tried and failed two preferred injectable product formulations. Failure is defined as lack of efficacy, contraindication to therapy, allergy, intolerable side effects, significant drug-drug interaction, severe needle phobia, or member (or parent/caregiver) is unable to administer preferred CGRP inhibitor injectable formulation due to limited functional ability (such as vision impairment, limited manual dexterity and/or limited hand strength). <p>Preferred Medications for Acute Migraine Treatment (must meet all of the following):</p> <ul style="list-style-type: none"> • The requested medication is being used as acute treatment for migraine headache AND • Member has history of trial and failure of two triptans (failure is defined as lack of efficacy with 4-week trial, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interaction, severe needle phobia, or member (or parent/caregiver) is unable to administer preferred triptan injectable formulation due to limited functional ability (such as vision impairment, limited manual dexterity and/or limited hand strength). <p>Non-Preferred Medications for Migraine Prevention (must meet all of the following):</p> <ul style="list-style-type: none"> • The requested medication is being used as preventive therapy for episodic or chronic migraine AND • Member has diagnosis of migraine with or without aura AND • Member has tried and failed two oral preventive pharmacological agents listed as Level A per the most current American Headache Society/American Academy of Neurology guidelines (such as divalproex, topiramate, | | |

metoprolol, propranolol). Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction AND

- The requested medication is not being used in combination with another CGRP medication AND
- The member has history of adequate trial and failure of three preferred products indicated for preventive therapy (failure is defined as lack of efficacy with 4-week trial, contraindication to therapy, allergy, intolerable side effects, significant drug-drug interaction, severe needle phobia, or member (or parent/caregiver) is unable to administer preferred triptan injectable formulation due to limited functional ability (such as vision impairment, limited manual dexterity and/or limited hand strength).

Non-Preferred Medications for Acute Migraine Treatment (must meet all of the following):

- Member is 18 years of age or older AND
- Medication is being prescribed to treat migraine headache with moderate to severe pain AND
- The requested medication is not being used in combination with another CGRP medication AND
- Member has history of trial and failure with all of the following (failure is defined as lack of efficacy with 4-week trial, allergy, contraindication, intolerable side effects, or significant drug-drug interaction):
 - Two triptans AND
 - One NSAID agent AND
 - One preferred agent indicated for acute migraine treatment

Non-Preferred Medications for Treatment of Episodic Cluster Headache (must meet all of the following):

- Member is 19-65 years of age AND
- Member meets diagnostic criteria for episodic cluster headache (has had no more than 8 attacks per day, a minimum of one attack every other day, and at least 4 attacks during the week prior to this medication being prescribed) AND
- Member is not taking other preventive medications to reduce the frequency of cluster headache attacks AND
- Member has history of trial and failure of all of the following (failure is defined as lack of efficacy with 4-week trial, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interaction):
 - Oxygen therapy AND
 - Sumatriptan subcutaneous or intranasal OR zolmitriptan intranasal
- Initial authorization will be limited to 8 weeks. Continuation (12-month authorization) will require documentation of clinically relevant improvement with no less than 30% reduction in headache frequency in a 4-week period.

Age Limitations:

All products: ≥ 18 years

Table 1. Calcitonin Gene-Related Peptide Inhibitor Quantity Limits

| Drug Name | Maximum Dosing |
|-------------------------------|--|
| Aimovig (erenumab) | one 140 mg autoinjector per 30 days |
| Ajovy (fremanezumab) | one 225 mg autoinjector or syringe per 30 days or three 225 mg autoinjectors or syringes every 90 days |
| Emgality 100mg (galcanezumab) | three 100 mg prefilled syringes per 30 days |

| | | | |
|--|--|--------------------------------|---|
| | | Emgality 120 mg (galcanezumab) | two 120 mg pens or prefilled syringes once as first loading dose then one 120 mg pen or prefilled syringe per 30 days |
| | | Nurtec (rimegepant) | Prevention: 16 tablets/30 days; Acute Treatment: 8 tablets/30 days |
| | | Qulipta (atogepant) | 30 tablets/30 days |
| | | Ubrelvy 50 mg (ubrogepant) | 16 tablets/30 days |
| | | Ubrelvy 100 mg (ubrogepant) | 16 tablets/30 days |
| | | ZAVZPRET (zavegepant) | 6 unit-dose nasal spray devices per 30 days |

Members with current prior authorization approval on file for a preferred agent may receive approval for continuation of therapy with the preferred agent.

Therapeutic Drug Class: LITHIUM AGENTS – Effective 4/1/2025

| No PA Required | PA Required | |
|-----------------------------------|--|---|
| Lithium carbonate capsule, tablet | <i>Non-preferred brand name medications do not require a prior authorization when the equivalent generic is preferred and “dispense as written” is indicated on the prescription.</i> | Non-preferred products may be approved with trial and failure of one preferred agent (failure is defined as lack of efficacy with 6-week trial, allergy, intolerable side effects, significant drug-drug interactions, intolerance to dosage form). |
| Lithium citrate solution | LITHOBID ER (lithium ER) tablet | Members currently stabilized on a non-preferred product may receive approval to continue therapy with that product. |
| Lithium ER tablet | | |

Therapeutic Drug Class: NEUROCOGNITIVE DISORDER AGENTS – Effective 4/1/2025

| Preferred *Must meet eligibility criteria | Non-Preferred PA Required | |
|--|--|---|
| *Donepezil 5mg, 10mg tablet | ADLARITY (donepezil) patch | *Eligibility criteria for Preferred Agents – Preferred products may be approved for a diagnosis of neurocognitive disorder (eligible for AutoPA automated approval). |
| *Donepezil ODT | ARICEPT (donepezil) tablet | Non-preferred products may be approved if the member has failed treatment with one of the preferred products in the last 12 months. (Failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions) |
| *Galantamine IR tablet | Donepezil 23mg tablet | Members currently stabilized on a non-preferred product may receive approval to continue on that agent for one year if medically necessary and if there is a diagnosis of neurocognitive disorder. |
| *Memantine IR tablet, dose pack | EXELON (rivastigmine) patch | |
| *Memantine ER capsule | Galantamine solution, ER capsule | |
| *Rivastigmine capsule, patch | Memantine IR solution | |
| | MESTINON (pyridostigmine) IR/ER tablet, syrup | |
| | Nemantine/donepezil ER capsule, | |
| | NAMZARIC (memantine/donepezil ER) capsule, dose pack | |

| | | |
|--|--------------------------------------|---|
| | Pyridostigmine syrup, IR/ER tablet | |
| Therapeutic Drug Class: SEDATIVE HYPNOTICS – Effective 4/1/2025 | | |
| Non-Benzodiazepines | | |
| Preferred No PA Required* (Unless age, dose, or duplication criteria apply) | Non-Preferred PA Required | |
| Eszopiclone tablet | AMBIEN (zolpidem) tablet | Non-preferred non-benzodiazepine sedative hypnotics may be approved for members who have failed treatment with two preferred non-benzodiazepine agents (failure is defined as lack of efficacy with a 2-week trial, allergy, intolerable side effects, or significant drug-drug interaction). |
| Ramelteon tablet | AMBIEN CR (zolpidem ER) tablet | <u>Children:</u> Prior authorization will be required for all agents for members < 18 years of age. |
| Zaleplon capsule | BELSOMRA (suvorexant) tablet | <u>Duplications:</u> Only one agent in the sedative hypnotic drug class will be approved at a time (concomitant use of agents in the same sedative hypnotic class or differing classes will not be approved). |
| Zolpidem IR, ER tablet | DAYVIGO (lemborexant) tablet | All sedative hypnotics will require prior authorization for members ≥ 65 years of age when exceeding 90 days of therapy. |
| | Doxepin tablet | |
| | EDLUAR (zolpidem) SL tablet | Belsomra (suvorexant) may be approved for adult members that meet the following: |
| | HETLIOZ (tasimelteon) capsule | <ul style="list-style-type: none"> Member has trialed and failed therapy with two preferred agents (failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction) AND |
| | HETLIOZ LQ (tasimelteon) suspension | <ul style="list-style-type: none"> Member is not receiving strong CYP3A4 inhibitors (such as erythromycin, clarithromycin, telithromycin, itraconazole, ketoconazole, posaconazole, fluconazole, voriconazole, delavirdine, and milk thistle) or strong CYP3A4 inducers (such as carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifampin, rifabutin, rifapentine, dexamethasone, efavirenz, etravirine, nevirapine, darunavir/ritonavir, ritonavir, and St John's Wort) AND |
| | LUNESTA (eszopiclone) tablet | <ul style="list-style-type: none"> Member does not have a diagnosis of narcolepsy |
| | QUVIVIQ (daridorexant) tablet | |
| | ROZEREM (ramelteon) tablet | Dayvigo (lemborexant) may be approved for adult member that meet the following: |
| | SILENOR (doxepin) tablet | <ul style="list-style-type: none"> Member has trialed and failed therapy with two preferred agents AND Belsomra (suvorexant). Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction AND |
| | Tasimelteon capsule | <ul style="list-style-type: none"> Member is not receiving strong CYP3A4 inhibitors (such as erythromycin, clarithromycin, telithromycin, itraconazole, ketoconazole, posaconazole, fluconazole, voriconazole, delavirdine, and milk thistle) or strong CYP3A4 inducers (such as carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifampin, rifabutin, rifapentine, dexamethasone, efavirenz, etravirine, nevirapine, darunavir/ritonavir, ritonavir, and St John's Wort) AND |
| | Zolpidem capsule, SL tablet | <ul style="list-style-type: none"> Member does not have a diagnosis of narcolepsy |
| | | Hetlioz (tasimelteon) capsules may be approved for members meeting the following criteria: |
| | | <ul style="list-style-type: none"> Member is ≥18 years of age and has a documented diagnosis of Non-24-hour sleep wake disorder (Non-24) OR |

| | | |
|--|---|--|
| | | <ul style="list-style-type: none"> Member is ≥ 16 years of age and has a documented diagnosis of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) AND The requested medication is being prescribed by a sleep specialist or a practitioner who has sufficient education and experience to safely prescribe tasimelteon <p>Hetlioz LQ (tasimelteon) oral suspension may be approved for members meeting the following criteria:</p> <ul style="list-style-type: none"> Member is 3 to 15 years of age and has a documented diagnosis of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) AND the requested medication is being prescribed by a sleep specialist or a practitioner who has sufficient education and experience to safely prescribe tasimelteon. <p>Silenor (doxepin) may be approved for adult members that meet ONE of the following criteria:</p> <ul style="list-style-type: none"> Member has tried and failed two preferred oral sedative hypnotics (Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction) OR Provider attests to the medical necessity of prescribing individual doxepin doses of less than 10 mg, OR Member's age is ≥ 65 years <p>Prior authorization will be required for prescribed doses exceeding maximum (Table 1) below.</p> |
| <p>Preferred No PA Required* (Unless age, dose, or duplication criteria apply)</p> <p>Temazepam 15mg, 30mg capsule Triazolam tablet</p> | <p>Non-Preferred PA Required</p> <p>DORAL (quazepam) tablet Estazolam tablet Flurazepam capsule HALCION (triazolam) tablet Quazepam tablet RESTORIL (temazepam) capsule Temazepam 7.5mg, 22.5mg capsule</p> | <p>Benzodiazepines</p> <p>Non-preferred benzodiazepine sedative hypnotics may be approved for members who have trialed and failed therapy with two preferred benzodiazepine agents (failure is defined as lack of efficacy with a 2-week trial, allergy, intolerable side effects, or significant drug-drug interaction).</p> <p>Temazepam 22.5 mg may be approved if the member has trialed and failed temazepam 15mg or 30mg AND one other preferred product (failure is defined as lack of efficacy with a 2-week trial, allergy, intolerable side effects, or significant drug-drug interaction).</p> <p>Temazepam 7.5 mg may be approved if provider attests to the medical necessity of prescribing individual temazepam doses of less than 15 mg.</p> <p><u>Children:</u> Prior authorization will be required for all sedative hypnotic agents when prescribed for members < 18 years of age.</p> <p><u>Duplications:</u> Only one agent in the sedative hypnotic drug class will be approved at a time (concomitant use of agents in the same sedative hypnotic class or differing classes will not be approved).</p> <p>All sedative hypnotics will require prior authorization for member's ≥ 65 years of age when exceeding 90 days of therapy.</p> <p>Members currently stabilized on a non-preferred benzodiazepine medication may receive authorization to continue that medication.</p> <p>Prior authorization will be required for prescribed doses exceeding maximum (Table 1).</p> |

Table 1: Sedative Hypnotic Maximum Dosing

| Brand | Generic | Maximum Dose |
|--------------------|---------------------|---|
| Non-Benzodiazepine | | |
| Ambien CR | Zolpidem CR | 12.5 mg/day |
| Ambien IR | Zolpidem IR | 10 mg/day |
| Belsomra | Suvorexant | 20 mg/day |
| Dayvigo | Lemborexant | 10 mg/day |
| Edluar | Zolpidem sublingual | 10 mg/day |
| - | Zolpidem sublingual | Men: 3.5mg/day Women: 1.75 mg/day |
| Hetlioz | Tasimelteon capsule | 20 mg/day |
| Hetlioz LQ | Tasimelteon liquid | ≤ 28 kg: 0.7 mg/kg/day > 28 kg : 20 mg/day |
| Lunesta | Eszopiclone | 3 mg/day |
| Quviqui | Daridorexant | 50 mg/day |
| - | Zaleplon | 20 mg/day |
| Rozerem | Ramelteon | 8 mg/day |
| Benzodiazepine | | |
| Halcion | Triazolam | 0.5 mg/day |
| Restoril | Temazepam | 30 mg/day |
| Silenor | Doxepin | 6mg/day |
| - | Estazolam | 2 mg/day |
| - | Flurazepam | 30 mg/day |
| Doral | Quazepam | 15 mg/day |

Therapeutic Drug Class: SKELETAL MUSCLE RELAXANTS – Effective 4/1/2025

| No PA Required (*if under 65 years of age) | PA Required | |
|---|--|---|
| Baclofen tablet | AMRIX ER (cyclobenzaprine ER) capsule | All agents in this class will require a PA for members 65 years of age and older. The maximum allowable approval will be for a 7-day supply. |
| Cyclobenzaprine tablet | Baclofen solution, suspension | Authorization for any CARISOPRODOL product will be given for a maximum 3-week one-time authorization for members with acute, painful musculoskeletal conditions who have failed treatment with three preferred products within the last 6 months. |
| Methocarbamol tablet | Carisoprodol tablet | |
| Tizanidine tablet | Carisoprodol/Aspirin tablet Chlorzoxazone tablet Cyclobenzaprine ER capsule DANTRIUM (dantrolene) capsule | <p>*Dantrolene may be approved for members who have trialed and failed‡ one preferred agent and meet the following criteria:</p> <ul style="list-style-type: none"> • Documentation of age-appropriate liver function tests AND • One of following diagnoses: Multiple Sclerosis, Cerebral Palsy, stroke, upper motor neuron disorder, or spinal cord injury • Dantrolene will be approved for the period of one year • If a member is stabilized on dantrolene, they may continue to receive approval |

| | | |
|--|---|--|
| | <p>*Dantrolene capsule</p> <p>FEXMID (cyclobenzaprine) tablet</p> <p>FLEQSUVY (baclofen) solution</p> <p>LORZONE (chlorzoxazone) tablet</p> <p>LYVISPAH (baclofen) granules</p> <p>Metaxalone tablet</p> <p>NORGESIC/NORGESIC FORTE (orphenadrine/aspirin/caffeine) tablet</p> <p>Orphenadrine ER tablet</p> <p>Orphenadrine/Aspirin/Caffeine tablet</p> <p>SOMA (carisoprodol) tablet</p> <p>Tizanidine capsule</p> <p>ZANAFLEX (tizanidine) capsule, tablet</p> | <p>All other non-preferred skeletal muscle relaxants may be approved for members who have trialed and failed‡ three preferred agents. ‡Failure is defined as: lack of efficacy with 14-day trial, allergy, intolerable side effects, contraindication to, or significant drug-drug interactions.</p> |
|--|---|--|

Therapeutic Drug Class: STIMULANTS AND RELATED AGENTS – Effective 4/1/2025

| Preferred *No PA Required (if age, max daily dose, and diagnosis met) | Non-Preferred PA Required | <p>*Preferred medications may be approved through AutoPA for indications listed in Table 1 (preferred medications may also receive approval for off-label use for fatigue associated with multiple sclerosis).</p> <p>Non-preferred medications may be approved for members meeting the following criteria (for Sunosi (solriamfetol) and Wakix (pitolisant), refer to specific criteria listed below):</p> <ul style="list-style-type: none"> • Prescription meets indication/age limitation criteria (Table 1) AND • <u>If member is ≥ 6 years of age:</u> <ul style="list-style-type: none"> ○ Has documented trial and failure‡ with three preferred products in the last 24 months AND ○ If the member is unable to swallow solid oral dosage forms, two of the trials must be methylphenidate solution, dexmethylphenidate ER, Vyvanse, Adderall XR, or any other preferred product that can be taken without the need to swallow a whole capsule. <p>OR</p> <ul style="list-style-type: none"> • <u>If member is 3–5 years of age:</u> <ul style="list-style-type: none"> ○ Has documented trial and failure‡ with one preferred product in the last 24 months AND |
|--|---|---|
| <p><i>Brand/generic changes effective 08/08/2024</i></p> <p>Amphetamine salts, mixed ER (generic Adderall XR) capsule</p> <p>Amphetamine salts, mixed (generic Adderall IR) tablet</p> <p>Armodafinil tablet</p> <p>Atomoxetine capsule</p> <p>Clonidine ER tablet</p> <p>DAYTRANA^{BNR} (methylphenidate) patch</p> | <p>ADDERALL IR (amphetamine salts, mixed IR) tablet</p> <p>ADDERALL XR (amphetamine salts, mixed ER) capsule</p> <p>ADZENYS XR-ODT (amphetamine)</p> <p>Amphetamine tablet (generic Evekeo)</p> <p>APTENSIO XR (methylphenidate ER) capsule</p> <p>AZSTARYS (serdexmethylphenidate/ dexmethylphenidate) capsule</p> <p>CONCERTA (methylphenidate ER) tablet</p> <p>COTEMPLA XR-ODT (methylphenidate ER)</p> | <p>*Preferred medications may be approved through AutoPA for indications listed in Table 1 (preferred medications may also receive approval for off-label use for fatigue associated with multiple sclerosis).</p> <p>Non-preferred medications may be approved for members meeting the following criteria (for Sunosi (solriamfetol) and Wakix (pitolisant), refer to specific criteria listed below):</p> <ul style="list-style-type: none"> • Prescription meets indication/age limitation criteria (Table 1) AND • <u>If member is ≥ 6 years of age:</u> <ul style="list-style-type: none"> ○ Has documented trial and failure‡ with three preferred products in the last 24 months AND ○ If the member is unable to swallow solid oral dosage forms, two of the trials must be methylphenidate solution, dexmethylphenidate ER, Vyvanse, Adderall XR, or any other preferred product that can be taken without the need to swallow a whole capsule. <p>OR</p> <ul style="list-style-type: none"> • <u>If member is 3–5 years of age:</u> <ul style="list-style-type: none"> ○ Has documented trial and failure‡ with one preferred product in the last 24 months AND |

| | | |
|---|---|--|
| Dexmethylphenidate IR tablet | DESOXYN (methamphetamine) tablet | <ul style="list-style-type: none"> ○ If the member is unable to swallow solid oral dosage forms, the trial must be methylphenidate solution, dexmethylphenidate ER, Vyvanse, Adderall XR, or any other preferred product that can be taken without the need to swallow a whole capsule. |
| Dexmethylphenidate ER capsule | DEXEDRINE (dextroamphetamine) Spansule | |
| Guanfacine ER tablet | Dextroamphetamine ER capsule, solution, tablet | |
| Methylphenidate (generic Methylin/Ritalin) solution, tablet | DYANAVEL XR (amphetamine) suspension, tablet | SUNOSI (solriamfetol) prior authorization may be approved if member meets the following criteria: <ul style="list-style-type: none"> ● Member is 18 years of age or older AND ● Member has diagnosis of either narcolepsy or obstructive sleep apnea (OSA) and is experiencing excessive daytime sleepiness AND ● Member does not have end stage renal disease AND ● If Sunosi is being prescribed for OSA, member has 1 month trial of CPAP AND ● Member has trial and failure[‡] of modafinil AND armodafinil AND one other agent in stimulant PDL class. |
| Methylphenidate ER tablet (generic Concerta) | EVEKEO (amphetamine) ODT, tablet | |
| Modafinil tablet | FOCALIN (dexmethylphenidate) tablet, XR capsule | |
| VYVANSE ^{BNR} (lisdexamfetamine) capsule | INTUNIV (guanfacine ER) tablet | |
| | JORNAY PM (methylphenidate) capsule | WAKIX (pitolisant) prior authorization may be approved if member meets the following criteria: <ul style="list-style-type: none"> ● Member is 6 years of age or older AND ● Member has diagnosis of narcolepsy and is experiencing excessive daytime sleepiness AND ● Member does not have end stage renal disease (eGFR <15 mL/minute) AND ● Member does not have severe hepatic impairment AND ● Member has trial and failure[‡] of modafinil AND armodafinil AND one other agent in the stimulant PDL class AND ● Member has been counseled that Wakix may reduce the efficacy of hormonal contraceptives and counseled regarding use of an alternative non-hormonal method of contraception during Wakix therapy and for at least 21 days after discontinuing treatment. |
| | Lisdexamfetamine capsule, chewable tablet | |
| | Methamphetamine tablet | |
| | METHYLIN (methylphenidate) solution | |
| | Methylphenidate CD/ER/LA capsule, chewable tablet, ER tablet (generic Relexxi/Ritalin), patch | |
| | MYDAYIS ER (dextroamphetamine/ amphetamine) capsule | Maximum Dose (all products): See Table 2 |
| | NUVIGIL (armodafinil) tablet | |
| | ONYDA XR (clonidine) suspension | Exceeding Maximum Dose: Prior authorization may be approved for doses that are higher than the listed maximum dose (Table 2) for members meeting the following criteria: <ul style="list-style-type: none"> ● Member is taking medication for indicated use listed in Table 1 AND ● Member has 30-day trial and failure[‡] of three different preferred or non-preferred agents at maximum doses listed in Table 2 AND ● Documentation of member's symptom response to maximum doses of three other agents is provided AND ● Member is not taking a sedative hypnotic medication (such as temazepam, triazolam, or zolpidem from the Sedative Hypnotic PDL class). |
| | PROCENTRA (dextroamphetamine) solution | |
| | PROVIGIL (modafinil) tablet | |
| | QUELBREE (viloxazine ER) capsule | |
| | QUILLICHEW ER (methylphenidate) chewable tablet, XR suspension | |
| | RELEXXII (methylphenidate ER) tablet | |
| | RITALIN (methylphenidate) IR/ER tablet, ER capsule | |
| | STRATTERA (atomoxetine) capsule | |

[‡]Failure is defined as: lack of efficacy with 4-week trial, allergy, intolerable side effects, or significant drug-drug interaction.

| | |
|--|--|
| SUNOSI (solriamfetol) tablet | |
| VYVANSE (lisdexamfetamine) chewable tablet | |
| WAKIX (pitolisant) tablet | |
| XELTRYM (dextroamphetamine) patch | |
| ZENZEDI (dextroamphetamine) tablet | |

Table 1: Diagnosis and Age Limitations

- Approval for medically accepted indications not listed in Table 1 may be given with prior authorization review and may require submission of peer-reviewed literature or medical compendia showing safety and efficacy of the medication used for the prescribed indication.
- Preferred medications may also receive approval for off-label use for fatigue associated with multiple sclerosis if meeting all other criteria for approval.
- Bolded drug names are preferred** (subject to preferential coverage changes for brand/generic equivalents)

| Drug | Diagnosis and Age Limitations |
|---|--|
| Stimulants—Immediate Release | |
| Amphetamine sulfate (EVEKEO) | ADHD (Age \geq 3 years), Narcolepsy (Age \geq 6 years) |
| Dexmethylphenidate IR (FOCALIN) | ADHD (Age \geq 6 years) |
| Dextroamphetamine IR tablet (ZENZEDI) | ADHD (Age 3 to 16 years), Narcolepsy (Age \geq 6 years) |
| Dextroamphetamine solution (PROCENTRA) | ADHD (Age 3 to 16 years), Narcolepsy (Age \geq 6 years) |
| Methamphetamine (DESOXYN) | ADHD (Age \geq 6 years) |
| methylphenidate IR (generic METHYLIN, RITALIN) | ADHD (Age \geq 6 years [†]), Narcolepsy (Age \geq 6 years), OSA. [†] Prior Authorization for members 3-6 years of age with a diagnosis of ADHD may be approved with prescriber attestation to the following: <ul style="list-style-type: none"> Member's symptoms have not significantly improved despite adequate behavior interventions AND Member experiences moderate-to-severe continued disturbance in functioning AND Prescriber has determined that the potential benefits of starting methylphenidate before the age of 6 years outweigh the potential harm of delaying treatment. |
| Mixed amphetamine salts IR (generic ADDERALL) | ADHD (Age \geq 3 years), Narcolepsy (Age \geq 6 years) |
| Stimulants –Extended-Release | |
| Amphetamine ER (ADZENYS XR-ODT and ADZENYS ER suspension) | ADHD (Age \geq 6 years) |
| Amphetamine ER (DYANAVEL XR) | ADHD (Age \geq 6 years) |
| Mixedamphetamine salts ER (ADDERALL XR) | ADHD (Age \geq 6 years) |
| Dexmethylphenidate ER (generic Focalin XR) | ADHD (Age \geq 6 years) |
| Dextroamphetamine ER (DEXEDRINE) | ADHD (Age 6 to 16 years), Narcolepsy (Age \geq 6 years) |
| Dextroamphetamine ER/amphetamine ER (MYDAYIS ER) | ADHD (Age \geq 13 years) |

| | |
|--|---|
| Dextroamphetamine ER patch (XELTRYM) | ADHD (Age \geq 6 years) |
| Lisdexamfetamine dimesylate (VYVANSE capsule, Vyvanse chewable) | ADHD (Age \geq 6 years), Moderate to severe binge eating disorder in adults (Age \geq 18 years) |
| Methylphenidate ER OROS (CONCERTA) | ADHD (Age \geq 6 years), Narcolepsy (Age \geq 6 years), OSA |
| Methylphenidate patch (DAYTRANA) | ADHD (Age \geq 6 years) |
| Methylphenidate SR (METADATE ER) | ADHD (Age \geq 6 years), Narcolepsy (Age \geq 6 years) |
| Methylphenidate ER (METADATE CD) | ADHD (Age \geq 6 years) |
| Methylphenidate ER (QUILLICHEW ER) | ADHD (Age 6 years to \leq 65 years), Narcolepsy (Age \geq 6 years) |
| Methylphenidate ER (QUILLIVANT XR) | ADHD (Age \geq 6 years), Narcolepsy (Age \geq 6 years) |
| Methylphenidate ER (RELEXXI ER) | ADHD (Age 6 to 65 years) |
| Methylphenidate ER (RITALIN LA) | ADHD (Age \geq 6 years) ^t Prior Authorization for members 4-6 years of age with a diagnosis of ADHD may be approved with prescriber attestation to the following: <ul style="list-style-type: none">• Member's symptoms have not significantly improved despite adequate behavior interventions AND• Member experiences moderate-to-severe continued disturbance in functioning AND Prescriber has determined that the potential benefits of starting methylphenidate before the age of 6 years outweigh the potential harm of delaying treatment. |
| Methylphenidate ER (ADHANSIA XR) | ADHD (Age \geq 6 years) |
| Methylphenidate ER (JORNAY PM) | ADHD (Age \geq 6 years) |
| Methylphenidate XR (APTENSIO XR) | ADHD (Age \geq 6 years) |
| Methylphenidate XR ODT (COTEMPLA XR-ODT) | ADHD (Age 6 to 17 years) |
| Serdexmethylphenidate/dexmethylphenidate (AZSTARYS) | ADHD (Age \geq 6 years) |
| Non-Stimulants | |
| Atomoxetine (generic STRATTERA) | ADHD (Age \geq 6 years) |
| Clonidine ER | ADHD as monotherapy or adjunctive therapy to stimulants (Age \geq 6 years) |
| Guanfacine ER (generic INTUNIV) | ADHD as monotherapy or adjunctive therapy to stimulants (Age \geq 6 years) |
| Viloxazine ER (QUEBREE) | ADHD (Age \geq 6 years) |
| Wakefulness-promoting Agents | |
| Armodafinil (generic NUVIGIL) | Excessive sleepiness associated with narcolepsy, OSA, SWD, and adjunct therapy to treat fatigue and sleepiness in patients with major depressive disorder (MDD) (Age \geq 18 years) |
| Modafinil (PROVIGIL) | Excessive sleepiness associated with narcolepsy, OSA, SWD, and adjunct therapy to treat fatigue and sleepiness in patients with major depressive disorder (MDD), antipsychotic medication-related fatigue (Age \geq 18 years) |
| Pitolisant (WAKIX) | Excessive sleepiness associated with narcolepsy (Age \geq 6 years) |
| Solriamfetol (SUNOSI) | Excessive sleepiness associated with narcolepsy, OSA (Age \geq 18 years) |
| KEY: ADHD —attention-deficit/hyperactivity disorder, OSA —obstructive sleep apnea, SWD —shift work disorder | |

Table 2: Maximum Dose

| Drug | Maximum Daily Dose |
|-----------------------|--|
| ADDERALL | 60 mg |
| ADDERALL XR | 60 mg |
| ADHANSIA XR | 85 mg |
| ADZENYS XR ODT | 18.8 mg (age 6-12) |
| ADZENYS ER SUSPENSION | 12.5 mg (age \geq 13) |
| AMPHETAMINE SALTS | 40 mg |
| APTENSIO XR | 60 mg |
| CONCERTA | 54 mg (age 6-12) or 72 mg (\geq age 13) |
| AZSTARYS | 52.3 mg serdexmethylphenidate and 10.4 mg dextmethylphenidate |
| CLONIDINE ER | 0.4 mg |
| COTEMPLA XR-ODT | 51.8 mg |
| DEXTROAMPHETAMINE ER | 60 mg |
| DAYTRANA | 30 mg/9 hour patch (3.3 mg/hr) |
| DESOXYN | 25 mg |
| DEXEDRINE | 60 mg |
| DYANAVEL XR | 20 mg |
| EVEKEO | 60 mg |
| FOCALIN | 20 mg |
| FOCALIN XR | 40 mg |
| GUANFACINE ER | 4 mg (age 6-12) or 7 mg (age \geq 13) |
| INTUNIV ER | 4 mg (age 6-12) or 7 mg (age \geq 13) |
| JORNAY PM | 100 mg |
| METADATE CD | 60 mg |
| METADATE ER | 60 mg |
| METHYLIN | 60 mg |
| METHYLIN ER | 60 mg |
| METHYLIN SUSPENSION | 60 mg |
| METHYLPHENIDATE | 60 mg |
| METHYLPHENIDATE ER | 60 mg |
| MYDAYIS ER | 25 mg (age 13-17) or 50 mg (age \geq 18) |
| NUVIGIL | 250 mg |
| PROCENTRA | 60 mg |
| PROVIGIL | 400 mg |
| QELBREE | 400 mg (age 6-17) or 600 mg (age \geq 18) |
| QUILLICHEW ER | 60 mg |
| QUILLIVANT XR | 60 mg |
| RELEXXII | 54 mg (ages 6-12) or 72 mg (\geq age 13) |

| | |
|---------------------------------------|---------------|
| RITALIN IR | 60 mg |
| RITALIN SR | 60 mg |
| RITALIN LA | 60 mg |
| STRATTERA | 100mg |
| SUNOSI | 150 mg |
| VYVANSE CAPSULES AND CHEWABLE TABLETS | 70 mg |
| WAKIX | 35.6 mg |
| XELTRYM ER PATCH | 18 mg/9 hours |
| ZENZEDI | 60 mg |
| | |

Therapeutic Drug Class: TRIPANTS, DITANS AND OTHER MIGRAINE TREATMENTS - Oral – Effective 4/1/2025

| No PA Required (Quantity limits may apply) | PA Required | Reyvow (lasmiditan) may be approved if meeting the following: <ul style="list-style-type: none"> Member has trialed and failed three preferred products OR member is unable to use triptan therapy due to cardiovascular risk factors AND Member has trialed and failed two preferred agents in the CGRP Inhibitors drug class indicated for the acute treatment of migraine. All other non-preferred oral products may be approved for members who have trialed and failed three preferred oral products. Failure is defined as lack of efficacy with 4-week trial, allergy, documented contraindication to therapy, intolerable side effects, or significant drug-drug interaction. | | | | | | | | | | |
|---|--|--|---|----------------|---------------------------------|----------------|---|----------------|----------------------|-----------------|---------------------|----------------|
| Eletriptan tablet (generic Relpax) | Almotriptan tablet | | | | | | | | | | | |
| Naratriptan tablet (generic Amerge) | FROVA (frovatriptan) tablet | | | | | | | | | | | |
| Rizatriptan tablet, ODT (generic Maxalt) | Frovatriptan tablet | | | | | | | | | | | |
| Sumatriptan tablet (generic Imitrex) | IMITREX (sumatriptan) tablet | | | | | | | | | | | |
| Zolmitriptan tablet (generic Zomig) | MAXALT/MAXALT MLT (rizatriptan) tablet, ODT RELPAX (eletriptan) tablet REYVOW (lasmiditan) tablet Sumatriptan/Naproxen tablet SYMBRAVO (rizatriptan/meloxicam) tablet Zolmitriptan ODT ZOMIG (zolmitriptan) tablet | Quantity Limits: <table border="1"> <tr> <td>Amerge (naratriptan), Frova (frovatriptan), Imitrex (sumatriptan), Zomig (zolmitriptan)</td> <td>9 tabs/30 days</td> </tr> <tr> <td>Treximet (sumatriptan/naproxen)</td> <td>9 tabs/30 days</td> </tr> <tr> <td>Axert (almotriptan) and Relpax (eletriptan)</td> <td>6 tabs/30 days</td> </tr> <tr> <td>Maxalt (rizatriptan)</td> <td>12 tabs/30 days</td> </tr> <tr> <td>Reyvow (lasmiditan)</td> <td>8 tabs/30 days</td> </tr> </table> | Amerge (naratriptan), Frova (frovatriptan), Imitrex (sumatriptan), Zomig (zolmitriptan) | 9 tabs/30 days | Treximet (sumatriptan/naproxen) | 9 tabs/30 days | Axert (almotriptan) and Relpax (eletriptan) | 6 tabs/30 days | Maxalt (rizatriptan) | 12 tabs/30 days | Reyvow (lasmiditan) | 8 tabs/30 days |
| Amerge (naratriptan), Frova (frovatriptan), Imitrex (sumatriptan), Zomig (zolmitriptan) | 9 tabs/30 days | | | | | | | | | | | |
| Treximet (sumatriptan/naproxen) | 9 tabs/30 days | | | | | | | | | | | |
| Axert (almotriptan) and Relpax (eletriptan) | 6 tabs/30 days | | | | | | | | | | | |
| Maxalt (rizatriptan) | 12 tabs/30 days | | | | | | | | | | | |
| Reyvow (lasmiditan) | 8 tabs/30 days | | | | | | | | | | | |

Therapeutic Drug Class: TRIPANTS, DITANS, AND OTHER MIGRAINE TREATMENTS - Non-Oral – Effective 4/1/2025

| No PA Required (Quantity limits may apply) | PA Required | Zembrace Symtouch injection, Tosymra nasal spray, or Onzetra Xsail nasal powder may be approved for members who have trialed and failed one preferred non-oral triptan products AND two oral triptan agents with different active ingredients. Failure is defined as lack of efficacy with 4-week trial, allergy, intolerable side effects, significant drug-drug interaction, or documented inability to take alternative dosage form. |
|---|---|--|
| Dihydroergotamine nasal spray | Dihydroergotamine injection | |
| IMITREX (sumatriptan) nasal spray | IMITREX (sumatriptan) cartridge, pen injector | |
| Sumatriptan cartridge, pen injector | TOSYMRA (sumatriptan) nasal spray TRUDHESA (dihydroergotamine) nasal spray | All other non-preferred products may be approved for members who have trialed and failed one preferred non-oral triptan product AND one preferred oral triptan product. Failure is defined as lack of |

| | | | | | | | | | | | | | | | | | | |
|---|---|--|--|-------------------|---------------------------------|-----------------------|-----------------------------------|----------------------|---|--------------------------------|--|-------------------------|-----------------------------------|----------------------------------|---|----------------|----------------------------------|----------------------|
| MIGRANAL ^{BNR} (dihydroergotamine) nasal spray Sumatriptan nasal spray*, vial | ZEMBRACE SYMTOUCH (sumatriptan) auto-injector Zolmitriptan nasal spray ZOMIG (zolmitriptan) nasal spray | efficacy with 4-week trial, allergy, intolerable side effects or significant drug-drug interactions, documented inability to tolerate dosage form. | | | | | | | | | | | | | | | | |
| <p>Quantity Limits:</p> <table border="1"> <tr> <td>Dihydroergotamine mesylate vial 1mg/mL</td> <td>24 vials/ 28 days</td> </tr> <tr> <td>Imitrex (sumatriptan) injection</td> <td>4 injectors / 30 days</td> </tr> <tr> <td>Imitrex (sumatriptan) nasal spray</td> <td>6 inhalers / 30 days</td> </tr> <tr> <td>Migranal (dihydroergotamine mesylate) nasal spray</td> <td>8 nasal spray devices/ 30 days</td> </tr> <tr> <td>Onzetra Xsail (sumatriptan) nasal powder</td> <td>16 nosepieces / 30 days</td> </tr> <tr> <td>Tosymra (sumatriptan) nasal spray</td> <td>12 nasal spray devices / 30 days</td> </tr> <tr> <td>Zembrace Symtouch (sumatriptan) injection</td> <td>36mg / 30 days</td> </tr> <tr> <td>Zomig (zolmitriptan) nasal spray</td> <td>6 inhalers / 30 days</td> </tr> </table> <p>Members currently utilizing a non-oral dihydroergotamine product formulation (based on recent claims history) may receive one year approval to continue therapy with that medication.</p> | | | Dihydroergotamine mesylate vial 1mg/mL | 24 vials/ 28 days | Imitrex (sumatriptan) injection | 4 injectors / 30 days | Imitrex (sumatriptan) nasal spray | 6 inhalers / 30 days | Migranal (dihydroergotamine mesylate) nasal spray | 8 nasal spray devices/ 30 days | Onzetra Xsail (sumatriptan) nasal powder | 16 nosepieces / 30 days | Tosymra (sumatriptan) nasal spray | 12 nasal spray devices / 30 days | Zembrace Symtouch (sumatriptan) injection | 36mg / 30 days | Zomig (zolmitriptan) nasal spray | 6 inhalers / 30 days |
| Dihydroergotamine mesylate vial 1mg/mL | 24 vials/ 28 days | | | | | | | | | | | | | | | | | |
| Imitrex (sumatriptan) injection | 4 injectors / 30 days | | | | | | | | | | | | | | | | | |
| Imitrex (sumatriptan) nasal spray | 6 inhalers / 30 days | | | | | | | | | | | | | | | | | |
| Migranal (dihydroergotamine mesylate) nasal spray | 8 nasal spray devices/ 30 days | | | | | | | | | | | | | | | | | |
| Onzetra Xsail (sumatriptan) nasal powder | 16 nosepieces / 30 days | | | | | | | | | | | | | | | | | |
| Tosymra (sumatriptan) nasal spray | 12 nasal spray devices / 30 days | | | | | | | | | | | | | | | | | |
| Zembrace Symtouch (sumatriptan) injection | 36mg / 30 days | | | | | | | | | | | | | | | | | |
| Zomig (zolmitriptan) nasal spray | 6 inhalers / 30 days | | | | | | | | | | | | | | | | | |

V. Dermatological

Therapeutic Drug Class: ACNE AGENTS– Topical – Effective 10/1/2025

| Preferred No PA Required (if age and diagnosis criteria are met*) | Non-Preferred PA Required | <p>Authorization will not be approved for acne agents prescribed solely for cosmetic purposes.</p> <p>Preferred topical clindamycin and erythromycin products may be approved by AutoPA verification of ICD-10 diagnosis code for acne vulgaris, psoriasis, cystic acne, comedonal acne, disorders of keratinization, neoplasms, folliculitis, hidradenitis suppurativa, or perioral dermatitis (erythromycin only). Approval of preferred topical clindamycin and erythromycin products for other medically accepted indications may be considered following clinical prior authorization review by a call center pharmacist.</p> <p>All other preferred topical acne agents may be approved if meeting the following criteria:</p> <ul style="list-style-type: none"> For members > 25 years of age, may be approved following prescriber verification that the medication is not being utilized for cosmetic purposes AND prescriber verification that the indicated use is for acne vulgaris, psoriasis, cystic acne, disorders of keratinization, neoplasms, or comedonal acne. These medications are only eligible for prior authorization approval for the aforementioned diagnoses. For members ≤ 25 years of age, may be approved for a diagnosis of acne vulgaris, psoriasis, cystic acne, disorders of keratinization, neoplasms, or comedonal acne. Diagnosis will be verified through automated verification (AutoPA) of the appropriate corresponding ICD-10 diagnosis code related to the indicated use of the medication. <p>Non-preferred topical products may be approved for members meeting all of the following criteria:</p> <ul style="list-style-type: none"> Member has trialed/failed three preferred topical products with different mechanisms (such as tretinoin, antibiotic). Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction AND |
|---|---|---|
| <p>*Adapalene gel</p> <p>*Adapalene/benzoyl peroxide gel (generic Epiduo), gel pump (generic Epiduo Forte)</p> <p>*Clindamycin phosphate gel, lotion, solution, medicated swab/pledget</p> <p>*Clindamycin/benzoyl peroxide gel jar (generic Benzaclin)</p> <p>*Clindamycin/benzoyl peroxide gel tube (generic Duac)</p> <p>*Dapsone gel</p> <p>*Erythromycin solution</p> <p>*Erythromycin/Benzoyl peroxide gel (generic Benzamycin)</p> | ACANYA (clindamycin/benzoyl peroxide) gel, pump Adapalene cream, gel pump, solution ALTRENO (tretinoin) lotion ARAZLO (tazarotene) lotion ATRALIN (tretinoin) gel BENZAMYCIN (erythromycin/benzoyl peroxide) gel BP (sulfacetamide sodium/sulfur/urea) cleansing wash CABTREO (adapalene/benzoyl peroxide/clindamycin) gel CLEOCIN-T (clindamycin) lotion CLINDACIN ETZ/PAC (clindamycin phosphate) kit CLINDAGEL gel | <p>Authorization will not be approved for acne agents prescribed solely for cosmetic purposes.</p> <p>Preferred topical clindamycin and erythromycin products may be approved by AutoPA verification of ICD-10 diagnosis code for acne vulgaris, psoriasis, cystic acne, comedonal acne, disorders of keratinization, neoplasms, folliculitis, hidradenitis suppurativa, or perioral dermatitis (erythromycin only). Approval of preferred topical clindamycin and erythromycin products for other medically accepted indications may be considered following clinical prior authorization review by a call center pharmacist.</p> <p>All other preferred topical acne agents may be approved if meeting the following criteria:</p> <ul style="list-style-type: none"> For members > 25 years of age, may be approved following prescriber verification that the medication is not being utilized for cosmetic purposes AND prescriber verification that the indicated use is for acne vulgaris, psoriasis, cystic acne, disorders of keratinization, neoplasms, or comedonal acne. These medications are only eligible for prior authorization approval for the aforementioned diagnoses. For members ≤ 25 years of age, may be approved for a diagnosis of acne vulgaris, psoriasis, cystic acne, disorders of keratinization, neoplasms, or comedonal acne. Diagnosis will be verified through automated verification (AutoPA) of the appropriate corresponding ICD-10 diagnosis code related to the indicated use of the medication. <p>Non-preferred topical products may be approved for members meeting all of the following criteria:</p> <ul style="list-style-type: none"> Member has trialed/failed three preferred topical products with different mechanisms (such as tretinoin, antibiotic). Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction AND |

| | | |
|--|--|---|
| <p>*Sulfacetamide sodium suspension</p> <p>*Tretinoin cream</p> <p>*Tretinoin gel (Mylan only)</p> | <p>Clindamycin phosphate foam</p> <p>Clindamycin/Benzoyl peroxide gel pump</p> <p>Clindamycin/tretinoin gel</p> <p>Dapsone gel pump</p> <p>ERY/ERYGEL (erythromycin/ethanol) gel, medicated swabs/pads</p> <p>Erythromycin gel</p> <p>EVOCLIN (clindamycin) foam</p> <p>FABIOR (tazarotene) foam</p> <p>KLARON (sulfacetamide) suspension</p> <p>NEUAC (clindamycin/benzoyl peroxide/emollient) kit</p> <p>ONEXTON (clindamycin/benzoyl peroxide) gel, gel pump</p> <p>RETIN-A MICRO (tretinoin) (all products)</p> <p>ROSULA (sulfacetamide sodium/sulfur) cloths, wash</p> <p>SSS 10-5 (sulfacetamide sodium/sulfur) foam</p> <p>Sulfacetamide sodium cleanser, cleansing gel, lotion, shampoo, wash</p> <p>Sulfacetamide sodium/sulfur cleanser, cream, pad, suspension, wash</p> <p>SUMADAN/XLT (sulfacetamide sodium/sulfur) kit, wash</p> <p>SUMAXIN/ CP/TS (sulfacetamide sodium/sulfur) kit, pads, suspension, wash</p> <p>Tazarotene cream, foam, gel</p> <p>Tretinoin gel (all other manufacturers)</p> <p>Tretinoin microspheres (all products)</p> | <ul style="list-style-type: none"> Prescriber verification that the medication is being prescribed for one of the following diagnoses: acne vulgaris, psoriasis, cystic acne, disorders of keratinization, neoplasms, or comedonal acne. |
|--|--|---|

| | | |
|--|---|--|
| | WINLEVI (clascoterone) cream ZIANA (clindamycin/tretinoin) gel | |
|--|---|--|

Therapeutic Drug Class: ACNE AGENTS– ORAL ISOTRETINOIN – Effective 7/1/2025

| PA Required for all agents | | |
|--|---|---|
| Preferred | Non-Preferred | |
| AMNESTEEM capsule | ABSORICA capsule | Preferred products may be approved for adults and children ≥ 12 years of age for treating severe acne vulgaris or for treating moderate acne vulgaris in members unresponsive to conventional therapy. |
| CLARAVIS capsule | ABSORICA LD capsule | Non-preferred products may be approved for members meeting the following: |
| Isotretinoin 10 mg, 20 mg, 30 mg, 40 mg capsule <i>(Mayne-Pharma, Upsher-Smith, Zydus only)</i> | Isotretinoin 10 mg, 20 mg, 30 mg, 40 mg capsule (<i>All manufacturers except Mayne-Pharma, Upsher-Smith, Zydus</i>) | <ul style="list-style-type: none"> • Member has trialed/failed one preferred agent (failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction) AND • Member is an adult or child ≥ 12 years of age with severe, recalcitrant nodulocystic acne and has been unresponsive to conventional therapy. |
| ZENATANE capsule | Isotretinoin 25 mg, 35 mg capsule MYORISAN capsule | |

Therapeutic Drug Class: ANTI-PSORIATICS - Oral – Effective 7/1/2025

| No PA Required | PA Required | |
|-----------------------|---------------------|---|
| Acitretin capsule | Methoxsalen capsule | Prior authorization for non-preferred oral agents may be approved with failure of two preferred anti-psoriatic agents, one of which must be a preferred oral agent. Failure is defined as lack of efficacy of a 4-week trial, allergy, intolerable side effects or significant drug-drug interaction. |

Therapeutic Drug Class: VITAMIN D ANALOGUES -Topical – Effective 7/1/2025

| No PA Required | PA Required | |
|---|--|---|
| Calcipotriene cream, foam, ointment, solution | Calcipotriene/betamethasone dipropionate suspension | Preferred and non-preferred products that contain a corticosteroid ingredient (such as betamethasone) will be limited to 4 weeks of therapy. Continued use will require one week of steroid-free time in between treatment periods. |
| Calcipotriene/betamethasone dipropionate ointment | Calcitriol ointment ENSTILAR (calcipotriene/betamethasone) foam | Non-preferred topical agents may be approved with failure of two preferred topical agents. If non-preferred topical agent being requested is a combination product, trial of two preferred agents must include a preferred combination agent. Failure is defined as lack of efficacy of a 4-week trial, allergy, intolerable side effects or significant drug-drug interaction. |
| TACLONEX SCALP ^{BNR} (calcipotriene/betamethasone) suspension | SORILUX (calcipotriene) foam | |

| | | |
|---|--|---|
| TACLONEX (calcipotriene/betamethasone) ointment | | Members with >30% of their body surface area affected may not use Enstilar (calcipotriene/betamethasone DP) foam or Taclonex (calcipotriene/betamethasone DP) ointment products as safety and efficacy have not been established. |
|---|--|---|

Therapeutic Drug Class: **IMMUNOMODULATORS, TOPICAL** – Effective 7/15/2025

Newer Agents

| No PA Required (Unless indicated*) | PA Required | |
|---------------------------------------|---|---|
| ELIDEL (pimecrolimus) cream | ANZUPGO (delgocitinib) cream | EUCRISA (crisaborole) may be approved if the following criteria are met: |
| *EUCRISA (crisaborole) ointment | DUOBRII (halobetasol/tazarotene) lotion | <ul style="list-style-type: none"> • Member is \geq 3 months of age AND • Member has a diagnosis of mild to moderate atopic dermatitis AND • Member tried and failed[‡] one preferred agent OR one medium-to-very high potency topical corticosteroid AND • Eucrisa (crisaborole) is being prescribed by or in consultation with a dermatologist or allergist/immunologist. |
| *OPZELURA (ruxolitinib) cream | VTAMA (tapinarof) 1% cream | OPZELURA (ruxolitinib) cream may be approved if the following criteria are met based on prescribed indication: |
| Pimecrolimus cream | ZORYVE (roflumilast) 0.15% cream, 0.3% foam | <p><u>Atopic Dermatitis</u></p> <ul style="list-style-type: none"> • Member is \geq 2 years of age AND • Member has a diagnosis of mild to moderate atopic dermatitis AND • Medication is being prescribed by or in consultation with a dermatologist or allergist/immunologist AND • Member has trialed and failed[‡] one preferred agent OR one medium potency to very high potency topical corticosteroid (such as mometasone furoate, betamethasone dipropionate, or fluocinonide) or prescriber verifies that member is not a candidate for topical corticosteroids. |
| Tacrolimus ointment | | <p><u>Nonsegmental Vitiligo</u></p> <ul style="list-style-type: none"> • Member is \geq 12 years of age AND • Member is immunocompetent AND • Member has a diagnosis of stable nonsegmental vitiligo, defined as no increase in the size of existing lesions and the absence of new lesions in the previous 3 to 6 months, AND • Medication is being prescribed by or in consultation with a dermatologist AND • Member has trialed and failed[‡] one preferred agent AND one medium potency to very high potency topical corticosteroid (such as mometasone furoate, betamethasone dipropionate, or fluocinonide) or prescriber verifies that member is not a candidate for topical corticosteroids <p><u>Quantity limit:</u> 60 grams/week</p> <p>Non-preferred topical immunomodulator products may be approved for atopic dermatitis following adequate trial and failure[‡] of one prescription topical corticosteroid AND two preferred agents.</p> |

ZORYVE (roflumilast) 0.15% cream and 0.3% foam may receive approval if meeting the following based on prescribed indication:

Atopic dermatitis (0.15% cream formulation only):

- 6 years of age and older AND
- Member has a diagnosis of mild atopic dermatitis in adult and pediatric patients AND
- Request meets trial and failure criteria for non-preferred agents listed above

Plaque psoriasis (0.3% cream formulation only):

- Member is \geq 6 years of age AND
- Member has a diagnosis of plaque psoriasis AND
- Member has body surface area (BSA) involvement of $\leq 20\%$ AND
- Member does not have moderate or severe hepatic impairment (Child-Pugh B or C) AND
- Medication is being prescribed by or in consultation with a dermatologist AND
- If the affected area is limited to the scalp:
 - Prescriber attests that member has been counseled regarding alternative treatment options, including over-the-counter (OTC) emollients, vitamin D analogs, and coal tar shampoo when appropriate

AND

- Member has documented trial and failure (with a minimum 2-week treatment period) of a topical corticosteroid. Failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interaction.
- If the affected area includes the face or body:
 - Member has documented trial and failure (with a minimum 2-week treatment period) of at least one product from ALL of the following categories. (Failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interaction):
 - Topical corticosteroid
 - Topical calcineurin inhibitor (such as pimecrolimus, tacrolimus)

Plaque psoriasis (0.3% foam formulation only):

- Member is ≥ 12 years of age AND
- Member has a diagnosis of plaque psoriasis AND
- Member has body surface area (BSA) involvement of $\leq 20\%$ AND
- Member does not have moderate or severe hepatic impairment (Child-Pugh B or C) AND
- Medication is being prescribed by or in consultation with a dermatologist AND
- If the affected area is limited to the scalp:
 - Prescriber attests that member has been counseled regarding alternative treatment options, including over-the-counter (OTC) emollients, vitamin D analogs, and coal tar shampoo when appropriate AND

- Member has documented trial and failure (with a minimum 2-week treatment period) of a topical corticosteroid. Failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interaction.
- If the affected area includes the face or body:
 - Member has documented trial and failure (with a minimum 2-week treatment period) of at least one product from ALL of the following categories (Failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interaction):
 - Topical corticosteroid
 - Topical calcineurin inhibitor (such as pimecrolimus, tacrolimus)

Seborrheic dermatitis (0.3% foam formulation only):

- Member is \geq 9 years of age AND
- Member has a diagnosis of seborrheic dermatitis AND
- Member does not have moderate or severe hepatic impairment (Child-Pugh B or C) AND
- Medication is being prescribed by or in consultation with a dermatologist AND
- Member has been counseled that Zoryve foam is flammable. Fire, flame, or smoking during and immediately following application must be avoided.
- If the affected area is limited to the scalp:
 - Prescriber attests that member has been counseled regarding alternative treatment options, including over-the-counter (OTC) antifungal shampoo (such as selenium sulfide, zinc pyrithione) and OTC coal tar shampoo, when appropriate

AND

- Member has documented trial and failure (with a minimum 2-week treatment period) of at least one prescription product for seborrheic dermatitis, such as ketoconazole 2% antifungal shampoo or a topical corticosteroid. Failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interaction.

- If the affected area includes the face or body:
 - Member has documented trial and failure (with a minimum 2-week treatment period) with at least one product from ALL of the following categories (Failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interaction):
 - Topical antifungal (such as ketoconazole, ciclopirox)
 - Topical corticosteroid
 - Topical calcineurin inhibitor (such as pimecrolimus, tacrolimus)

Quantity limit: 60 grams/30 days

Initial approval: 8 weeks

| | | |
|--|--|---|
| | | <p>Members may not apply Zoryve (roflumilast) cream to >20% of affected body surface area, as safety and efficacy have not been established.</p> <p><u>Reauthorization:</u> Reauthorization for one year may be approved based on provider attestation that member's symptoms improved during the initial 8 weeks of treatment and continuation of therapy is justified.</p> <p>‡Failure is defined as a lack of efficacy with a 2-week trial, allergy, intolerable side effects, contraindication, or significant drug-drug interaction</p> |
|--|--|---|

| Antineoplastic Agents | | |
|---|---|--|
| Preferred No PA Required (Unless indicated*) | Non-Preferred PA Required | |
| *Diclofenac 3% gel (generic Solaraze) | Bexarotene gel | *Diclofenac 3% gel (generic Solaraze) may be approved if the member has a diagnosis of actinic keratosis (AK). |
| Fluorouracil 5% cream (generic Efudex) | CARAC (fluorouracil) cream | TARGRETIN (bexarotene) gel or VALCHLOR (mechlorethamine) gel may be approved for members who meet the following criteria: <ul style="list-style-type: none"> • Member is \geq 18 years of age AND • Member has been diagnosed with Stage IA or IB cutaneous T-cell lymphoma (CTCL) AND • Member has refractory or persistent CTCL disease after other therapies OR has not tolerated other therapies AND • Member and partners have been counseled on appropriate use of contraception |
| Fluorouracil 2%, 5% solution | EFUDEX (fluorouracil) cream Fluorouracil 0.5% (generic Carac) cream PANRETIN (alitretinoin) gel TARGRETIN (bexarotene) gel VALCHLOR (mechlorethamine) gel | Non-preferred agents may be approved for members who have failed an adequate trial of all preferred products FDA-approved for that indication. Failure is defined as lack of efficacy, allergy, intolerable side effects, contraindication, or significant drug-drug interaction. |

| Other Agents | | |
|---|--|---|
| No PA Required | PA Required | |
| Imiquimod (generic Aldara) cream Podofilox gel, solution | CONDYLOX (podofilox) gel HYFTOR (sirolimus) gel Imiquimod (generic Zyclara) cream, cream pump VEREGEN (sinecatechins) ointment ZYCLARA (imiquimod) cream, cream pump | Hyftor (sirolimus) gel <ul style="list-style-type: none"> • Member has a diagnosis of facial angiofibroma associated with tuberous sclerosis AND • Member is \geq 6 years of age AND • Provider has evaluated, and member has received, all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating treatment with HYFTOR <u>Initial approval:</u> 6 months <p><u>Reauthorization:</u> An additional 6 months may be approved based on provider attestation that symptoms improved during the initial 6 months of treatment and the provider has assessed use of all vaccinations recommended by current immunization guidelines.</p> <p><u>Maximum dose:</u> one 10-gram tube/28 days</p> <p>Veregen (sinecatechins) may be approved if the following criteria are met:</p> |

| | |
|--|---|
| | <ul style="list-style-type: none"> • Member has a diagnosis of external genital and/or perianal warts (Condylomata acuminata) AND • Member is \geq 18 years of age AND Member is immunocompetent AND • Member has tried and failed two preferred products. Failure is defined as lack of efficacy, allergy, intolerable side effects, contraindication, or significant drug-drug interaction. <p>Zyclara (imiquimod) 2.5% cream may be approved if the following criteria are met:</p> <ul style="list-style-type: none"> • Member has a diagnosis of clinically typical visible or palpable actinic keratoses (AK) of the full face or balding scalp AND • Member is \geq 18 years of age AND • Member is immunocompetent AND • Member has tried and failed one preferred product in the Antineoplastic Agents class (such as diclofenac gel or fluorouracil) AND the preferred imiquimod (generic Aldara) product. Failure is defined as lack of efficacy, allergy, intolerable side effects, contraindication, or significant drug-drug interaction. <p>Zyclara (imiquimod) 3.75% cream may be approved for:</p> <ul style="list-style-type: none"> • Treatment of clinically typical visible or palpable, actinic keratoses (AK) of the full face or balding scalp if the following criteria are met: <ul style="list-style-type: none"> • Member is \geq 18 years of age AND • Member is immunocompetent AND • Member has tried and failed one preferred product from the Antineoplastic Agents class (such as diclofenac gel or fluorouracil) AND the preferred imiquimod (generic Aldara) product. Failure is defined as lack of efficacy, allergy, intolerable side effects, contraindication, or significant drug-drug interaction. <p>OR</p> <ul style="list-style-type: none"> • Treatment of external genital and/or perianal warts (Condylomata acuminata) if the following criteria are met: <ul style="list-style-type: none"> • Member is \geq 12 years of age AND • Member has tried and failed two preferred products. Failure is defined as lack of efficacy, allergy, intolerable side effects, contraindication, or significant drug-drug interaction. <p>All other non-preferred products may be approved for members who have trialed and failed all preferred products that are FDA-approved for use for the prescribed indication. Failure is defined as lack of efficacy, allergy, intolerable side effects, contraindication, or significant drug-drug interaction.</p> <p><u>Quantity Limits:</u> Aldara (imiquimod) cream has a quantity limit of 12 packets/28 days.</p> |
| Therapeutic Drug Class: ROSACEA AGENTS – Effective 7/1/2025 | |
| No PA Required | PA Required |

| | | |
|-----------------------------|--|--|
| Azelaic acid gel | Brimonidine gel pump | Prior authorization for non-preferred products in this class may be approved if meeting the following criteria for the prescribed diagnosis: |
| FINACEA (azelaic acid) gel | *Doxycycline monohydrate DR capsule (generic Oracea) | <u>Rosacea:</u> |
| FINACEA (azelaic acid) foam | Ivermectin cream | <ul style="list-style-type: none"> • Member has a diagnosis of persistent (non-transient) facial erythema with inflammatory papules and pustules due to rosacea AND • Prescriber attests that medication is not being used solely for cosmetic purposes AND • Member has tried and failed two preferred agents of different mechanisms of action (Failure is defined as lack of efficacy with 4-week trial, allergy, contraindication, or intolerable side effects) |
| Metronidazole cream, lotion | Metronidazole 1% gel, gel pump | |
| Metronidazole 0.75% gel | MIRVASO (Brimonidine gel pump) | |
| | NORITATE (metronidazole) cream | <u>Demodex Blepharitis:</u> |
| | RHOFADE (oxymetazoline) cream | <ul style="list-style-type: none"> • Requests for non-preferred topical ivermectin cream may be approved for treatment of moderate to severe Demodex blepharitis |
| | ROSADAN (metronidazole/skin cleanser) cream kit, gel kit | *Doxycycline monohydrate DR (generic Oracea) may be approved if the following criteria are met: <ul style="list-style-type: none"> • Member has taken generic doxycycline for a minimum of three months and failed therapy in the last 6 months. Failure is defined as: lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions AND • Member has history of an adequate trial/failure (8 weeks) of 2 other preferred agents (oral or topical). Failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions AND • Member is \geq 18 years of age and has been diagnosed with rosacea with inflammatory lesions (papules and pustules) |

| Therapeutic Drug Class: TOPICAL STEROIDS – <i>Effective 7/1/2025</i> | | |
|---|--|--|
| Low potency | | |
| No PA Required | PA Required | |
| DERMA-SMOOTH-E-FS (fluocinolone) 0.01% body oil/scalp oil ^{BNR} | Alclometasone 0.05% cream, ointment | Non-preferred Low Potency topical corticosteroids may be approved following adequate trial and failure of two preferred agents in the Low Potency class (failure is defined as lack of efficacy with 4-week trial, allergy, intolerable side effects or significant drug-drug interactions). |
| Desonide 0.05% cream, ointment | CAPEX (fluocinolone) 0.01% shampoo | |
| Fluocinolone 0.01% cream, 0.01% solution | Desonide 0.05% lotion | |
| Hydrocortisone (Rx) cream, lotion, ointment | Fluocinolone 0.01% body oil, 0.01% scalp oil | |
| | PROCTOCORT (hydrocortisone) (Rx) 1% cream | |
| | SYNALAR (fluocinolone) 0.01% solution | |
| | SYNALAR TS (fluocinolone/skin cleanser) Kit | |
| | TEXACORT (hydrocortisone) 2.5% solution | |

| Medium potency | | |
|--|---|---|
| No PA Required | PA Required | |
| Betamethasone dipropionate 0.05% cream, lotion, ointment | BESER (fluticasone) lotion, emollient kit | Non-preferred Medium Potency topical corticosteroids may be approved following adequate trial and failure of two preferred agents in the Medium Potency class (failure is defined as: lack of efficacy with 4-week trial, allergy, intolerable side effects or significant drug-drug interactions). |
| Betamethasone valerate 0.1% cream, ointment | Betamethasone valerate 0.1% lotion, 0.12% foam | |
| Fluocinolone 0.025% cream, 0.05% cream, 0.005% ointment | Clocortolone 0.1% cream, cream pump | |
| Fluticasone cream, ointment | CLODERM (clocortolone) 0.1% cream, cream pump | |
| Hydrocortisone valerate 0.2% cream | CUTIVATE (fluticasone) 0.05% cream, lotion | |
| Mometasone 0.1% cream, 0.1% ointment, 0.1% solution | Diflorasone 0.05% cream | |
| Triamcinolone acetonide 0.025% cream, 0.1% cream, 0.025% ointment, 0.05% ointment, 0.1% ointment, 0.025% lotion, 0.1% lotion | Fluocinolone 0.025% ointment | |
| Triamcinolone 0.1% dental paste | Fluocinonide-E 0.05% cream | |
| | Flurandrenolide 0.05% cream, lotion, ointment | |
| | Fluticasone 0.05% lotion | |
| | Hydrocortisone butyrate 0.1% cream, lotion, solution, ointment, lipid/lipocream | |
| | Hydrocortisone valerate 0.2% ointment | |
| | KENALOG (triamcinolone) spray | |
| | LOCOID (hydrocortisone butyrate) 0.1% lotion | |
| | LOCOID LIPOCREAM (hydrocortisone butyrate-emollient) 0.1% cream | |
| | LUXIQ (betamethasone valerate) 0.12% foam | |
| | ORALONE (Triamcinolone) 0.1% dental paste | |
| | PANDEL (hydrocortisone probutate) 0.1% cream | |
| | Prednicarbate 0.1% cream, ointment | |
| | PSORCON (diflorasone) 0.05% cream | |
| | SYNALAR (fluocinolone) 0.025% cream/kit, ointment/kit | |

| | | |
|--|---------------------------------|--|
| | Triamcinolone 0.147 mg/gm spray | |
| High potency | | |
| No PA Required (*unless exceeds duration of therapy) | PA Required | <p>Non-preferred High Potency topical corticosteroids may be approved following adequate trial and failure of two preferred agents in the High Potency class (failure is defined as lack of efficacy with 4-week trial, allergy, intolerable side effects or significant drug-drug interactions).</p> <p>*All High Potency topical corticosteroids will require prior authorization beyond 4 weeks of therapy. The provider will be encouraged to transition to a medium or low potency topical steroid after this time has elapsed.</p> <p>Claims for compounded products containing high-potency topical steroids will be limited to a maximum of 60 grams or 60 mL of a high-potency ingredient per 4-week treatment period. Claims exceeding this quantity limit will require prior authorization with prescriber's justification for use of the product at the prescribed dose.</p> |
| Very high potency | | |
| No PA Required (Unless exceeds duration of therapy*) | PA Required | <p>Non-preferred Very High Potency topical corticosteroids may be approved following adequate trial and failure of clobetasol propionate in the same formulation as the product being requested (if the formulation of the requested non-preferred product is not available in preferred clobetasol product options, then trial and failure of any preferred clobetasol product formulation will be required). Failure is defined as lack of efficacy with 2-week trial, allergy, intolerable side effects or significant drug-drug interactions.</p> <p>*All Very High Potency topical corticosteroids will require prior authorization beyond 2 weeks of therapy. If clobetasol propionate shampoo is being used to treat plaque psoriasis, then prior authorization will be required beyond 4 weeks of therapy. The provider will be encouraged to transition to a medium or low potency topical steroid after this time has elapsed.</p> |

LEXETTE (halobetasol) 0.05% foam
 OLUX (clobetasol) 0.05% foam
 TOPICORT (desoximetasone) 0.25% spray
 TOVET EMOLLIENT (clobetasol) 0.05% foam
 ULTRAVATE (halobetasol) 0.05% lotion
 VANOS (fluocinonide) 0.1% cream

VI. Endocrine

Therapeutic Drug Class: ANDROGENIC AGENTS, Topical, Injectable, Oral – Effective 10/1/2025

| PA Required for all agents in this class | | |
|---|---|---|
| Preferred | Non-Preferred | |
| Testosterone cypionate IM injection | ANDROGEL (testosterone) gel packet | <u>Hypogonadotropic or Primary Hypogonadism (may be secondary to Klinefelter Syndrome):</u> Preferred products may be approved for members meeting the following: |
| Testosterone gel packet | ANDROGEL (testosterone) gel 1.62% pump | <ul style="list-style-type: none"> • Member is a male patient \geq 16 years of age with a documented diagnosis of hypogonadotropic or primary hypogonadism OR \geq 12 years of age with a diagnosis of hypogonadotropic or hypogonadism secondary to Klinefelter Syndrome (all other diagnoses will require manual review) AND • Member has two documented low serum testosterone levels below the lower limit of normal range for testing laboratory prior to initiation of therapy AND • Member does not have a diagnosis of breast or prostate cancer AND • If the member is $>$ 40 years of age, has prostate-specific antigen (PSA) $<$ 4 ng/mL or has no palpable prostate nodule AND • Member has baseline hematocrit $<$ 50% |
| Testosterone 1.62% gel pump <i>Injectable testosterone cypionate is a pharmacy benefit when self-administered. Administration in an office setting is a medical benefit.</i> | DEPO-TESTOSTERONE (testosterone cypionate) IM injection JATENZO (testosterone undecanoate) capsule KYZATREX (testosterone undecanoate) capsule METHITEST (methyltestosterone) tablet Methyltestosterone capsule NATESTO (testosterone) nasal spray | Reauthorization Criteria (requests for renewal of a currently expiring prior authorization for a preferred product may be approved for members meeting the following criteria): |

| | |
|---|---|
| <p>TESTIM (testosterone) gel</p> <p>Testosterone 1% gel tube, 30 mg/1.5 ml pump</p> <p>Testosterone enanthate IM injection</p> <p>TLANDO (testosterone undecanoate) capsule</p> <p>UNDECATREX (testosterone undecanoate) capsule</p> <p>XYOSTED (testosterone enanthate) SC injection</p> | <ul style="list-style-type: none"> Member is a male patient ≥ 16 years of age with a documented diagnosis of hypogonadotropic or primary hypogonadism OR ≥ 12 years of age with a diagnosis of hypogonadotropic or hypogonadism secondary to Klinefelter Syndrome AND Serum testosterone is being regularly monitored (at least annually) to achieve total testosterone level in the middle tertile of the normal reference range AND Member does not have a diagnosis of breast or prostate cancer AND Member has a hematocrit $< 54\%$ <p><u>Gender Transition/Affirming Hormone Therapy:</u></p> <p>Preferred androgenic drugs may be approved for members meeting the following:</p> <ol style="list-style-type: none"> Female sex assigned at birth and has reached Tanner stage 2 of puberty AND Is undergoing female to male transition AND Has a negative pregnancy test prior to initiation AND Hematocrit (or hemoglobin) is being monitored. <p>Non-Preferred Products:</p> <p>Non-preferred topical androgenic agents may be approved for members meeting the above criteria with trial and failed[‡] therapy with two preferred topical androgen formulations.</p> <p>Non-preferred injectable androgenic agents may be approved for members meeting the above criteria with trial and failed[‡] therapy with a preferred injectable androgenic drug.</p> <p>Prior authorization for oral androgen agents (tablet, capsule, buccal) may be approved if member has trialed and failed[‡] therapy with a preferred topical agent AND testosterone cypionate injection.</p> <p>[‡]Failure is defined as lack of efficacy with 8 week trial, allergy, intolerable side effects, contraindication to, or significant drug-drug interaction.</p> <p>For all agents and diagnoses, members < 16 years of age will require a manual prior authorization review by a pharmacist (with exception of members ≥ 12 years of age with a diagnosis of hypogonadotropic or hypogonadism secondary to Klinefelter Syndrome).</p> |
|---|---|

Therapeutic Drug Class: BONE RESORPTION SUPPRESSION AND RELATED AGENTS – Effective 10/1/2025

Bisphosphonates

| No PA Required | PA Required | |
|------------------------------|---|---|
| Alendronate solution, tablet | ACTONEL (risedronate) tablet | Non-preferred bisphosphonates may be approved for members who have failed treatment with one preferred product at treatment dose. Failure is defined as lack of efficacy with a 12-month trial, allergy, intolerable side effects, or significant drug-drug interaction. |
| Ibandronate tablet | ATELVIA (risedronate) tablet | |
| Risedronate tablet | <p>BINOSTO (alendronate) effervescent tablet</p> <p>FOSAMAX (alendronate) tablet</p> <p>FOSAMAX plus D (alendronate/vit D) tablet</p> | For members who have a low risk of fracture, discontinuation of bisphosphonate therapy and drug holiday should be considered following 5 years of treatment. Low risk is defined as having a bone mineral density, based on the most recent T-score, of greater than (better than) -2.5 AND no history of low trauma or fragility fracture. |

| Non-Bisphosphonates | | | | | | |
|---|---|---|---------------------------|-------------------------------|--|--|
| PREFERRED | Non-Preferred | | | | | |
| FORTEO (teriparatide) SC pen ^{BNR*} Raloxifene tablet | BONSITY (teriparatide) SC pen Calcitonin salmon nasal spray EVISTA (raloxifene) tablet Teriparatide SC pen TYMLOS (abaloparatide) SC pen | <p>*FORTEO (teriparatide) or generic teriparatide may be approved if the following criteria are met:</p> <ul style="list-style-type: none"> Member has one of the following diagnoses: <ul style="list-style-type: none"> Male primary or hypogonadal osteoporosis (BMD T-score of -2.5 or less) Osteoporosis due to corticosteroid use Postmenopausal osteoporosis <p>AND</p> <ul style="list-style-type: none"> Member is at very high risk for fracture[†] OR member has history of trial and failure of one preferred bisphosphonate. Failure is defined as lack of efficacy with a 12-month trial, allergy, intolerable side effects, or significant drug-drug interaction. Prior authorization will be given for one year and total exposure of parathyroid hormone analogs (teriparatide and abaloparatide) shall not exceed two years <p>TYMLOS (abaloparatide) may be approved if the member meets the following criteria:</p> <ul style="list-style-type: none"> Member has a diagnosis of postmenopausal osteoporosis (BMD T-score of -2.5 or less) AND Member is post-menopausal with very high risk for fracture[†] OR member has history of trial and failure of FORTEO (teriparatide). Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction. AND Prior authorization will be given for one year and total exposure of parathyroid hormone analogs (teriparatide and abaloparatide) shall not exceed two years. <p>All other non-preferred non-bisphosphonates may be approved for FDA-labeled indications for members who have failed treatment with one preferred bisphosphonate or non-bisphosphonate product at treatment dose. Failure is defined as lack of efficacy with a 12-month trial, allergy, unable to use oral therapy, intolerable side effects, or significant drug-drug interaction.</p> <p>[†]Members at very high risk for fracture: Members will be considered at very high risk for fracture if they meet <u>one</u> of the following:</p> <ul style="list-style-type: none"> A history of fracture within the past 12 months OR Fractures experienced while receiving guideline-supported osteoporosis therapy OR A history of multiple fractures OR A history of fractures experienced while receiving medications that cause skeletal harm (such as long-term glucocorticoids) OR A very low T-score (less than -3.0) OR A high risk for falls or a history of injurious falls OR A very high fracture probability by FRAX (> 30% for a major osteoporosis fracture or > 4.5% for hip fracture). | | | | |
| | <table border="1"> <thead> <tr> <th>Non-Bisphosphonate Product</th> <th>FDA-approved Maximum Dose</th> </tr> </thead> <tbody> <tr> <td>Calcitonin salmon nasal spray</td> <td>1 metered dose spray (200 units) daily</td> </tr> </tbody> </table> | Non-Bisphosphonate Product | FDA-approved Maximum Dose | Calcitonin salmon nasal spray | 1 metered dose spray (200 units) daily | |
| Non-Bisphosphonate Product | FDA-approved Maximum Dose | | | | | |
| Calcitonin salmon nasal spray | 1 metered dose spray (200 units) daily | | | | | |

| | | | | | |
|--|--|--|---|--------------|--|
| | | | Evista (raloxifene) oral tablet | 60 mg daily | |
| | | | Forteo (teriparatide) subcutaneous injection | 20 mcg daily | |
| | | | Tymlos (abaloparatide) subcutaneous injection | 80 mcg daily | |

Note: Prior authorization criteria for Prolia (denosumab) and other injectable bone resorption and related agents are listed on Appendix P.

Therapeutic Drug Class: CONTRACEPTIVES - Topical – Effective 07/10/2025

Effective 01/14/22, topical contraceptive patch products are eligible for coverage with a written prescription by an enrolled pharmacist. Additional information regarding pharmacist enrollment can be found at <https://hcpf.colorado.gov/pharm-serv>.

| No PA Required | PA Required | |
|--|--|---|
| ANNOVERA (segestrone acetate/EE) vaginal ring | Etonorgestrel/EE vaginal ring (<i>all other manufacturers</i>) | Non-preferred topical contraceptive products may be approved following a trial and failure of one preferred topical contraceptive product. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction. |
| Etonorgestrel/EE vaginal ring (<i>Prasco Labs</i>) | Norelgestromin/EE TD patch (generic XULANE) | |
| *PHEXXI (lactic acid/citric/potassium) vaginal gel | NUVARING (etonorgestrel/EE) vaginal ring | *PHEXXI (lactic acid/citric/potassium) vaginal gel quantity limit: 120 grams per 30 days |
| TWIRLA (levonorgestrel/EE) TD patch | ZAFEMY (norelgestromin/EE) TD patch | Effective 7/1/2022: Prescriptions are eligible to be filled for up to a twelve-month supply. |
| XULANE (norelgestromin/EE) TD patch | | <i>Note: IUD and select depot product formulations are billed through the medical benefit</i> |

Therapeutic Drug Class: DIABETES MANAGEMENT CLASSES, INSULINS – Effective 02/27/2025

Rapid-Acting

| No PA Required | PA Required | |
|--|---|---|
| HUMALOG (insulin lispro) cartridge, vial | ADMELOG (insulin lispro) Solostar pen, vial | All non-preferred products may be approved following trial and failure of treatment with two preferred products, one of which is the same rapid-acting insulin analog (lispro or aspart) as the non-preferred product being requested. (Failure is defined as allergy [hives, maculopapular rash, erythema multiforme, pustular rash, severe hypotension, bronchospasm, and angioedema] or intolerable side effects). |
| Insulin aspart cartridge, pen, vial | AFREZZA (regular insulin) cartridge, unit | |
| Insulin lispro Kwikpen, Jr. Kwikpen, vial (<i>Eli Lilly</i>) | APIDRA (insulin glulisine) Solostar pen, vial | Afrezza (human insulin) may be approved if meeting the following criteria: |
| NOVOLOG (insulin aspart) cartridge, FlexPen, vial | FIASP (insulin aspart) FlexPen, PenFill, pump cartridge, vial | <ul style="list-style-type: none"> • Member is 18 years or older AND • Member has trialed and failed treatment with two preferred products (failure is defined as allergy [hives, maculopapular rash, erythema multiforme, pustular rash, severe hypotension, bronchospasm, or angioedema] or intolerable side effects) AND • Member must not have chronic lung disease such as COPD or asthma AND |
| | HUMALOG (insulin lispro) 200 U/mL Kwikpen | |

| | | |
|---|---|---|
| | <p>HUMALOG Tempo Pen 100 U/mL</p> <p>HUMALOG 100U/mL KwikPen, vial</p> <p>HUMALOG Jr. (insulin lispro) KwikPen</p> <p>Insulin lispro 100 U/mL vial (<i>all other manufacturers</i>)</p> <p>KIRSTY (insulin aspart-xjhz) Kwikpen, vial, Tempo pen</p> <p>LYUMJEV (insulin lispro-aabc) Kwikpen, vial, Tempo pen</p> <p>MERILOG (insulin aspart-szjj) pen, vial</p> | <ul style="list-style-type: none"> • If member has type 1 diabetes, must use in conjunction with long-acting insulin AND • Prescriber acknowledges that AfreZZA is not recommended in patients who smoke or have recently stopped smoking. |
| Short-Acting | | |
| No PA Required HUMULIN R U-100 (insulin regular) vial (OTC) NOVOLIN R U-100 (insulin regular) FlexPen (OTC) | PA Required NOVOLIN R U-100 (insulin regular) vial (OTC) | Non-preferred products may be approved following trial and failure of treatment with one preferred product (failure is defined as allergy or intolerable side effects). |
| Intermediate-Acting | | |
| No PA Required HUMULIN N U-100 (insulin NPH), KwikPen (OTC), vial (OTC) NOVOLIN N U-100 (insulin NPH) FlexPen (OTC) | PA Required NOVOLIN N U-100 (insulin NPH) vial (OTC) | Non-preferred products may be approved following trial and failure of treatment with one preferred product (failure is defined as allergy or intolerable side effects). |
| Long-Acting | | |
| Preferred LANTUS ^{BNR} (insulin glargine) Solostar, vial TRESIBA ^{BNR} (insulin degludec)* FlexTouch, vial | Non-Preferred BASAGLAR (insulin glargine) Kwikpen, Tempo pen Insulin degludec FlexTouch, vial Insulin glargine solostar, vial Insulin glargine MAX solostar Insulin glargine-yfgn pen, vial LEVEMIR (insulin detemir) FlexTouch, vial | <p>*Preferred Tresiba pen and vial formulations may be approved for members who have trialed and failed‡ Lantus.</p> <p>Non-preferred products may be approved if the member has tried and failed‡ treatment with Lantus AND a preferred insulin degludec product.</p> <p>‡Failure is defined as lack of efficacy, allergy, or intolerable side effects.</p> |

| | | |
|--|--|---|
| | REZVOGLAR (insulin glargine-aglr) Kwikpen SEMGLEE (insulin glargine-yfgn) pen, vial TOUJEO (insulin glargine) Solostar TOUJEO MAX (insulin glargine) Solostar | |
| Concentrated | | |
| No PA Required HUMULIN R U-500 (insulin regular) concentrated vial, Kwikpen | PA Required | Non-preferred products may be approved following trial and failure of treatment with one preferred product (failure is defined as allergy or intolerable side effects). |
| Mixtures | | |
| No PA Required HUMALOG MIX 50/50 Kwikpen HUMALOG MIX 75/25 vial HUMULIN 70/30 (OTC) Kwikpen, vial Insulin aspart protamine/insulin aspart 70/30 FlexPen, vial (generic Novolog Mix) Insulin lispro protamine/insulin lispro 75/25 Kwikpen (generic Humalog Mix) NOVOLOG MIX 70/30 FlexPen, vial | PA Required HUMALOG MIX 75/25 Kwikpen NOVOLIN 70/30 FlexPen, vial (OTC) | Non-preferred products may be approved if the member has failed treatment with two of the preferred products (failure is defined as: allergy or intolerable side effects). |
| Therapeutic Drug Class: DIABETES MANAGEMENT CLASSES, NON- INSULINS – 2/1/2026 | | |
| Amylin | | |
| | PA Required SYMLIN (pramlintide) pen | SYMLIN (pramlintide) may be approved following trial and failure of metformin AND trial and failure of a DPP-4 inhibitor or GLP-1 analogue. Failure is defined as lack of efficacy (such as not meeting hemoglobin A1C goal despite adherence to regimen) following 3-month trial, allergy, intolerable side effects, or a significant drug-drug interaction. Prior authorization may be approved for Symlin (pramlintide) products for members with a diagnosis of Type 1 diabetes without requiring trial and failure of other products. Maximum Dose: Prior authorization will be required for doses exceeding FDA-approved dosing listed in product package labeling. |
| Biguanides | | |

| No PA Required | PA Required | |
|---|--|--|
| Metformin IR tablets | GLUMETZA ER (metformin) tablet | Non-preferred products may be approved for members who have failed treatment with two preferred products. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction. |
| Metformin ER 500mg, 750mg tablets (generic Glucophage XR) | Metformin 625 mg tablets | Liquid metformin may be approved for members that are unable to use a solid oral dosage form. |
| | Metformin ER (generic Fortamet, Glumetza, <i>Bayshore Pharma</i>) | |
| | Metformin solution (generic Riomet) | |
| | RIOMET (metformin) solution | |
| | RIOMET ER (metformin) suspension | |

Dipeptidyl Peptidase 4 Enzyme inhibitors (DPP-4 Inhibitors)

| Preferred | Non-Preferred PA Required | | | | | | | | | | | | | | | |
|--------------------------------|--|---|-----------------|---------------------------------|-----------------------------|-----------|-----------------------|------------|---------------------|-----------|-----------------------|----------|-------------------------|----------|-----------------------|------------|
| TRADJENTA (linagliptin) tablet | Alogliptin tablet BRYNOVIN (Sitagliptin) tablet for suspension JANUVIA (sitagliptin) tablet NESINA (alogliptin) tablet ONGLYZA (saxagliptin) tablet Saxagliptin tablet Sitagliptin (generic Zituvio) ZITUVIO (sitagliptin tablet) | <p>Non-preferred DPP-4 inhibitors may be approved after a member has failed a 3-month trial of one preferred product. Failure is defined as lack of efficacy (such as not meeting hemoglobin A1C goal despite adherence to regimen), allergy, contraindication, intolerable side effects, or a significant drug-drug interaction.</p> <p><u>Continuation of therapy:</u> Members currently stabilized on Januvia (sitagliptin) may receive approval for continuation of therapy with that agent.</p> <p><u>Maximum Dose:</u> Prior authorization will be required for doses exceeding the FDA-approved maximum dosing listed in the following table:</p> <table border="1"> <thead> <tr> <th>DPP-4 Inhibitor</th> <th>FDA-Approved Maximum Daily Dose</th> </tr> </thead> <tbody> <tr> <td>Alogliptin (generic Nesina)</td> <td>25 mg/day</td> </tr> <tr> <td>Januvia (sitagliptin)</td> <td>100 mg/day</td> </tr> <tr> <td>Nesina (alogliptin)</td> <td>25 mg/day</td> </tr> <tr> <td>Onglyza (saxagliptin)</td> <td>5 mg/day</td> </tr> <tr> <td>Tradjenta (linagliptin)</td> <td>5 mg/day</td> </tr> <tr> <td>Zituvio (sitagliptin)</td> <td>100 mg/day</td> </tr> </tbody> </table> | DPP-4 Inhibitor | FDA-Approved Maximum Daily Dose | Alogliptin (generic Nesina) | 25 mg/day | Januvia (sitagliptin) | 100 mg/day | Nesina (alogliptin) | 25 mg/day | Onglyza (saxagliptin) | 5 mg/day | Tradjenta (linagliptin) | 5 mg/day | Zituvio (sitagliptin) | 100 mg/day |
| DPP-4 Inhibitor | FDA-Approved Maximum Daily Dose | | | | | | | | | | | | | | | |
| Alogliptin (generic Nesina) | 25 mg/day | | | | | | | | | | | | | | | |
| Januvia (sitagliptin) | 100 mg/day | | | | | | | | | | | | | | | |
| Nesina (alogliptin) | 25 mg/day | | | | | | | | | | | | | | | |
| Onglyza (saxagliptin) | 5 mg/day | | | | | | | | | | | | | | | |
| Tradjenta (linagliptin) | 5 mg/day | | | | | | | | | | | | | | | |
| Zituvio (sitagliptin) | 100 mg/day | | | | | | | | | | | | | | | |

DPP-4 Inhibitors – Combination with Metformin

| Preferred | Non-Preferred PA Required | <p>Non-preferred combination products may be approved for members who have been stable on the two individual ingredients of the requested combination for three months AND have had adequate three-month trial and failure of a preferred combination agent. Failure is defined as lack of efficacy (such as not meeting hemoglobin A1C goal despite adherence to regimen), contraindication, allergy, intolerable side effects, or a significant drug-drug interaction.</p> <p><u>Continuation of therapy:</u> Members currently stabilized on Janumet (sitagliptin/metformin) or Janumet XR (sitagliptin ER/metformin ER) may receive approval for continuation of therapy with those agents.</p> <p><u>Maximum Dose:</u> Prior authorization will be required for doses exceeding the FDA-approved maximum dosing listed in the following table:</p> <table border="1" data-bbox="1459 518 2413 1021"> <thead> <tr> <th data-bbox="1459 518 2024 616">DPP-4 Inhibitor Combination</th><th data-bbox="2024 518 2413 616">FDA Approved Maximum Daily Dose</th></tr> </thead> <tbody> <tr> <td data-bbox="1459 616 2024 698">Alogliptin/metformin tablet</td><td data-bbox="2024 616 2413 698">25 mg alogliptin/2,000 mg metformin</td></tr> <tr> <td data-bbox="1459 698 2024 780">Janumet and Janumet XR (sitagliptin/metformin)</td><td data-bbox="2024 698 2413 780">100 mg sitagliptin/2,000 mg of metformin</td></tr> <tr> <td data-bbox="1459 780 2024 861">Jentadueto and Jentadueto XR (linagliptin/metformin)</td><td data-bbox="2024 780 2413 861">5 mg linagliptin/2,000 mg metformin</td></tr> <tr> <td data-bbox="1459 861 2024 943">Kazano (alogliptin/metformin)</td><td data-bbox="2024 861 2413 943">25 mg alogliptin/2,000 mg metformin</td></tr> <tr> <td data-bbox="1459 943 2024 1021">Kombiglyze XR (saxagliptin ER/metformin ER) tablet</td><td data-bbox="2024 943 2413 1021">5 mg saxagliptin/2,000 mg metformin</td></tr> </tbody> </table> | DPP-4 Inhibitor Combination | FDA Approved Maximum Daily Dose | Alogliptin/metformin tablet | 25 mg alogliptin/2,000 mg metformin | Janumet and Janumet XR (sitagliptin/metformin) | 100 mg sitagliptin/2,000 mg of metformin | Jentadueto and Jentadueto XR (linagliptin/metformin) | 5 mg linagliptin/2,000 mg metformin | Kazano (alogliptin/metformin) | 25 mg alogliptin/2,000 mg metformin | Kombiglyze XR (saxagliptin ER/metformin ER) tablet | 5 mg saxagliptin/2,000 mg metformin |
|--|--|--|-----------------------------|---------------------------------|-----------------------------|-------------------------------------|--|--|--|-------------------------------------|-------------------------------|-------------------------------------|--|-------------------------------------|
| DPP-4 Inhibitor Combination | FDA Approved Maximum Daily Dose | | | | | | | | | | | | | |
| Alogliptin/metformin tablet | 25 mg alogliptin/2,000 mg metformin | | | | | | | | | | | | | |
| Janumet and Janumet XR (sitagliptin/metformin) | 100 mg sitagliptin/2,000 mg of metformin | | | | | | | | | | | | | |
| Jentadueto and Jentadueto XR (linagliptin/metformin) | 5 mg linagliptin/2,000 mg metformin | | | | | | | | | | | | | |
| Kazano (alogliptin/metformin) | 25 mg alogliptin/2,000 mg metformin | | | | | | | | | | | | | |
| Kombiglyze XR (saxagliptin ER/metformin ER) tablet | 5 mg saxagliptin/2,000 mg metformin | | | | | | | | | | | | | |

| Glucagon-like Peptide-1 Receptor Agonists (GLP-1 Analogues) | | |
|---|---|--|
| Preferred *Must meet eligibility criteria *Liraglutide pen (<i>Teva</i>) *OZEMPIC (semaglutide) pen *TRULICITY (dulaglutide) pen *VICTOZA (liraglutide) pen **WEGOVY (semaglutide) pen, tablet | Non-Preferred PA Required Exenatide pen Liraglutide pen (<i>all other manufacturers</i>) MOUNJARO (tirzepatide) pen RYBELSUS (semaglutide) oral tablet | <p>*Preferred products may be approved for members with a diagnosis of type 2 diabetes.</p> <p>**WEGOVY (semaglutide) may be approved if meeting the following criteria:</p> <ul style="list-style-type: none"> • Member is 18 years of age or older AND • Member has established cardiovascular disease (history of myocardial infarction, stroke, or symptomatic peripheral arterial disease) and either obesity or overweight (defined as a BMI $\geq 25 \text{ kg/m}^2$) AND • Member does not have a diagnosis of Type 2 diabetes AND • Wegovy (semaglutide) is being prescribed to decrease the risk of adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) AND • Member has been counseled regarding implementation of lifestyle interventions (diet modification and exercise) to promote weight loss. |

| | |
|------------------------|--|
| ZEPBOUND (tirzepatide) | <p>ZEPBOUND (tirzepatide) may be approved if meeting the following criteria:</p> <ul style="list-style-type: none"> • Member is 18 years of age or older AND • Member has a documented diagnosis of moderate to severe obstructive sleep apnea (OSA) AND • Member has a BMI $\geq 30 \text{ kg/m}^2$ indicating obesity documented in medical chart notes AND • Diagnosis of OSA is confirmed by a sleep test that is approved by the Food and Drug Administration (FDA) as a diagnostic device AND • A polysomnogram has been performed at baseline with a documented result of Apnea-Hypopnea Index (AHI) ≥ 15 events/hour (submission of sleep study documentation required) AND • Member is not pregnant or planning to become pregnant AND • Member has been counseled regarding the risk of medullary thyroid cancer (MTC) with the use of Zepbound (tirzepatide) and does not have a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) AND • The requested medication is being prescribed by or in consultation with a neurologist, pulmonologist, otolaryngologist, or other sleep medicine specialist AND • Member has been counseled regarding and is engaged in implementation of lifestyle interventions (diet modification and exercise) to promote weight loss AND • Member has failed a 6-month trial of continuous positive airway pressure (CPAP) or has a contraindication to the use of PAP therapy. <p>Reauthorization: Reauthorization for one year may be approved if meeting the following criteria:</p> <ul style="list-style-type: none"> • Member has previous PA approval on file (requests for members that do not have a historic PA approval on file will be subject to meeting “Initial Authorization” criteria listed above) AND • Prescriber attests that an in-person clinical re-evaluation of OSA from baseline has been performed by the treating practitioner AND • Clinical improvement in OSA symptoms has been documented in clinical chart notes AND • Adherence to use of Zepbound (tirzepatide) regimen has been evaluated by the treating practitioner. <p>Requests for GLP-1 analogues that are FDA-indicated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) may be approved if meeting the following:</p> <ul style="list-style-type: none"> • Member has a diagnosis of MASH with stage F2 to F3 fibrosis that has been confirmed by clinical presentation along with liver biopsy or imaging results AND • Member meets the FDA-labeled minimum age requirement for the prescribed product AND • Member does not have cirrhosis or significant liver disease other than MASH AND • The requested medication is being prescribed for use for the FDA-labeled indication and as outlined in product package labeling AND • Medication is prescribed by or in consultation with a gastroenterologist, endocrinologist, obesity medicine specialist, hepatologist, or liver transplant provider AND • Requests for non-preferred agents will be subject to meeting non-preferred criteria listed below. <p>All other non-preferred products may be approved for members with an FDA-labeled diagnosis (excluding labeled use solely for weight loss) following a trial and failure[‡] of three preferred agents that are FDA-labeled for use for the prescribed indication</p> <p>Continuation of therapy: Members that are currently stabilized on therapy with Mounjaro (tirzepatide) 7.5 mg, 10 mg, 12.5 mg, or 15 mg strengths may receive approval for continuation of therapy with that product strength.</p> |
|------------------------|--|

Maximum Dose:

Prior authorization is required for all products exceeding maximum dose listed in product package labeling.

| Table 1: GLP-1 Analogue Maximum Dose | |
|--------------------------------------|---------------|
| Mounjaro (tirzepatide) | 15 mg weekly |
| Ozempic (semaglutide) | 2 mg weekly |
| Rybelsus (semaglutide) | 14 mg daily |
| Trulicity (dulaglutide) | 4.5 mg weekly |
| Victoza (liraglutide) | 1.8 mg daily |
| Wegovy (semaglutide) | 2.4 mg weekly |
| | |

Failure is defined as lack of efficacy with a 3-month trial (such as not meeting hemoglobin A1C goal despite adherence to regimen), allergy, intolerable side effects, limited dexterity resulting in the inability to administer doses of a preferred product, or a significant drug-drug interaction.

Note: Prior Authorization for GLP-1 analogues prescribed solely for weight loss will not be approved.

Other Hypoglycemic Combinations

PA Required

Alogliptin/pioglitazone tablet

Glipizide/metformin tablet

Glyburide/metformin tablet

GLYXAMBI (empagliflozin/linagliptin) tablet

OSENI (alogliptin/pioglitazone) tablet

Pioglitazone/glimepiride tablet

QTERN (dapagliflozin/saxagliptin) tablet

SOLIQUA (insulin glargine/lixisenatide) pen

STEGLUJAN (ertugliflozin/sitagliptin) tablet

TRIJARDY XR tablet(empagliflozin/linagliptin/metformin)

XULTOPHY (insulin degludec/liraglutide) pen

Non-preferred products may be approved for members who have been stable on each of the individual ingredients in the requested combination for 3 months (including cases where the ingredients are taken as two separate 3-month trials or when taken in combination for at least 3 months).

SOLIQUA (insulin glargine/lixisenatide) may be approved if member has had a trial and failure with one preferred GLP-1 AND one preferred insulin glargine product (Failure is defined as lack of efficacy (such as not meeting hemoglobin A1C goal despite adherence to regimen), allergy, intolerable side effects, or significant drug-drug interaction.)

Meglitinides

| | | |
|--|--|---|
| Repaglinide tablet | PA Required Nateglinide tablet | Non-preferred products may be approved for members who have failed treatment with one preferred product. Failure is defined as: lack of efficacy (such as not meeting hemoglobin A1C goal despite adherence to regimen), allergy, intolerable side effects, or significant drug-drug interaction. |
| Meglitinides Combination with Metformin | | |
| | PA Required Repaglinide/metformin | Non-preferred products may be approved for members who have been stable on the two individual ingredients of the requested combination for 3 months. |
| Sodium-Glucose Cotransporter Inhibitors (SGLT inhibitors) | | |
| No PA Required FARXIGA ^{BNR} (dapagliflozin) tablet | PA Required Dapagliflozin tablet INPEFA (sotagliflozin) tablet INVOKANA (canagliflozin) tablet JARDIANCE (empagliflozin) tablet STEGLATRO (ertugliflozin) tablet | Non-preferred products may receive approval following trial and failure with one preferred product. Failure is defined as lack of efficacy with 3-month trial (such as not meeting hemoglobin A1C goal despite adherence to regimen), contraindication, allergy, intolerable side effects, or a significant drug-drug interaction. <u>Maximum Dose:</u> Prior authorization is required for all products exceeding maximum dose listed in product package labeling. |
| SGLT Inhibitor Combinations with Metformin | | |
| No PA Required XIGDUO XR ^{BNR} (dapagliflozin/metformin) tablet | PA Required Dapagliflozin/Metformin XR tablet INVOKAMET (canagliflozin/metformin) tablet INVOKAMET XR (canagliflozin/metformin) tablet SEGLUROMET (ertugliflozin/metformin) tablet SYNJARDY (empagliflozin/metformin) tablet SYNJARDY XR (empagliflozin/metformin) tablet | Non-preferred products may be approved for members who have been stable on the two individual ingredients of the requested combination for 3 months. INVOKAMET, INVOKAMET XR, SEGLUROMET, SYNJARDY, SYNJARDY XR and XIGDUO XR are contraindicated in patients with an eGFR less than 30 mL/min/1.73 m ² or on dialysis. |
| Thiazolidinediones (TZDs) | | |
| No PA Required Pioglitazone tablet | PA Required ACTOS (pioglitazone) tablet | Non-preferred agents may be approved following trial and failure of one preferred product. Failure is defined as lack of efficacy (such as not meeting hemoglobin A1C goal despite adherence to regimen) with a 3-month trial, allergy, intolerable side effects, or a significant drug-drug interaction. |
| Thiazolidinediones Combination with Metformin | | |

| | | | | | | | | | | | | | | | | | | | | |
|---|---|--|-------------------------|--------|---------------------------|--------|-------------------------|--------|-------------------------------|--------|--------------------------------|--------|---------------------------|--------|----------------------------|--------|-----------------------------|--------|-------------------------------|--------|
| Pioglitazone/metformin 50-1,500mg tablet | PA Required ACTOPLUS MET (pioglitazone/metformin) TABLET | Non-preferred products may be approved for members who have been stable on the two individual ingredients of the requested combination for 3 months. | | | | | | | | | | | | | | | | | | |
| | Pioglitazone/metformin 15-850mg tablet | | | | | | | | | | | | | | | | | | | |
| Therapeutic Drug Class: ESTROGEN AGENTS -Effective 10/1/2025 | | | | | | | | | | | | | | | | | | | | |
| No PA Required | PA Required | | | | | | | | | | | | | | | | | | | |
| Parenteral | | | | | | | | | | | | | | | | | | | | |
| DELESTROGEN 10mg ^{BNR} (estradiol valerate) vial DELESTROGEN 20mg, 40mg (estradiol valerate) vial | Estradiol valerate 10mg/mL vial | Non-preferred parenteral estrogen agents may be approved with trial and failure of one preferred parenteral agent. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction. | | | | | | | | | | | | | | | | | | |
| DEPO-ESTRODIOL (estradiol cypionate) vial Estradiol valerate 40mg/mL vial, 20mg/mL vial | | Non-preferred oral estrogen agents may be approved with trial and failure of one preferred oral agent. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction. | | | | | | | | | | | | | | | | | | |
| Oral/Transdermal | | | | | | | | | | | | | | | | | | | | |
| Estradiol oral tablet Estradiol (generic Climara) weekly patch MINIVELLE ^{BNR} (estradiol) patch VIVELLE-DOT ^{BNR} (estradiol) patch | CLIMARA (estradiol) patch DOTTI (estradiol) patch ESTRACE (estradiol) oral tablet Estradiol bi-weekly patch LYLLANA (estradiol) patch MENOSTAR (estradiol) patch | Non-preferred transdermal estrogen agents may be approved with trial and failure of two preferred transdermal agents. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction. | | | | | | | | | | | | | | | | | | |
| Table 1: Transdermal Estrogen FDA-Labeled Dosing | | | | | | | | | | | | | | | | | | | | |
| <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="padding: 2px;">ALORA (estradiol) patch</td> <td style="padding: 2px;">2/week</td> </tr> <tr> <td style="padding: 2px;">CLIMARA (estradiol) patch</td> <td style="padding: 2px;">1/week</td> </tr> <tr> <td style="padding: 2px;">DOTTI (estradiol) patch</td> <td style="padding: 2px;">2/week</td> </tr> <tr> <td style="padding: 2px;">Estradiol patch (once weekly)</td> <td style="padding: 2px;">1/week</td> </tr> <tr> <td style="padding: 2px;">Estradiol patch (twice weekly)</td> <td style="padding: 2px;">2/week</td> </tr> <tr> <td style="padding: 2px;">LYLLANA (estradiol) patch</td> <td style="padding: 2px;">2/week</td> </tr> <tr> <td style="padding: 2px;">MENOSTAR (estradiol) patch</td> <td style="padding: 2px;">1/week</td> </tr> <tr> <td style="padding: 2px;">MINIVELLE (estradiol) patch</td> <td style="padding: 2px;">2/week</td> </tr> <tr> <td style="padding: 2px;">VIVELLE-DOT (estradiol) patch</td> <td style="padding: 2px;">2/week</td> </tr> </table> | | | ALORA (estradiol) patch | 2/week | CLIMARA (estradiol) patch | 1/week | DOTTI (estradiol) patch | 2/week | Estradiol patch (once weekly) | 1/week | Estradiol patch (twice weekly) | 2/week | LYLLANA (estradiol) patch | 2/week | MENOSTAR (estradiol) patch | 1/week | MINIVELLE (estradiol) patch | 2/week | VIVELLE-DOT (estradiol) patch | 2/week |
| ALORA (estradiol) patch | 2/week | | | | | | | | | | | | | | | | | | | |
| CLIMARA (estradiol) patch | 1/week | | | | | | | | | | | | | | | | | | | |
| DOTTI (estradiol) patch | 2/week | | | | | | | | | | | | | | | | | | | |
| Estradiol patch (once weekly) | 1/week | | | | | | | | | | | | | | | | | | | |
| Estradiol patch (twice weekly) | 2/week | | | | | | | | | | | | | | | | | | | |
| LYLLANA (estradiol) patch | 2/week | | | | | | | | | | | | | | | | | | | |
| MENOSTAR (estradiol) patch | 1/week | | | | | | | | | | | | | | | | | | | |
| MINIVELLE (estradiol) patch | 2/week | | | | | | | | | | | | | | | | | | | |
| VIVELLE-DOT (estradiol) patch | 2/week | | | | | | | | | | | | | | | | | | | |
| <i>Note: Estrogen agents are a covered benefit for gender affirming hormone therapy and treating clinicians and mental health providers should be knowledgeable about the diagnostic criteria for gender-affirming hormone treatment and have sufficient training and experience in assessing related mental health conditions.</i> | | | | | | | | | | | | | | | | | | | | |
| Therapeutic Drug Class: GLUCAGON, SELF-ADMINISTERED – Effective 11/8/2024 | | | | | | | | | | | | | | | | | | | | |
| Preferred No PA Required | Non-Preferred PA Required | | | | | | | | | | | | | | | | | | | |

| | | |
|--|---|--|
| BAQSIMI (glucagon) nasal spray Glucagon Emergency Kit (<i>Eli Lilly, Fresenius, AmphaStar</i>) ZEGALOGUE (dasiglucagon) autoinjector | GVOKE (glucagon) Hypopen, Syringe, vial ZEGALOGUE (dasiglucagon) syringe | Non-preferred products may be approved if the member has failed treatment with two preferred products (failure is defined as allergy to ingredients in product, intolerable side effects, contraindication, or inability to administer dosage form). Quantity limit for all products: 2 doses per year unless used/ damaged/ lost |
|--|---|--|

Therapeutic Drug Class: GROWTH HORMONES – Effective 10/1/2025

| Preferred | Non-Preferred | <p>All preferred products may be approved if the member has one of the qualifying diagnoses listed below (diagnosis may be verified through AutoPA) AND if prescription does not exceed limitations for maximum dosing (Table 1).</p> <p>*Second line preferred products (NGENLA, SKYTROFA) require trial and failure of Genotropin (somatropin) OR Norditropin (somatropin).</p> <p>Non-preferred Growth Hormone products may be approved if the following criteria are met:</p> <ul style="list-style-type: none"> Member failed treatment with one preferred growth hormone product (failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions) AND Member has a qualifying diagnosis that includes any of the following conditions: <ul style="list-style-type: none"> Prader-Willi Syndrome (PWS) Chronic renal insufficiency/failure requiring transplantation (defined as Creatinine Clearance < 30mL/min) Turner's Syndrome Hypopituitarism: as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy or trauma verified by one of the following: <ul style="list-style-type: none"> Has failed at least one GH stimulation test (peak GH level < 10 ng/mL) Has at least one documented low IGF-1 level (below normal range for patient's age – refer to range on submitted lab document) Has deficiencies in ≥ 3 pituitary axes (such as TSH, LH, FSH, ACTH, ADH) Cachexia associated with AIDS Noonan Syndrome Short bowel syndrome Neonatal symptomatic growth hormone deficiency (limited to 3-month PA approval) Prescription does not exceed limitations for FDA-labeled maximum dosing for prescribed indication (Table 1) based on prescriber submission/verification of patient weight from most recent clinical documentation | | | |
|---|---|---|------------|--|--|
| GENOTROPIN (somatropin) cartridge, Miniquick pen NGENLA (Somatropin-ghla)* pen NORDITROPIN (somatropin) Flexpro pen SKYTROFA (lonapegsomatropin-tcgd)* cartridge | HUMATROPE (somatropin) cartridge NUTROPIN AQ (somatropin) Nuspin injector OMNITROPE (somatropin) cartridge, vial SAIZEN (somatropin) cartridge, vial SEROSTIM (somatropin) vial SOGROYA (somapacitan-boco) pen ZOMACTON (somatropin) vial | <p>Table 1: Growth Hormone Product Maximum Dosing*</p> <table border="1"> <thead> <tr> <th>Medication</th><th>Pediatric Maximum Dosing per week (age < 18 years)</th><th>Adult Maximum Dosing per week (age ≥ 18 years)</th></tr> </thead> </table> | Medication | Pediatric Maximum Dosing per week (age < 18 years) | Adult Maximum Dosing per week (age ≥ 18 years) |
| Medication | Pediatric Maximum Dosing per week (age < 18 years) | Adult Maximum Dosing per week (age ≥ 18 years) | | | |

| | | |
|---------------------|--|--|
| Genotropin | 0.48 mg/kg/week | 0.08 mg/kg/week |
| Humatrope | 0.47 mg/kg/week | 0.0875 mg/kg/week |
| Ngenla | 0.66 mg/kg/week | Not Indicated |
| Norditropin Flexpro | 0.47 mg/kg/week | 0.112 mg/kg/week |
| Nutropin AQ Nuspin | 0.7 mg/kg/week | 0.175 mg/kg/week for \leq 35 years of age 0.0875 mg/kg/week for $>$ 35 years of age |
| Omnitrope | 0.48 mg/kg/week | 0.08 mg/kg/week |
| Saizen | 0.18 mg/kg/week | 0.07 mg/kg/week |
| Serostim | Not Indicated | 42 mg/week for HIV wasting or cachexia (in combination with antiretroviral therapy) |
| Skytrofa | 1.68 mg/kg/week | Not Indicated |
| Sogroya | Dose Individualized for each patient, based on growth response | 8 mg/week |
| Zomacton | 0.47 mg/kg/week | 0.0875 mg/kg/week |
| Zorbtive | Not Indicated | 56 mg/week for up to 4 weeks for short bowel syndrome only |

*Based on FDA labeled indications and dosing

VII. Gastrointestinal

Therapeutic Drug Class: BILE SALTS – Effective 7/1/2025

| No PA Required | PA Required | Actigall (ursodiol) may be approved for members who meet the following criteria: <ul style="list-style-type: none"> • Member is \geq 18 years of age AND • Member has tried and failed therapy with a 12-month trial of a preferred ursodiol product (failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions). Chenodal (chenodiol) may be approved for members who meet the following criteria: <ul style="list-style-type: none"> • Member is $>$ 18 years of age AND • Member has tried and failed therapy with a 12-month trial of a preferred ursodiol product (failure is defined as lack of efficacy, contraindication, allergy, intolerable side effects or |
|------------------|---|---|
| Ursodiol capsule | BYLVAY (odevixibat) capsule, pellet | |
| Ursodiol tablet | CHENODAL (chenodiol) tablet CHOLBAM (cholic acid) capsule LIVMARLI (maralixibat) solution, tablet | |

| | |
|---|---|
| OCALIVA (obeticholic acid) tablet RELTONE (ursodiol) capsule URSO (ursodiol) tablet URSO FORTE (ursodiol) tablet | <p>significant drug-drug interactions). If chenodiol is being prescribed for treatment of cerebrotendinous xanthomatosis, no trial and failure of ursodiol is required.</p> <p>Cholbam (cholic acid) may be approved for members who meet the following criteria:</p> <ul style="list-style-type: none"> • Bile acid synthesis disorders: <ul style="list-style-type: none"> ○ Member age must be greater than 3 weeks old AND ○ Member has a diagnosis for bile acid synthesis disorder due to single enzyme defect (Single Enzyme-Defect Disorders: Defective sterol nucleus synthesis, 3β-hydroxy-Δ-c27-steroid oxidoreductase deficiency, AKR1D1 deficiency, CYP7A1 deficiency, Defective side-chain synthesis, CYP27A1 deficiency (cerebrotendinous xanthomatosis), 2-methylacyl-CoA racemase deficiency (AMACR), 25-hydroxylation pathway (Smith-Lemli-Opitz). • Peroxisomal disorder including Zellweger spectrum disorders: <ul style="list-style-type: none"> ○ Member age must be greater than 3 weeks old AND ○ Member has diagnosis of peroxisomal disorders (PDs) including Zellweger spectrum disorders AND ○ Member has manifestations of liver disease, steatorrhea or complications from decreased fat-soluble vitamin absorption. <p>Ocaliva (obeticholic acid) may be approved for members meeting the following criteria:</p> <ul style="list-style-type: none"> • Member is \geq 18 years of age AND • Medication is prescribed by or in consultation with a gastroenterologist, hepatologist, or liver transplant provider AND • Member has the diagnosis of primary biliary cholangitis without cirrhosis OR a diagnosis of primary biliary cholangitis with compensated cirrhosis with no evidence of portal hypertension AND • Member has failed treatment with a preferred ursodiol product for at least 6 months due to an inadequate response, intolerable side effects, drug-drug interaction, or allergy to preferred ursodiol formulations. <p>Reltone (ursodiol) may be approved for members meeting the following criteria:</p> <ul style="list-style-type: none"> • Member is \geq 18 years of age AND • The requested medication is prescribed by or in consultation with a gastroenterologist, hepatologist, or liver transplant provider AND • The requested medication is being prescribed for one of the following: <ul style="list-style-type: none"> ○ Treatment of radiolucent, noncalcified gallbladder stones < 20 mm in greatest diameter AND elective cholecystectomy would be undertaken except for the presence of increased surgical risk due to systemic disease, advanced age, idiosyncratic reaction to general anesthesia, or for those patients who refuse surgery OR ○ Prevention of gallstone formation in obese patients experiencing rapid weight loss AND • No compelling reasons for the member to undergo cholecystectomy exist, including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary-gastrointestinal fistula, AND |
|---|---|

| | |
|--|---|
| | <ul style="list-style-type: none"> Member has trialed and failed treatment with a preferred ursodiol product for at least 6 months due to an inadequate response, intolerable side effects, drug-drug interaction, or allergy to inactive ingredients contained in the preferred ursodiol formulations. <p><u>Initial approval:</u> 1 year</p> <p><u>Reauthorization:</u> May be reauthorized for 1 additional year with provider attestation that partial or complete stone dissolution was observed after completion of the initial year of Reltone therapy. Maximum cumulative approval per member is 24 months.</p> <p>Urso (ursodiol) and Urso Forte (ursodiol) may be approved for members meeting the following criteria:</p> <ul style="list-style-type: none"> Member is \geq 18 years of age AND Medication is prescribed by or in consultation with a gastroenterologist, hepatologist, or liver transplant provider AND Member has the diagnosis of Primary Biliary Cholangitis as evidenced by two of the following at the time of diagnosis: <ul style="list-style-type: none"> Evidence of cholestasis with an alkaline phosphatase elevation of at least 1.5 times the upper limit of normal Presence of antimitochondrial antibody with titer of 1:40 or higher Histologic evidence of nonsuppurative destruction cholangitis and destruction of interlobular bile ducts AND Member has failed treatment with a preferred ursodiol product for at least 6 months due to an inadequate response, intolerable side effects, drug-drug interaction, or allergy to inactive ingredients contained in the preferred ursodiol formulations. <p>Requests for drug products that are FDA-indicated for the treatment of nonalcoholic steatohepatitis (NASH) may be approved if meeting the following:</p> <ul style="list-style-type: none"> A diagnosis of NASH has been confirmed through liver biopsy AND Member meets the FDA-labeled minimum age requirement for the prescribed product AND Member does not have significant liver disease other than NASH, AND The requested medication is being prescribed for use for the FDA-labeled indication and as outlined in product package labeling AND Medication is prescribed by or in consultation with a gastroenterologist, hepatologist, or liver transplant provider. <p>Non-preferred products prescribed for FDA-labeled indications not identified above may receive approval for use as outlined in product package labeling.</p> |
|--|---|

| Therapeutic Drug Class: ANTI-EMETICS, Oral – <i>Effective 7/1/2025</i> | |
|--|---|
| No PA Required DICLEGIS DR ^{BNR} tablet (doxylamine/pyridoxine) | PA Required AKYNZEO (netupitant/palonosetron) capsule |

| | | |
|---|--|--|
| Meclizine (Rx) 12.5 mg, 25 mg tablet Metoclopramide solution, tablet Ondansetron ODT; 4mg, 8mg tablet Ondansetron oral suspension/ solution Prochlorperazine tablet Promethazine syrup, tablet | ANTIVERT (meclizine) 50 mg tablet ANZEMET (dolasetron) tablet Aprepitant capsule, tripack BONJESTA ER (doxylamine/pyridoxine) tablet Doxylamine/pyridoxine tablet (generic Diclegis) Dronabinol capsule EMEND (aprepitant) capsule, powder for suspension, dose/tri-pack Granisetron tablet MARINOL (dronabinol) capsule Ondansetron 16mg tablet REGLAN (metoclopramide) tablet Trimethobenzamide capsule ZOFTRAN (ondansetron) tablet | Emend (aprepitant) TriPack or Emend (aprepitant) powder kit may be approved following trial and failure of two preferred products AND Emend (aprepitant) <u>capsule</u> . Failure is defined as lack of efficacy with 14-day trial, allergy, intolerable side effects, or significant drug-drug interaction. Doxylamine/pyridoxine tablet (generic) or Bonjesta (doxylamine/pyridoxine) may be approved for 9 months if meeting the following criteria: <ul style="list-style-type: none">• Member has nausea and vomiting associated with pregnancy AND• Member has trialed and failed Diclegis DR tablet AND one of the following (failure is defined as lack of efficacy with a 7-day trial, allergy, intolerable side effects, or significant drug-drug interaction):<ul style="list-style-type: none">◦ Antihistamine (such as diphenhydramine, dimenhydrinate, meclizine) OR◦ Dopamine antagonist (such as metoclopramide, prochlorperazine, promethazine) OR◦ Serotonin antagonist (ondansetron, granisetron) All other non-preferred products may be approved for members who have trialed and failed treatment with two preferred products. Failure is defined as lack of efficacy with 14-day trial, allergy, intolerable side effects, or significant drug-drug interaction. Dronabinol prior authorization may be approved for members meeting above non-preferred criteria OR via AutoPA for members with documented HIV diagnosis. Promethazine product formulations require prior authorization for members < 2 years of age due to risk of fatal respiratory depression. |
|---|--|--|

Therapeutic Drug Class: ANTI-EMETICS, Non-Oral – Effective 7/1/2025

| No PA Required | PA Required | |
|---|--|--|
| Prochlorperazine 25 mg suppository | PROMETHEGAN 50 mg (Promethazine) suppository | Non-preferred products may be approved for members who have trialed and failed treatment with two preferred products. Failure is defined as lack of efficacy with 14-day trial, allergy, intolerable side effects, contraindication, or significant drug-drug interaction. |
| Promethazine 12.5 mg, 25 mg suppository | SANCUSO (granisetron) patch | |
| Scopolamine patch | TRANSDERM-SCOP (scopolamine) patch | |

Therapeutic Drug Class: GI MOTILITY, CHRONIC – Effective 7/1/2025

| | |
|---|--|
| PA Required for all agents in this class | |
|---|--|

| Preferred | Non-Preferred | |
|--|--|--|
| LINZESS (linaclotide) capsule Lubiprostone capsule MOVANTIK (naloxegol) tablet | Alosetron tablet AMITIZA (lubiprostone) capsule IBSRELA tablet LOTRONEX (alosetron) tablet MOTEGRITY (prucalopride) tablet Prucalopride tablet RELISTOR (methylnaltrexone) syringe, tablet, vial SYMPROIC (naldemedine) tablet TRULANCE (plecanatide) tablet VIBERZI (eluxadoline) tablet | <p>All agents will only be approved for FDA labeled indications and up to FDA approved maximum doses listed below.</p> <p>Preferred agents may be approved if the member meets the following criteria:</p> <ul style="list-style-type: none"> Has diagnosis of Irritable Bowel Syndrome – Constipation (IBS-C), Chronic Idiopathic Constipation (CIC), Functional Constipation (FC), or Opioid Induced Constipation (OIC) in patients with opioids prescribed for noncancer pain AND Member does not have a diagnosis of GI obstruction AND For indication of OIC, member opioid use must exceed 4 weeks of treatment AND For indications of CIC, OIC, IBS-C; member must have documentation of adequate trial of two or more over-the-counter motility agents (polyethylene glycol, docusate or bisacodyl, for example). OR If the member cannot take oral medications, then the member must fail a 7-day trial with a nonphosphate enema (docusate or bisacodyl enema). Failure is defined as a lack of efficacy for a 7-day trial, allergy, intolerable side effects, contraindication to, or significant drug-drug interaction AND For indication of IBS-D, must have documentation of adequate trial and failure with loperamide and trial and failure with dicyclomine or hyoscyamine. Failure is defined as a lack of efficacy for a 7-day trial, allergy, intolerable side effects, contraindication to, or significant drug-drug interaction. <p>Non-preferred agents may be approved if the member meets the following criteria:</p> <ul style="list-style-type: none"> Member meets all listed criteria for preferred agents AND Member has trialed and failed two preferred agents OR if the indication is OIC caused by methadone, then a non-preferred agent may be approved after an adequate trial of MOVANTIK (naloxegol). Failure is defined as a lack of efficacy for a 7-day trial, allergy, intolerable side effects, contraindication to, or significant drug-drug interaction AND If prescribed Viberzi (eluxadoline) or Lotronex (alosetron), member meets the additional criteria for those agents listed below. <p>VIBERZI (eluxadoline) may be approved for members who meet the following additional criteria:</p> <ul style="list-style-type: none"> Diagnosis of Irritable Bowel Syndrome – Diarrhea (IBS-D) AND Member has a gallbladder AND Member does not have severe hepatic impairment (Child-Pugh C), history of severe constipation, known mechanical gastrointestinal obstruction, biliary duct obstruction, history of pancreatitis or structural disease of the pancreas AND Member does not drink more than 3 alcoholic drinks per day <p>LOTRONEX (alosetron) and generic alosetron may be approved for members who meet the following additional criteria:</p> <ul style="list-style-type: none"> Member is a female with Irritable Bowel Syndrome – Diarrhea (IBS-D) with symptoms lasting 6 months or longer AND Member does not have severe hepatic impairment (Child-Pugh C), history of severe constipation or ischemic colitis, hypercoagulable state, Crohn's disease or ulcerative colitis, or |

| | | |
|--|--|--|
| | | known mechanical gastrointestinal obstruction. |
| Medication | | |
| Amitiza (lubiprostone) | IBS-C (females only), CIC, OIC (not caused by methadone) | 48mcg/day |
| Linzess (linaclotide) | IBS-C, CIC (\geq 18 years) | 290mcg/day |
| Movantik (naloxegol) | OIC, FC (6 to 17 years) | 25mg/day (OIC), 72mcg/day (FC) |
| Viberzi (eluxadoline) | IBS-D | 200mg/day |
| Relistor subcutaneous injection (methylnaltrexone) | OIC | 12mg/day |
| Relistor oral (methylnaltrexone) | OIC | 450mg/day |
| Lotronex (alosetron) | IBS-D (women only) | 2mg/day (women only) |
| Symporic (Naldemedine) | OIC | 0.2mg/day |
| Trulance (plecanatide) | CIC, IBS-C | 3mg/day |
| Motegrity (prucalopride) | CIC | 2mg/day |

CIC – chronic idiopathic constipation, FC – functional constipation, OIC – opioid induced constipation, IBS – irritable bowel syndrome, D – diarrhea predominant, C – constipation predominant

Therapeutic Drug Class: **H. PYLORI TREATMENTS – Effective 7/1/2025**

| No PA Required | PA Required | |
|---|--|---|
| PYLERA ^{BNR} capsule (bismuth subcitrate/metronidazole tetracycline) | Amoxicillin/lansoprazole/clarithromycin pack Bismuth subcitrate/metronidazole tetracycline capsule OMECLAMOX-PAK (amoxicillin/ omeprazole/clarithromycin) TALICIA (omeprazole/amoxicillin/ rifabutin) tablet VOQUEZNA DUAL (vonoprazan/amoxicillin) dose pack VOQUEZNA TRIPLE (vonoprazan/amoxicillin/ clarithromycin dose pack | Non-preferred <i>H. pylori</i> treatments should be used as individual product ingredients unless one of the individual products is not commercially available, then a PA for the combination product may be given. |

Therapeutic Drug Class: **HEMORRHOIDAL, ANORECTAL, AND RELATED TOPICAL ANESTHETIC AGENTS – Effective 7/1/2025**

| Hydrocortisone single agent | |
|-----------------------------|-------------|
| No PA Required | PA Required |

| | | |
|---|--|---|
| ANUSOL-HC (hydrocortisone) 2.5% cream with applicator CORTIFOAM (hydrocortisone) 10% aerosol Hydrocortisone 1% cream with applicator Hydrocortisone 2.5% cream with applicator Hydrocortisone enema | CORTENEMA (hydrocortisone) enema PROCORT cream | Non-preferred products may be approved following trial and failure of therapy with 3 preferred products (failure is defined as lack of efficacy with 4-week trial, allergy, intolerable side effects or significant drug-drug interactions). |
| Lidocaine single agent | | |
| No PA Required Lidocaine 3% cream, 5% ointment | PA Required | |
| Other and Combinations | | |
| No PA Required Lidocaine-Hydrocortisone 3-0.5% cream with applicator Lidocaine-Prilocaine Cream (<i>all other manufacturers</i>) PROCTOFOAM-HC (hydrocortisone-pramoxine) 1%-1% foam | PA Required ANALPRAM HC (Hydrocortisone-Pramoxine) 1%-1% cream, 2.5%-1% cream EPIFOAM (Hydrocortisone-Pramoxine) 1%-1% foam Hydrocortisone-Pramoxine 1%-1%, 2.5%-1% cream Lidocaine-Hydrocortisone in Coleus 2%-2% cream kit Lidocaine-Hydrocortisone 2.8%-0.55% gel Lidocaine-Hydrocortisone 3%-0.5% cream w/o applicator, cream kit Lidocaine-Hydrocortisone 3%-1% cream kit Lidocaine-Hydrocortisone 3%-2.5% gel kit Lidocaine-Prilocaine Cream (<i>Fougera only</i>) PLIAGLIS (lidocaine-tetracaine) 7%-7% cream PROCORT (Hydrocortisone-Pramoxine) 1.85%-1.15% cream RECTIV (nitroglycerin) 0.4% ointment | RECTIV (nitroglycerin) ointment may be approved if meeting the following: <ul style="list-style-type: none"> • Member has a diagnosis of anal fissure AND • Prescriber attests that member has trialed and maximized use of appropriate supportive therapies including sitz bath, fiber, topical analgesics (such as lidocaine), and stool softeners/laxatives. |

| Therapeutic Drug Class: PANCREATIC ENZYMES – Effective 7/1/2025 | | |
|--|--|---|
| No PA Required | PA Required | |
| CREON (pancrelipase) capsule | PERTZYE (pancrelipase) capsule | Non-preferred products may be approved for members who have failed an adequate trial (4 weeks) with at least two preferred products. Failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interaction. |
| VIOKACE (pancrelipase) tablet | | |
| ZENPEP (pancrelipase) capsule | | |
| Therapeutic Drug Class: PROTON PUMP INHIBITORS – Effective 7/1/2025 | | |
| No PA Required | PA Required | |
| Esomeprazole DR packet for oral suspension, capsule (RX) | ACIPHEX (rabeprazole) tablet, sprinkle capsule | For members treating GERD symptoms that are controlled on PPI therapy, it is recommended that the dose of the PPI be re-evaluated or step-down with an H2 blocker (such as famotidine) be trialed in order to reduce long-term PPI use. |
| Lansoprazole DR capsules (RX) | DEXILANT (dexlansoprazole) capsule | Prior authorization for non-preferred proton pump inhibitors may be approved if all of the following criteria are met: |
| Lansoprazole ODT (RX) <i>(for members under 2 years)</i> | Dexlansoprazole capsule | <ul style="list-style-type: none"> ● Member has a qualifying diagnosis (below) AND ● Member has trialed and failed therapy with three preferred agents within the last 24 months. (Failure is defined as: lack of efficacy following 4-week trial, allergy, intolerable side effects, or significant drug-drug interaction) AND ● Member has been diagnosed using one of the following diagnostic methods: <ul style="list-style-type: none"> ○ Diagnosis made by GI specialist ○ Endoscopy ○ X-ray ○ Biopsy ○ Blood test ○ Breath Test |
| Omeprazole DR capsule (RX) | KONVOME (Omeprazole/Na bicarbonate) suspension | |
| Pantoprazole tablet | Lansoprazole DR capsule OTC | |
| PROTONIX (pantoprazole DR) packet for oral suspension ^{BNR} | Lansoprazole ODT (OTC) | |
| | NEXIUM (esomeprazole) capsule (RX), oral suspension packet, 24HR (OTC) | |
| | Omeprazole/Na bicarbonate capsule, packet for oral suspension | Qualifying Diagnoses: |
| | Omeprazole DR tablet (OTC), ODT (OTC) | Barrett's esophagus, duodenal ulcer, erosive esophagitis, gastric ulcer, GERD, GI Bleed, H. pylori infection, hypersecretory conditions (Zollinger-Ellison), NSAID-induced ulcer, pediatric esophagitis, requiring mechanical ventilation, requiring a feeding tube |
| | Pantoprazole packet for oral suspension | |
| | PREVACID (lansoprazole) capsule, Solutab, suspension | Quantity Limits: |
| | PRILOSEC (omeprazole) suspension | All agents will be limited to once daily dosing except when used for the following diagnoses: Barrett's esophagus, GI Bleed, H. pylori infection, hypersecretory conditions (Zollinger-Ellison), or members who have spinal cord injury with associated acid reflux. |
| | PROTONIX (pantoprazole DR) tablet | |
| | Rabeprazole tablet | Adult members with GERD on once daily, high-dose PPI therapy who continue to experience symptoms may receive initial prior authorization approval for a 4-week trial of twice daily, high-dose PPI therapy. Continuation of the twice daily dosing regimen for GERD beyond 4 weeks will require additional prior authorization approval verifying adequate member response to the dosing regimen and approval may be placed for one year. If a member with symptomatic GERD does not respond to twice daily, high-dose PPI therapy, this should be considered a treatment failure. |
| | VOQUEZNA (vonoprazan) tablet | |

| | | |
|--|---|---|
| | ZEGERID (omeprazole/Na bicarbonate) capsule, packet for oral suspension | <p>Pediatric members (< 18 years of age) on once daily dosing of a PPI who continue to experience symptoms may receive one-year prior authorization approval for twice daily PPI therapy.</p> <p>Age Limits: Nexium 24H and Zegerid will not be approved for members less than 18 years of age.</p> <p>Prevacid Solutab may be approved for members < 2 years of age OR for members \geq 2 years of age with a feeding tube.</p> <p>Continuation of Care: Members currently taking Dexilant (dexlansoprazole) capsules may continue to receive approval for that medication.</p> |
|--|---|---|

Therapeutic Drug Class: NON-BIOLOGIC ULCERATIVE COLITIS AGENTS- Oral – Effective 11/21/2025

| No PA Required | PA Required | |
|---|--|--|
| APRISO (mesalamine ER) capsule | AZULFIDINE (sulfasalazine) Entab, tablet | Prior authorization for non-preferred oral formulations will require trial and failure of two preferred oral products with different active ingredients AND one preferred rectal product. If inflammation is not within reach of topical therapy, trial of preferred rectal product is not required. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction. |
| Mesalamine DR tablet (generic Lialda) (<i>Takeda, Lannet, GSMS, and Bryant Ranch Manufacturers</i>) | Balsalazide capsule | |
| Mesalamine ER capsule (generic Apriso) (<i>Teva only</i>) | Budesonide DR tablet | Uceris (budesonide) tablet: Prior authorization may be approved following trial and failure of one preferred oral product AND one preferred rectal product. If inflammation is not within reach of topical therapy, trial of preferred rectal product is not required. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction. Approval will be placed for 8 weeks. Further prior authorization may be approved if 7 days of steroid-free time has elapsed, and member continues to meet the above criteria. |
| PENTASA ^{BNR} (mesalamine) capsule | COLAZAL (balsalazide) capsule | |
| Sulfasalazine IR and DR tablet | DELZICOL (mesalamine DR) capsule | |
| | DIPENTUM (olsalazine) capsule | |
| | LIALDA (mesalamine DR) tablet | |
| | Mesalamine DR tablet (generic Asacol HD, Lialda – all other manufacturers) | |
| | Mesalamine DR/ER capsule (generic Delzicol and Pentasa) | |
| | UCERIS (budesonide) tablet | |

Therapeutic Drug Class: NON-BIOLOGIC ULCERATIVE COLITIS AGENTS- Rectal – Effective 7/1/2025

| No PA Required | PA Required | |
|--|---------------------------------|--|
| Mesalamine suppository | Budesonide foam | Prior authorization for non-preferred rectal formulations will require trial and failure of one preferred rectal formulation and one preferred oral formulation (Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction). |
| Mesalamine 4gm/60 ml enema (generic SF ROWASA) | CANASA (mesalamine) suppository | Uceris (budesonide) foam: If the above criteria are met, Uceris (budesonide) foam prior authorization may be approved for 6 weeks. Further prior authorization may be approved if 7 days of steroid-free time has elapsed, and member continues to meet the above criteria. |
| SF ROWASA enema, kit (mesalamine) | Mesalamine enema, kit | |

| | | |
|--|--|--|
| | ROWASA enema, kit (mesalamine) UCERIS (budesonide) foam | |
|--|--|--|

VIII. Hematological

Therapeutic Drug Class: ANTICOAGULANTS- Oral – Effective 7/1/2025

| No PA Required | PA Required | |
|---|---------------------------------------|--|
| Dabigatran capsule | PRADAXA (dabigatran) capsule, pellet | SAVAYSA (edoxaban) may be approved if all the following criteria have been met: |
| ELIQUIS (apixaban) tablet, tablet pack | Rivaroxaban tablet | <ul style="list-style-type: none"> • The member has failed therapy with two preferred agents. (Failure is defined as lack of efficacy, allergy, intolerable side effects, contraindication, or significant drug-drug interaction) AND |
| Warfarin tablet | Rivaroxaban oral suspension | <ul style="list-style-type: none"> • Member is not on dialysis AND |
| XARELTO (rivaroxaban) ^{BNR} 10 mg, 15 mg, 20 mg tablet, dose pack | SAVAYSA (edoxaban) tablet | <ul style="list-style-type: none"> • Member does not have CrCl > 95 mL/min AND • The member has a diagnosis of deep vein thrombosis (DVT), pulmonary embolism (PE) OR • The member has a diagnosis of non-valvular atrial fibrillation AND • The member does not have a mechanical prosthetic heart valve |
| | XARELTO (rivaroxaban) 2.5 mg tablet | XARELTO 2.5mg (rivaroxaban) may be approved for members meeting all of the following criteria: |
| | XARELTO (rivaroxaban) oral suspension | <ul style="list-style-type: none"> • Xarelto 2.5mg is being prescribed to reduce major CV events in members diagnosis of chronic coronary artery disease (CAD) or peripheral artery disease AND • Xarelto 2.5mg is being taken twice daily and in combination with aspirin 75-100mg daily AND • Member must not be receiving dual antiplatelet therapy, other non-aspirin antiplatelet therapy, or other oral anticoagulant AND • Member must not have had an ischemic, non-lacunar stroke within the past month AND • Member must not have had a hemorrhagic or lacunar stroke at any time |
| | | XARELTO (rivaroxaban) oral suspension may be approved without prior authorization for members <18 years of age who require a rivaroxaban dose of less than 10 mg OR with prior authorization verifying the member is unable to use the solid oral dosage form. |
| | | All other non-preferred oral agents require trial and failure of two preferred oral agents. Failure is defined as lack of efficacy, allergy, intolerable side effects, contraindication, or significant drug-drug interaction. |
| | | Continuation of Care: Members with current prior authorization approval on file for a non-preferred <u>oral</u> anticoagulant medication may continue to receive approval for that medication |

Therapeutic Drug Class: ANTICOAGULANTS- Parenteral – Effective 7/1/2025

| No PA Required | PA Required | |
|--------------------|--------------------------------|--|
| Enoxaparin syringe | ARIXTRA (fondaparinux) syringe | Non-preferred parenteral anticoagulants may be approved if member has trial and failure of one preferred parenteral agent. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction |
| Enoxaparin vial | Fondaparinux syringe | |

| | | |
|--|--|--|
| | FRAGMIN (dalteparin) vial, syringe LOVENOX (enoxaparin) syringe, vial | ARIIXTRA (fondaparinux) may be approved if the following criteria have been met: <ul style="list-style-type: none"> • Member is 18 years of age or older AND • Member has a CrCl > 30 ml/min AND • Member weighs > 50 kg AND • Member has a documented history of heparin induced-thrombocytopenia OR • Member has a contraindication to enoxaparin Members currently stabilized on fondaparinux (Arixtra) or dalteparin (Fragmin) may receive prior authorization approval to continue receiving that medication. |
|--|--|--|

| Therapeutic Drug Class: ANTI-PLATELETS – <i>Effective 4/8/2025</i> | | |
|--|-----------------------------|---|
| No PA Required | PA Required | |
| Aspirin/dipyridamole ER capsule | EFFIENT (prasugrel) tablet | Zontivity (vorapaxar) may be approved for patients with a diagnosis of myocardial infarction or peripheral artery disease without a history of stroke, transient ischemic attack, intracranial bleeding, or active pathological bleeding. Patients must also be taking aspirin and/or clopidogrel concomitantly. |
| BRILINTA (ticagrelor) tablet ^{BNR} | PLAVIX (clopidogrel) tablet | Non-preferred products without criteria will be reviewed on a case-by-case basis. |
| Cilostazol tablet | Ticagrelor tablet | |
| Clopidogrel tablet | | |
| Dipyridamole tablet | | |
| Pentoxifylline ER tablet | | |
| Prasugrel tablet | | |

| Therapeutic Drug Class: COLONY STIMULATING FACTORS – <i>Effective 7/1/2025</i> | | |
|--|--|---|
| PA Required for all agents in this class* | | |
| Preferred | Non-Preferred | |
| FULPHILA (pegfilgrastim-jmdb) syringe | FYLNETRA (pegfilgrastim-jmdb) syringe | *Prior authorization for preferred agents may be approved if meeting the following criteria: <ul style="list-style-type: none"> • Medication is being used for one of the following indications: <ul style="list-style-type: none"> ◦ Patient with cancer receiving myelosuppressive chemotherapy –to reduce incidence of infection (febrile neutropenia) (Either the post nadir ANC is less than 10,000 cells/mm³ or the risk of neutropenia for the member is calculated to be greater than 20%) ◦ Acute Myeloid Leukemia (AML) patients receiving chemotherapy ◦ Bone Marrow Transplant (BMT) ◦ Peripheral Blood Progenitor Cell Collection and Therapy ◦ Hematopoietic Syndrome of Acute Radiation Syndrome ◦ Severe Chronic Neutropenia (Evidence of neutropenia infection exists or ANC is below 750 cells/mm³) |
| NEUPOGEN (filgrastim) vial, syringe | GRANIX (tbo-filgrastim) syringe, vial | Prior authorization for non-preferred agents may be approved if meeting the following criteria: <ul style="list-style-type: none"> • Medication is being used for one of the following indications: <ul style="list-style-type: none"> ◦ Patient with cancer receiving myelosuppressive chemotherapy –to reduce incidence of infection (febrile neutropenia) (Either the post nadir ANC is less than 10,000 cells/mm³ or the risk of neutropenia for the member is calculated to be greater than 20%) |
| | LEUKINE (sargramostim) vial | |
| | NEULASTA (pegfilgrastim) kit, syringe | |
| | NIVESTYM (filgrastim-aafi) syringe, vial | |
| | NYVEPRIA (pegfilgrastim-apgf) syringe | |
| | RELEUKO (filgrastim-ayow) syringe, vial | |
| | RYZNEUTA (efbemalenograstim alfa-vuxw) syringe | |

| | | |
|--|--|---|
| | <p>STIMUFEND (pegfilgrastim-fpgk) syringe</p> <p>UDENYCA (pegfilgrastim-cbqv) autoinjector, On-Body, syringe</p> <p>ZARXIO (filgrastim-sndz) syringe</p> <p>ZIEXTENZO (pegfilgrastim-bmez) syringe</p> | <ul style="list-style-type: none"> ○ Acute Myeloid Leukemia (AML) patients receiving chemotherapy ○ Bone Marrow Transplant (BMT) ○ Peripheral Blood Progenitor Cell Collection and Therapy ○ Hematopoietic Syndrome of Acute Radiation Syndrome ○ Severe Chronic Neutropenia (Evidence of neutropenia infection exists or ANC is below 750 cells/mm³) <p>AND</p> <ul style="list-style-type: none"> ● Member has history of trial and failure of Neupogen AND one other preferred agent. Failure is defined as a lack of efficacy with a 3-month trial, allergy, intolerable side effects, significant drug-drug interactions, or contraindication to therapy. Trial and failure of Neupogen will not be required if meeting one of the following: <ul style="list-style-type: none"> ○ Member has limited access to caregiver or support system for assistance with medication administration OR ○ Member has inadequate access to healthcare facility or home care interventions. |
|--|--|---|

Therapeutic Drug Class: **ERYTHROPOIESIS STIMULATING AGENTS** – Effective 7/1/2025

| PA Required for all agents in this class* | | |
|--|--|---|
| Preferred | Non-Preferred | |
| EPOGEN (epoetin alfa) vial | ARANESP (darbepoetin alfa) syringe, vial | *Prior Authorization is required for all products and may be approved if meeting the following: <ul style="list-style-type: none"> ● Medication is being administered in the member's home or in a long-term care facility AND ● Member meets <u>one</u> of the following: <ul style="list-style-type: none"> ○ A diagnosis of cancer, currently receiving chemotherapy, with chemotherapy-induced anemia, and hemoglobin[†] of 10g/dL or lower OR ○ A diagnosis of chronic renal failure, and hemoglobin[†] below 10g/dL OR ○ A diagnosis of hepatitis C, currently taking ribavirin and failed response to a reduction of ribavirin dose, and hemoglobin[†] less than 10g/dL (or less than 11g/dL if symptomatic) OR ○ A diagnosis of HIV, currently taking zidovudine, hemoglobin[†] less than 10g/dL, and serum erythropoietin level of 500 mU/mL or less OR ○ Member is undergoing elective, noncardiac, nonvascular surgery and medication is given to reduce receipt of allogenic red blood cell transfusions, hemoglobin[†] is greater than 10g/dL, but less than or equal to 13g/dL and high risk for perioperative blood loss. Member is not willing or unable to donate autologous blood pre-operatively <p>AND</p> <ul style="list-style-type: none"> ● For any non-preferred product, member has trialed and failed treatment with one preferred product. Failure is defined as lack of efficacy with a 6-week trial, allergy, intolerable side effects, or significant drug-drug interaction. |
| RETACRIT (epoetin alfa-epbx) (<i>Pfizer only</i>) vial | MIRCERA (methoxy peg-epoetin beta) syringe | |

[†]Hemoglobin results must be from the last 30 days.

IX. Immunological

Therapeutic Drug Class: **IMMUNE GLOBULINS** – Effective 1/1/2026

| PA Required for all agents in this class* | | Preferred agents may be approved for members meeting at least one of the approved conditions for immune globulin use listed below for prescribed doses not exceeding maximum (Table 1). | | | | | | | | |
|--|----------------------------------|---|-------------------|-----------------------------|--------------------|------------------------------|--------------------|------------------------------|-------------------------------|----------------------|
| Preferred | Non-Preferred | | | | | | | | | |
| BIVIGAM 10% IV liquid | ALYGLO 10% IV liquid | Non-preferred agents may be approved for members meeting the following: | | | | | | | | |
| CUTAQUIG 16.5% SQ liquid | ASCENIV 10% IV liquid | <ul style="list-style-type: none"> Member meets at least one of the approved conditions listed below AND | | | | | | | | |
| CUVITRU 20% SQ liquid | FLEBOGAMMA DIF 5%, 10% IV liquid | <ul style="list-style-type: none"> Member has history of trial and failure of two preferred agents (failure is defined as lack of efficacy with 4-week trial, allergy, intolerable side effects or significant drug-drug interactions) AND | | | | | | | | |
| GAMMAGARD 10% IV/SQ liquid | GAMMAGARD S/D vial | <ul style="list-style-type: none"> Prescribed dose does not exceed listed maximum (Table 1) | | | | | | | | |
| GAMMAKED 10% IV/SQ liquid | GAMMAPLEX 5%, 10% IV liquid | Approved Conditions for Immune Globulin Use: | | | | | | | | |
| GAMUNEX-C 10% IV/SQ liquid | HIZENTRA 20% SQ syringe, vial | <ul style="list-style-type: none"> Primary Humoral Immunodeficiency disorders including: <ul style="list-style-type: none"> Common Variable Immunodeficiency (CVID) Severe Combined Immunodeficiency (SCID) X-Linked Agammaglobulinemia X-Linked with Hyperimmunoglobulin M (IgM) Immunodeficiency Wiskott-Aldrich Syndrome Members < 13 years of age with pediatric Human Immunodeficiency Virus (HIV) and CD-4 count > 200/mm³ | | | | | | | | |
| PRIVIGEN 10% IV liquid | HYQVIA 10% SQ liquid | <ul style="list-style-type: none"> Neurological disorders including: <ul style="list-style-type: none"> Guillain-Barré Syndrome Relapsing-Remitting Multiple Sclerosis Chronic Inflammatory Demyelinating Polyneuropathy Myasthenia Gravis Polymyositis and Dermatomyositis Multifocal Motor Neuropathy | | | | | | | | |
| <i>If immune globulin is being administered in a long-term care facility or in a member's home by a home healthcare provider, it should be billed as a pharmacy claim. All other claims must be submitted through the medical benefit.</i> | | <ul style="list-style-type: none"> Kawasaki Syndrome Chronic Lymphocytic Leukemia (CLL) Autoimmune Neutropenia (AN) with absolute neutrophil count < 800 mm and history of recurrent bacterial infections Autoimmune Hemolytic Anemia (AHA) Liver or Intestinal Transplant Immune Thrombocytopenia Purpura (ITP) including: <ul style="list-style-type: none"> Requiring preoperative therapy for undergoing elective splenectomy with platelet count < 20,000/mcL Members with active bleeding & platelet count < 30,000/mcL Pregnant members with platelet counts < 10,000/mcL in the third trimester Pregnant members with platelet count 10,000 to 30,000/mcL who are bleeding Multisystem Inflammatory Syndrome in Children (MIS-C) Measles post-exposure prophylaxis (PEP) | | | | | | | | |
| Table 1: FDA-Approved Maximum Immune Globulin Dosing | | | | | | | | | | |
| <table border="1"> <tr> <td>Alyglo – IV admin</td><td>800mg/kg every 3 to 4 weeks</td></tr> <tr> <td>Asceniv – IV admin</td><td>800 mg/kg every 3 to 4 weeks</td></tr> <tr> <td>Bivigam – IV admin</td><td>800 mg/kg every 3 to 4 weeks</td></tr> <tr> <td>Cutaquig – subcutaneous admin</td><td>See product labeling</td></tr> </table> | | | Alyglo – IV admin | 800mg/kg every 3 to 4 weeks | Asceniv – IV admin | 800 mg/kg every 3 to 4 weeks | Bivigam – IV admin | 800 mg/kg every 3 to 4 weeks | Cutaquig – subcutaneous admin | See product labeling |
| Alyglo – IV admin | 800mg/kg every 3 to 4 weeks | | | | | | | | | |
| Asceniv – IV admin | 800 mg/kg every 3 to 4 weeks | | | | | | | | | |
| Bivigam – IV admin | 800 mg/kg every 3 to 4 weeks | | | | | | | | | |
| Cutaquig – subcutaneous admin | See product labeling | | | | | | | | | |

| | | |
|---|---|--|
| Cuvitru –subcutaneous admin | 12 grams protein/site for up to four sites weekly (48grams/week) | |
| Flebogamma DIF – IV admin | 600 mg/kg every 3 weeks | |
| Gammaplex 5% – IV admin | 1 gram/kg for 2 consecutive days (ITP) 800 mg/kg every 3 to 4 weeks (PI) | |
| Gammagard liquid subcutaneous or IV admin | 2.4 grams/kg/month (IV for MMN) 2 grams/kg over 2 to 5 consecutive days (IV for CIDP) 600 mg/kg every 3 weeks (IV for PI) | |
| Gammaked –subcutaneous or IV admin | 2 grams/kg over 2 consecutive days (IV for ITP, CIDP) 600 mg/kg every 3 weeks (IV for PI) | |
| Gamunex-C –subcutaneous or IV admin | 2 grams/kg over 2 to 5 consecutive days (IV for ITP, CIDP) 600 mg/kg every 3 weeks (IV for PI) | |
| Hizentra –subcutaneous admin | 0.4 grams/kg per week over 2 consecutive days (CIDP) | |
| Octagam – IV admin | 2 grams/kg over 2 to 5 consecutive days (ITP, DM) 600 mg/kg every 3 weeks (PI) | |
| Panzyga – IV admin | 2 grams/kg over 2 consecutive days (ITP, CIDP) 600 mg/kg every 3 weeks (PI) | |
| Privigen – IV admin | 2 grams/kg over 2 to 5 consecutive days (ITP, CIDP) 800 mg/kg every 3 weeks (PI) | |
| Xembify – subcutaneous admin | 150 mg/kg/day for 5 consecutive days (PI loading dose) | |
| <i>CIDP=Chronic Inflammatory Demyelinating Polyneuropathy; DM=Dermatomyositis; ITP= Chronic Immune Thrombocytopenic Purpura; MMN=Multifocal Motor Neuropathy; PI=Primary Humoral Immunodeficiency</i> | | |
| Members currently receiving a preferred or non-preferred immunoglobulin product may receive approval to continue therapy with that product at prescribed doses not exceeding maximum (Table 1). | | |

| Therapeutic Drug Class: NEWER GENERATION ANTIHISTAMINES – Effective 1/1/2026 | | |
|---|--|--|
| No PA Required | PA Required | |
| <p>Cetirizine (OTC) syrup/solution (OTC/RX), tablet</p> <p>Desloratadine tablet (RX)</p> <p>Levocetirizine tablet (RX/OTC)</p> <p>Loratadine tablet (OTC), syrup/solution (OTC)</p> | | |
| | <p>Cetirizine (OTC) chewable tablet, softgel, UD cups solution</p> <p>CLARINEX (desloratadine) tablet</p> <p>Desloratadine ODT (RX)</p> <p>Fexofenadine tablet (OTC), suspension (OTC)</p> <p>Levocetirizine solution (RX)</p> <p>Loratadine chewable (OTC), ODT (OTC)</p> | <p>Non-preferred single agent antihistamine products may be approved for members who have failed treatment with two preferred products in the last 6 months. For members with respiratory allergies, an additional trial of an intranasal corticosteroid will be required in the last 6 months.</p> <p>Failure is defined as lack of efficacy with a 14-day trial, allergy, intolerable side effects, or significant drug-drug interaction.</p> |
| Therapeutic Drug Class: ANTIHISTAMINE/DECONGESTANT COMBINATIONS – Effective 1/1/2026 | | |
| No PA Required | PA Required | |
| <p>Cetirizine-PSE ER (OTC)</p> <p>Loratadine-D (OTC) tablet</p> | | |
| | <p>CLARINEX-D (desloratadine-D)</p> <p>Fexofenadine/PSE (OTC)</p> | <p>Non-preferred antihistamine/decongestant combinations may be approved for members who have failed treatment with the preferred product in the last 6 months. For members with respiratory allergies, an additional trial of an intranasal corticosteroid will be required in the last 6 months.</p> <p>Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction.</p> |
| Therapeutic Drug Class: INTRANASAL RHINITIS AGENTS – Effective 1/1/2026 | | |
| No PA Required | PA Required | |
| <p>Azelastine 137 mcg</p> <p>Budesonide (OTC)</p> <p>DYMISTA (azelastine/ fluticasone)^{BNR}</p> <p>Fluticasone (RX)</p> <p>Ipratropium</p> <p>Olopatadine</p> <p>Triamcinolone acetonide (OTC)</p> | | |
| | <p>Azelastine (Astupro) 0.15%</p> <p>Azelastine/Fluticasone</p> <p>BECONASE AQ (beclomethasone dipropionate)</p> <p>Flunisolide 0.025%</p> <p>Fluticasone (OTC)</p> <p>Mometasone</p> <p>NASONEX (mometasone)</p> <p>OMNARIS (ciclesonide)</p> <p>PATANASE (olopatadine)</p> | <p>Non-preferred products may be approved following trial and failure of treatment with three preferred products (failure is defined as lack of efficacy with a 2-week trial, allergy, intolerable side effects or significant drug-drug interactions).</p> <p>Non-preferred combination agents may be approved following trial of individual products with same active ingredients AND trial and failure of one additional preferred agent (failure is defined as lack of efficacy with 2-week trial, allergy, intolerable side effects or significant drug-drug interactions).</p> |

| | | |
|--|--|--|
| | QNASL (beclomethasone) RYALTRIS (olopatadine/mometasone) XHANCE (fluticasone) ZETONNA (ciclesonide) | |
|--|--|--|

Therapeutic Drug Class: LEUKOTRIENE MODIFIERS – Effective 1/1/2026

| No PA Required | PA Required | |
|------------------------------|--|--|
| Montelukast tablet, chewable | ACCOLATE (zafirlukast) tablet Montelukast granules SINGULAIR (montelukast) tablet, chewable, granules Zafirlukast tablet Zileuton ER tablet ZYFLO (zileuton) tablet | <p>Non-preferred products may be approved if meeting the following criteria:</p> <ul style="list-style-type: none"> Member has trialed and failed treatment with one preferred product (failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions) AND Member has a diagnosis of asthma. <p>Montelukast granules may be approved if a member has tried and failed montelukast chewable tablets AND has difficulty swallowing.</p> |

Therapeutic Drug Class: METHOTREXATE PRODUCTS – Effective 1/1/2026

| No PA Required | PA Required | |
|---------------------------|--|---|
| Methotrexate tablet, vial | JYLAMVO (methotrexate) solution OTREXUP (methotrexate) auto-injector RASUVO (methotrexate) auto-injector REDITREX (methotrexate) syringe TREXALL (methotrexate) tablet XATMEP (methotrexate) solution | <p>OTREXUP, REDITREX or RASUVO may be approved if meeting the following criteria:</p> <ul style="list-style-type: none"> Member has diagnosis of severe, active rheumatoid arthritis OR active polyarticular juvenile idiopathic arthritis (pJIA) OR inflammatory bowel disease (IBD) AND Member has trialed and failed preferred methotrexate tablet formulation (failure is defined as lack of efficacy, allergy, intolerable side effects, inability to take oral product formulation, or member has a diagnosis of pJIA and provider has determined that the subcutaneous formulation is necessary to optimize methotrexate therapy) AND Member (or parent/caregiver) is unable to administer preferred methotrexate vial formulation due to limited functional ability (such as vision impairment, limited manual dexterity and/or limited hand strength). <p>TREXALL may be approved if meeting the following criteria:</p> <ul style="list-style-type: none"> Member has trialed and failed preferred methotrexate tablet formulation. Failure is defined as allergy or intolerable side effects. <p>XATMEP may be approved for members who meet the following criteria:</p> <ul style="list-style-type: none"> Member is < 18 years of age Member has a diagnosis of acute lymphoblastic leukemia OR |

| | | |
|--|--|---|
| | | <ul style="list-style-type: none"> • Member has a diagnosis of active polyarticular juvenile idiopathic arthritis (pJIA) and has had an insufficient therapeutic response to, or is intolerant to, an adequate trial of first-line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs) AND • Member has a documented swallowing difficulty due to young age and/or a medical condition and is unable to use the preferred methotrexate tablet formulation <p><i>Methotrexate can cause serious embryo-fetal harm when administered during pregnancy and it is contraindicated for use during pregnancy for the treatment of non-malignant diseases. Advise members of reproductive potential to use effective contraception during and after treatment with methotrexate, according to FDA product labeling.</i></p> <p>Members currently stabilized on a non-preferred methotrexate product may receive approval to continue that agent.</p> |
|--|--|---|

Therapeutic Drug Class: MULTIPLE SCLEROSIS AGENTS – Effective 6/5/2025

Disease Modifying Therapies

| Preferred No PA Required (Unless indicated*) | Non-Preferred PA Required | |
|---|--|---|
| AVONEX (interferon beta 1a) pen, syringe | AUBAGIO (teriflunomide) tablet | *Kesimpta (ofatumumab) may be approved if member has trialed and failed treatment with one preferred agent (failure is defined as intolerable side effects, contraindication to therapy, drug-drug interaction, or lack of efficacy). |
| BETASERON (interferon beta 1b) injection | BAFIERTAM (monomethyl fumarate DR) capsule | <u>Non-Preferred Products:</u> Non-preferred products may be approved if meeting the following: |
| COPAXONE (glatiramer) 20mg injection ^{BNR} | COPAXONE (glatiramer) 40mg injection | <ul style="list-style-type: none"> • Member has a diagnosis of a relapsing form of multiple sclerosis AND • Member has previous trial and failure with three preferred agents. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction AND • Prescribed dose does not exceed the maximum FDA-approved dose for the medication being ordered AND • If indicated in the product labeling, a negative pre-treatment pregnancy test has been documented, AND • If indicated in the product labeling, an ophthalmologic examination has been performed and documented prior to medication initiation, AND • The request meets additional criteria listed for any of the following: |
| Dimethyl fumarate tablet, starter pack | EXTAVIA (interferon beta 1b) kit, vial | |
| Fingolimod capsule | GILENYA (fingolimod) capsule | |
| Glatiramer 40mg injection | Glatiramer 20mg | |
| *KESIMPTA (ofatumumab) pen ^{**2nd Line**} | GLATOPA (glatiramer) injection | |
| Teriflunomide tablet | MAVENCLAD (cladribine) tablet | |
| | MAYZENT (siponimod) tablet, pack | Mayzent (siponimod): |
| | PLEGRIDY (peg-interferon beta 1a) pen, syringe | <ul style="list-style-type: none"> • Member has previous trial and failure of three preferred agents, one of which must be Gilenya (fingolimod). Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction. |
| | PONVORY (ponesimod) tablet, pack | Mavenclad (cladribine): |
| | REBIF (interferon beta 1a) syringe | <ul style="list-style-type: none"> • Member has history of ≥ 1 relapse in the 12 months preceding initiation of therapy AND • Member has previous trial and failure of three other therapies for relapsing forms of multiple sclerosis (failure is defined as lack of efficacy with 3-month trial, allergy, intolerable side effects, or significant drug-drug interactions) |
| | REBIF REDIDOSE (interferon beta 1a) pen | |
| | TASCENO ODT (fingolimod) tablet | |

| | |
|---|--|
| <p>TECFIDERA (dimethyl fumarate) tablet, pack</p> <p>VUMERITY (diroximel DR) capsule</p> <p>ZEPOSIA (ozanimod) capsule, kit, starter pack</p> | <p>Vumerity (diroximel fumarate) or Bafiertam (monomethyl fumarate DR):</p> <ul style="list-style-type: none"> Member has previous trial and failure of three preferred agents, one of which must be Tecfidera (dimethyl fumarate). Failure is defined as lack of efficacy, allergy, significant drug-drug interactions, intolerable side effects (if GI adverse events, must meet additional criteria below) AND If the requested medication is being prescribed due to GI adverse events with Tecfidera therapy (and no other reason for failure of Tecfidera is given), then the following additional criteria must be met: <ul style="list-style-type: none"> Member has trialed a temporary dose reduction of Tecfidera (with maintenance dose being resumed within 4 weeks) AND Member has trialed taking Tecfidera with food AND GI adverse events remain significant despite maximized use of gastrointestinal symptomatic therapies (such as calcium carbonate, bismuth subsalicylate, PPIs, H2 blockers, anti-bloating/anti-constipation agents, anti-diarrheal, and centrally acting anti-emetics) AND Initial authorization will be limited to 3 months. Continuation (12-month authorization) will require documentation of clinically significant reduction in GI adverse events. <p>Members currently stabilized on a preferred second line (Kesimpta) or non-preferred product (may receive approval to continue therapy with that agent).</p> |
|---|--|

| Symptom Management Therapies | | |
|------------------------------|----------------------------------|---|
| No PA Required | PA Required | Non-preferred products may be approved with prescriber attestation that there is clinical rationale supporting why the preferred brand/generic equivalent product formulation is unable to be used. |
| Dalfampridine ER tablet | AMPYRA ER (dalfampridine) tablet | <p><u>Maximum Dose:</u> Ampyra (dalfampridine) 10mg twice daily</p> |

Therapeutic Drug Class: TARGETED IMMUNE MODULATORS – Effective 2/6/2026

Preferred agents: Adalimumab-aacf syringe, aaty and abdm; ADBRY (tralokinumab-ldrm); AMJEVITA (adalimumab-atto), YUFLYMA (adalimumab-atty)
Cyltezo (adalimumab-abdm); DUPIXENT (dupilumab); ENBREL (etanercept); FASENRA (benralizumab) pen; OTEZLA (apremilast) tablet; KEVZARA (sarilumab);
TALTZ (ixekizumab); TEZSPIRE (tezepelumab-ekko) pen; XELJANZ ER/IR (tofacitinib) tablet; XOLAIR (omalizumab) syringe; IMULDOSA (ustekinumab-slr); STEQEYMA (ustekinumab-stba) syringe;
SELARSDI (ustekinumab-AEKN) syringe

| Rheumatoid Arthritis, all other Arthritis (except psoriatic arthritis, see below), and Ankylosing Spondylitis | | |
|---|--|---|
| Preferred | Non-Preferred | First line preferred agents (preferred adalimumab products, ENBREL, and XELJANZ) may receive approval for use for FDA-labeled indications. |
| <p>No PA Required (If diagnosis met) (*Must meet eligibility criteria)</p> <p>Adalimumab-aacf syringe</p> | <p>PA Required</p> <p>ABRILADA (adalimumab-afzb) pen, syringe</p> <p>ACTEMRA (tocilizumab) syringe, Actpen</p> | <p>*TALTZ (ixekizumab) may receive approval for use for FDA-labeled indications following trial and failure‡ of a preferred adalimumab product or ENBREL.</p> |

| | | |
|---|--|--|
| Adalimumab-aaty pen | Adalimumab-aacf pen | * KEVZARA (sarilumab) may receive approval for use for FDA-labeled indications following trial and failure‡ of: <ul style="list-style-type: none"> • A preferred adalimumab product or ENBREL AND • XELJANZ. |
| Adalimumab-adbm pen (IJ Kit) | Adalimumab-adaz pen, syringe | * TYENNE (tocilizumab-aazg) may receive approval for use for FDA-labeled indications following trial and failure‡ of: <ul style="list-style-type: none"> • A preferred adalimumab product or ENBREL AND • XELJANZ. |
| AMJEVITA (adalimumab-atto) auto-injector, syringe | Adalimumab-adbm syringe, Crohns pen IJ Kit, PS-UV pen IJ kit | |
| CYLTEZO (adalimumab-adbm) pen, syringe | Adalimumab-fljp pen, syringe | |
| ENBREL (etanercept) | Adalimumab-ryvk auto-injector | |
| *KEVZARA (sarilumab) pen, syringe | Adalimumab-aaty (2 pack) 20 mg, 40 mg syringe (Celltrion manufacturer) | <u>Quantity Limits:</u> XELJANZ IR is limited to 2 tablets per day or 60 tablets for a 30-day supply XELJANZ XR is limited to 1 tablet per day or 30 tablets for a 30-day supply |
| *TALTZ (ixekizumab) 80 mg syringe, autoinjector | BIMZELX (bimekizumab-bkzx) pen | |
| *TYENNE (tocilizumab-aazg) pen, syringe | CIMZIA (certolizumab pegol) syringe, vial | |
| XELJANZ IR (tofacitinib) tablet | COSENTYX (secukinumab) syringe, pen-injector | Non-Preferred Agents: |
| XELJANZ XR (tofacitinib ER) tablet | HADLIMA (adalimumab-bwwd) Pushtouch, syringe | COSENTYX (secukinumab) may receive approval if meeting the following criteria: <ul style="list-style-type: none"> • The request meets general non-preferred criteria listed below OR • The requested drug is prescribed for treatment of enthesitis-related arthritis and meets the following: <ul style="list-style-type: none"> ◦ Member is \geq 4 years of age and weighs \geq 15 kg AND ◦ Member has had trialed and failed‡ NSAID therapy and either ENBREL or a preferred adalimumab product. |
| YUFLYMA (adalimumab-aaty) auto-injector, syringe | HULIO (adalimumab-fljp) pen, syringe | |
| | HUMIRA (adalimumab) | HUMIRA brand and non-preferred adalimumab agents may receive approval if meeting the following: <ul style="list-style-type: none"> • The request meets one of the following: <ul style="list-style-type: none"> ◦ The prescribed agent is a preferred adalimumab product OR ◦ If the prescribed agent is brand Humira or a non-preferred adalimumab product, then the member has trialed and failed at least one preferred adalimumab product. Failure is defined as lack of efficacy or intolerable side effects with the preferred adalimumab product. |
| | HYRIMOZ (adalimumab-adaz) pen, syringe | AND |
| | IDACIO (adalimumab-aacf) pen, syringe | <ul style="list-style-type: none"> • The general non-preferred criteria listed below are met. |
| | ILARIS (canakinumab) vial | |
| | KINERET (anakinra) syringe | KINERET (anakinra) may receive approval for: <ul style="list-style-type: none"> • Treatment of systemic juvenile idiopathic arthritis (sJIA) or Adult-Onset Still's Disease (AOSD) OR • Treatment of rheumatoid arthritis following trial and failure‡ of <ul style="list-style-type: none"> ◦ A preferred adalimumab product or ENBREL AND ◦ XELJANZ |
| | OLUMIANT (baricitinib) tablet | |
| | ORENCIA (abatacept) clickject, syringe | |
| | RINVOQ (upadacitinib), solution, tablet | |
| | SIMLANDI (adalimumab-ryvk) auto-injector | |
| | SIMPONI (golimumab) pen, syringe | |
| | SKYRIZI (risankizumab-rzaa) OnBody, SC pen, syringe | ILARIS (canakinumab) may receive approval if meeting the following: |

| | |
|--|--|
| <p>XELJANZ (tofacitinib) solution YUSIMRY (adalimumab-aqvh) pen</p> <p>Note: Product formulations in the physician administered drug (PAD) category are located on Appendix P</p> | <ul style="list-style-type: none"> Medication is being prescribed for systemic juvenile idiopathic arthritis (sJIA) or Adult-Onset Still's Disease (AOSD) AND The request meets general non-preferred drug criteria listed below. <p>Quantity Limit: 300mg (2mL) every 4 weeks</p> <p>XELJANZ (tofacitinib) oral solution may be approved with verification that the member cannot swallow a tofacitinib tablet</p> <p>All other non-preferred agents may receive approval for FDA-labeled indications following trial and failure[‡] of the following preferred agents when FDA-indicated or having strong evidence supporting use for the prescribed indication from clinically recognized guideline compendia:</p> <ul style="list-style-type: none"> Adalimumab or ENBREL AND XELJANZ AND TYENNE, KEVZARA, or TALTZ <p>Non-preferred agents that are being prescribed per FDA labeling to treat non-radiographic axial spondyloarthritis (nr-axSpA) will require trial and failure[‡] of preferred agents that are FDA-labeled for treating an axial spondyloarthritis condition, including ankylosing spondylitis (AS) or nr-axSpA.</p> <p><u>Continuation of therapy:</u> Members currently taking a preferred agent may receive approval to continue therapy with that agent. Members with current prior authorization approval on file for a non-preferred agent that does not have a preferred biosimilar may receive approval for continuation of therapy with the prescribed agent.</p> <p>[‡]Failure is defined as lack of efficacy, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interaction. Note that trial and failure of preferred TNF inhibitors will not be required when prescribed to treat polyarticular juvenile idiopathic arthritis (pJIA) in members with documented clinical features of lupus.</p> |
|--|--|

| Psoriatic Arthritis | | |
|--|--|---|
| Preferred No PA Required (If diagnosis met) (*Must meet eligibility criteria) | Non-Preferred PA Required | |
| Adalimumab-aacf syringe | ABRILADA (adalimumab-afzb) pen, syringe | First line preferred agents (preferred adalimumab products, ENBREL, XELJANZ) may receive approval for psoriatic arthritis indication. |
| Adalimumab-aaty pen | Adalimumab-aacf pen | *OTEZLA (apremilast) may receive approval for psoriatic arthritis indication following trial and failure [‡] of: |
| Adalimumab-adbm pen (IJ Kit) | Adalimumab-adbm syringe, Crohns pen IJ Kit, PS-UV pen IJ kit | <ul style="list-style-type: none"> • A preferred adalimumab product or ENBREL AND • XELJANZ |
| AMJEVITA (adalimumab-atto) auto-injector, syringe | Adalimumab-fkjp pen, syringe | *TALTZ (ixekizumab) may receive approval for psoriatic arthritis indication following trial and failure [‡] of: |
| CYLTEZO (adalimumab-adbm) pen, syringe | Adalimumab-ryvk auto-injector | <ul style="list-style-type: none"> • A preferred adalimumab product or ENBREL AND • XELJANZ |

| | | |
|--|---|---|
| <p>ENBREL (etanercept)</p> <p>*IMULDOSA (ustekinumab-SRLF) syringe</p> <p>*OTEZLA (apremilast) tablet</p> <p>*SELARSDI (ustekinumab-AEKN) syringe</p> <p>*STARJEMZA (ustekinumab-hmny) 45mg/0.5mL vial</p> <p>*STEQEYMA (ustekinumab-stba) syringe</p> <p>*TALTZ (ixekizumab) 80 mg syringe</p> <p>XELJANZ IR (tofacitinib) tablet</p> <p>XELJANZ XR (tofacitinib ER) tablet</p> <p>YUFLYMA (adalimumab-aaty) auto-injector, syringe</p> | <p>Adalimumab-aaty (2 pack) 20 mg, 40 mg syringe (Celltrion manufacturer)</p> <p>BIMZELX (bimekizumab-bkzx) pen</p> <p>CIMZIA (certolizumab pegol) syringe, vial</p> <p>COSENTYX (secukinumab) syringe, pen-injector</p> <p>HADLIMA (adalimumab-bwwd) Pushtouch, syringe</p> <p>HULIO (adalimumab-fkjp) pen, syringe</p> <p>HUMIRA (adalimumab)</p> <p>HYRIMOZ (adalimumab-adaz) pen, syringe</p> <p>IDACIO (adalimumab-aacf) pen, syringe</p> <p>ORENCIA (abatacept) syringe, clickject</p> <p>OTULFI (ustekinumab-aauz) syringe</p> <p>PYZCHIVA (ustekinumab-ttwe) syringe</p> <p>RINVOQ (upadacitinib) tablet</p> <p>RINVOQ LQ (upadacitinib) solution</p> <p>SIMLANDI (adalimumab-ryvk) auto-injector</p> <p>SIMPONI (golimumab) pen, syringe</p> <p>SKYRIZI (risankizumab-rzaa) OnBody, pen, syringe</p> <p>STARJEMZA (ustekinumab-hmny) all other formulations</p> <p>STELARA (ustekinumab) syringe</p> <p>TREMFYA (guselkumab) pen, injector, syringe</p> <p>Ustekinumab (generic Stelara, TTWE, AEKN) syringe, vial</p> <p>WEZLANA (ustekinumab-aaub) syringe, vial</p> | <p>*USTEKINUMAB preferred products (IMULDOSA, SELARSDI, STEQEYMA) may receive approval for psoriatic arthritis indication following trial and failure‡ of:</p> <ul style="list-style-type: none"> • A preferred adalimumab product or ENBREL AND • XELJANZ. <p>Quantity Limits: XELJANZ IR is limited to 2 tablets per day or 60 tablets for a 30-day supply XELJANZ XR is limited to 1 tablet per day or 30 tablets for a 30-day supply</p> <p>Non-Preferred Agents:</p> <p>COSENTYX (secukinumab) may receive approval for psoriatic arthritis indication for members ≥ 2 years of age and weighing ≥ 15 kg following trial and failure‡ of:</p> <ul style="list-style-type: none"> • A preferred adalimumab product or ENBREL AND • XELJANZ AND • TALTZ or OTEZLA or a preferred ustekinumab product <p>HUMIRA brand and non-preferred adalimumab agents may receive approval if meeting the following:</p> <ul style="list-style-type: none"> • The request meets one of the following: <ul style="list-style-type: none"> ◦ The prescribed agent is a preferred adalimumab product OR ◦ If the prescribed agent is brand Humira or a non-preferred adalimumab product, then the member has trialed and failed at least one preferred adalimumab product. Failure is defined as lack of efficacy or intolerable side effects with the preferred adalimumab product. <p>AND</p> <ul style="list-style-type: none"> • The general non-preferred criteria listed below are met. <p>STELARA brand and non-preferred ustekinumab agents may receive approval if meeting the following:</p> <ul style="list-style-type: none"> • The request meets one of the following: <ul style="list-style-type: none"> ◦ The prescribed agent is a preferred ustekinumab product OR ◦ If the prescribed agent is brand Stelara or a non-preferred ustekinumab product, then the member has trialed and failed at least one preferred ustekinumab product. Failure is defined as lack of efficacy or intolerable side effects with the preferred ustekinumab product. <p>AND</p> <ul style="list-style-type: none"> • The general non-preferred criteria listed below are met. <p>XELJANZ (tofacitinib) XR approval will require verification of the clinically relevant reason for use of the XELJANZ XR formulation versus the XELJANZ IR formulation, in addition to meeting non-preferred criteria listed below.</p> <p>All other non-preferred agents may receive approval for psoriatic arthritis following trial and failure‡ of:</p> |
|--|---|---|

| | | |
|--|--|---|
| | <p>XELJANZ (tofacitinib) solution</p> <p>YESINTEK (ustekinumab-kfce) syringe, vial</p> <p>YUSIMRY (adalimumab-aqvh) pen</p> <p>Note: Product formulations in the physician administered drug (PAD) category are located on Appendix P</p> | <ul style="list-style-type: none"> • A preferred adalimumab product or ENBREL AND • Two other preferred products (XELJANZ, TALTZ, OTEZLA, ustekinumab) <p>‡Failure is defined as lack of efficacy, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interaction.</p> <p>Continuation of therapy: Members currently taking a preferred agent may receive approval to continue therapy with that agent. Members with current prior authorization approval on file for a non-preferred agent may receive approval for continuation of therapy with the prescribed agent.</p> |
|--|--|---|

| Plaque Psoriasis | | |
|--|--|--|
| Preferred No PA Required (If diagnosis met) (*Must meet eligibility criteria) | Non-Preferred PA Required | |
| Adalimumab-aacf syringe | ABRILADA (adalimumab-afzb) pen, syringe | First line preferred agents (preferred adalimumab products, ENBREL) may receive approval for plaque psoriasis indication. |
| Adalimumab-aaty pen | Adalimumab-aacf pen | *Second line preferred agents (TALTZ, OTEZLA, preferred ustekinumab products) may receive approval for plaque psoriasis indication following trial and failure‡ of a preferred adalimumab product OR ENBREL. |
| Adalimumab-adbm pen (IJ Kit) | Adalimumab-adbm syringe, Crohns pen IJ Kit, PS-UV pen IJ kit | |
| AMJEVITA (adalimumab-atto) auto-injector, syringe | Adalimumab-fkjp pen, syringe | |
| CYLTEZO (adalimumab-adbm) pen, syringe | Adalimumab-ryvk auto-injector | |
| ENBREL (etanercept) | Adalimumab-aaty (2 pack) 20 mg, 40 mg syringe (Celltrion manufacturer) | |
| *IMULDOSA (ustekinumab-SRLF) syringe | BIMZELX (bimekizumab-bkzx) pen | |
| *OTEZLA (apremilast) tablet | CIMZIA (certolizumab pegol) syringe, vial | |
| *SELARSDI (ustekinumab-AEKN) syringe | COSENTYX (secukinumab) syringe, pen-injector | |
| *STARJEMZA (ustekinumab-hmny) 45mg/0.5mL vial | HADLIMA (adalimumab-bwwd) Pushtouch, syringe | |
| *STEQEYMA (ustekinumab-stba) syringe | HULIO (adalimumab-fkjp) pen, syringe | |
| *TALTZ (ixekizumab) 80 mg syringe | HYRIMOZ (adalimumab-adaz) pen, syringe | |
| YUFLYMA (adalimumab-aaty) auto-injector, syringe | HUMIRA (adalimumab) | |
| | IDACIO (adalimumab-aacf) pen, syringe | |
| | IMULDOSA (ustekinumab-SRLF) syringe, vial | |

Non-Preferred Agents:

HUMIRA brand and non-preferred adalimumab agents may receive approval if meeting the following:

- The request meets one of the following:
 - The prescribed agent is a preferred adalimumab product OR
 - If the prescribed agent is brand Humira or a non-preferred adalimumab product, then the member has trialed and failed at least one preferred adalimumab product. Failure is defined as lack of efficacy or intolerable side effects with the preferred adalimumab product.

AND

- The general non-preferred criteria listed below are met.

STELARA brand and non-preferred ustekinumab agents may receive approval if meeting the following:

- The request meets one of the following:
 - The prescribed agent is a preferred ustekinumab product OR
 - If the prescribed agent is brand Stelara or a non-preferred ustekinumab product, then the member has trialed and failed at least one preferred ustekinumab product. Failure is defined as lack of efficacy or intolerable side effects with the preferred ustekinumab product.

AND

- The general non-preferred criteria listed below are met.

| | |
|---|---|
| OTULFI (ustekinumab-aauz) syringe PYZCHIVA (ustekinumab-ttwe) syringe SELARSDI (ustekinumab-AEKN) syringe SILIQ (brodalumab) syringe SIMLANDI (adalimumab-ryvk) auto-injector SKYRIZI (risankizumab-rzaa) OnBody, pen, syringe SOTYKTU (ducravacitinib) oral tablet STARJEMZA (ustekinumab-hmny) all other formulations STELARA (ustekinumab) syringe STEQEYMA (ustekinumab-stba) syringe TALTZ (ixekizumab) 20mg, 40mg syringe TREMFYA (guselkumab) injector, syringe Ustekinumab (generic Stelara, TTWE, AEKN) syringe, vial WEZLANA (ustekinumab-aaub) syringe, vial YESINTEK (ustekinumab-kfce) syringe, vial YUSIMRY (adalimumab-aqvh) pen <i>Note: Product formulations in the physician administered drug (PAD) category are located on Appendix P</i> | All other non-preferred agents may receive approval for plaque psoriasis indication following trial and failure [‡] of one indicated first line agent (a preferred adalimumab product, ENBREL) AND two second line agents (TALTZ, OTEZLA, or a preferred ustekinumab product). [‡] Failure is defined as lack of efficacy, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interaction. <u>Continuation of therapy:</u> Members currently taking a preferred agent may receive approval to continue therapy with that agent. Members with current prior authorization approval on file for a non-preferred agent that does not have a preferred biosimilar may receive approval for continuation of therapy with the prescribed agent. |
|---|---|

| Crohn's Disease and Ulcerative Colitis | | |
|--|--|--|
| Preferred No PA Required (If diagnosis met) (*Must meet eligibility criteria) | Non-Preferred PA Required | First and second line preferred agents (preferred adalimumab products, preferred ustekinumab products, XELJANZ) may receive approval for Crohn's disease and ulcerative colitis indications. <u>Quantity Limits:</u> XELJANZ IR is limited to 2 tablets per day or 60 tablets for a 30-day supply XELJANZ XR is limited to 1 tablet per day or 30 tablets for a 30-day supply |
| Adalimumab-aacf syringe Adalimumab-aaty pen | ABRILADA (adalimumab-afzb) pen, syringe Adalimumab-aacf pen Adalimumab-adaz pen, syringe | <u>Non-Preferred Agents:</u> |
| | | |

| | | |
|--|--|--|
| <p>Adalimumab-adbm pen (IJ Kit)</p> <p>AMJEVITA (adalimumab-atto) auto-injector, syringe</p> <p>CYLTEZO (adalimumab-adbm) pen, syringe</p> <p>*IMULDOSA (ustekinumab-SRLF) syringe</p> <p>*SELARSDI (ustekinumab-AEKN) syringe</p> <p>*STARJEMZA (ustekinumab-hmny) 45mg/0.5mL vial</p> <p>*STEQEYMA (ustekinumab-stba) syringe</p> <p>*XELJANZ IR (tofacitinib) tablet</p> <p>*XELJANZ XR (tofacitinib ER) tablet</p> <p>YUFLYMA (adalimumab-aaty) auto-injector, syringe</p> | <p>Adalimumab-adbm syringe, Crohns pen IJ Kit, PS-UV pen IJ kit</p> <p>Adalimumab-fkjp pen, syringe</p> <p>Adalimumab-ryvk auto-injector</p> <p>Adalimumab-aaty (2 pack) 20 mg, 40 mg syringe (Celltrion manufacturer)</p> <p>CIMZIA (certolizumab pegol) syringe, vial</p> <p>COSENTYX (secukinumab) syringe, pen-injector</p> <p>ENTYVIO (vedolizumab) pen</p> <p>HADLIMA (adalimumab-bwwd) Pushtouch, syringe</p> <p>HULIO (adalimumab-fkjp) syringe</p> <p>HUMIRA (adalimumab)</p> <p>HYRIMOZ (adalimumab-adaz) pen, syringe</p> <p>IDACIO (adalimumab-aacf) pen, syringe</p> <p>OLUMIANT (baricitinib) tablet</p> <p>OMVOH (mirikizumab-mrkz) pen</p> <p>OTULFI (ustekinumab-aauz) syringe</p> <p>PYZCHIVA (ustekinumab-ttwe) syringe</p> <p>RINVOQ (upadacitinib) tablet</p> <p>RINVOQ LQ (upadacitinib) solution</p> <p>SIMLANDI (adalimumab-ryvk) auto-injector</p> <p>SIMPONI (golimumab) pen, syringe</p> <p>SKYRIZI (risankizumab-rzaa) OnBody, pen, syringe</p> <p>STARJEMZA (ustekinumab-hmny) all other formulations</p> | <p>HUMIRA brand and non-preferred adalimumab agents may receive approval if meeting the following:</p> <ul style="list-style-type: none"> • The request meets one of the following: <ul style="list-style-type: none"> ◦ The prescribed agent is a preferred adalimumab product OR ◦ If the prescribed agent is brand Humira or a non-preferred adalimumab product, then the member has trialed and failed at least one preferred adalimumab product. Failure is defined as lack of efficacy or intolerable side effects with the preferred adalimumab product. <p>AND</p> <ul style="list-style-type: none"> • The general non-preferred criteria listed below are met. <p>STELARA brand and non-preferred ustekinumab agents may receive approval if meeting the following:</p> <ul style="list-style-type: none"> • The request meets one of the following: <ul style="list-style-type: none"> ◦ The prescribed agent is a preferred ustekinumab product OR ◦ If the prescribed agent is brand Stelara or a non-preferred ustekinumab product, then the member has trialed and failed at least one preferred ustekinumab product. Failure is defined as lack of efficacy or intolerable side effects with the preferred ustekinumab product. <p>AND</p> <ul style="list-style-type: none"> • The general non-preferred criteria listed below are met. <p>All other non-preferred agents may receive approval for FDA-labeled indications if meeting the following:</p> <ul style="list-style-type: none"> • The requested medication is being prescribed for treating moderately-to-severely active Crohn's disease or moderately-to-severely active Ulcerative Colitis in alignment with indicated use outlined in FDA-approved product labeling AND • The requested medication meets FDA-labeled indicated age for prescribed use AND • Request meets one of the following: <ul style="list-style-type: none"> ◦ For treatment of moderately-to-severely acute ulcerative colitis, member has trial and failure[‡] of: <ul style="list-style-type: none"> ▪ One preferred adalimumab product or XELJANZ AND ▪ One preferred ustekinumab product. ◦ For treatment of moderately-to-severely active Crohn's disease, member has trial and failure[‡] of: <ul style="list-style-type: none"> ▪ One preferred adalimumab product AND ▪ One preferred ustekinumab product <p><u>Continuation of therapy:</u> Members currently taking a preferred agent may receive approval to continue therapy with that agent. Members with current prior authorization approval on file for a non-preferred agent that does not have a preferred biosimilar may receive approval for continuation of therapy with the prescribed agent.</p> <p>[‡]Failure is defined as lack of efficacy, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interaction. Note that trial and failure of Xeljanz (tofacitinib) will not be required</p> |
|--|--|--|

| | | |
|--|--|---|
| <p>STELARA (ustekinumab) syringe, vial Ustekinumab (generic Stelara, TTWE, AEKN) syringe, vial VELSIPITY (etrasimod) tablet WEZLANA (ustekinumab-aaub) syringe, vial XELJANZ (tofacitinib) solution YESINTEK (ustekinumab-kfce) syringe, vial YUSIMRY (adalimumab-aqvh) pen ZYMFENTRA (infliximab-dyyb) pen kit, syringe kit</p> | <p><i>Note: Product formulations in the physician administered drug (PAD) category are located on Appendix P</i></p> | <p>when prescribed for ulcerative colitis for members ≥ 50 years of age that have an additional CV risk factor.</p> |
|--|--|---|

| Asthma | | |
|--|---|--|
| Preferred PA Required <i>(*Must meet eligibility criteria)</i> | Non-Preferred PA Required | |
| <p>*DUPIXENT (dupilumab) pen, syringe *FASENRA (benralizumab) pen, syringe *TEZSPIRE (tezepelumab-ekko) pen *XOLAIR (omalizumab) syringe, autoinjector</p> | <p>NUCALA (mepolizumab) auto-injector, syringe</p> <p><i>Note: Product formulations in the physician administered drug (PAD) category are located on Appendix P</i></p> | <p>*Preferred products (Dupixent, Fasenra, Tezspire, Xolair) may receive approval if meeting the following:</p> <p>DUPIXENT (dupilumab):</p> <ul style="list-style-type: none"> • Member is 6 years of age or older AND • Member has an FDA-labeled indicated use for treating one of the following: <ul style="list-style-type: none"> ◦ Moderate to severe asthma (on medium to high dose inhaled corticosteroid and a long-acting beta agonist) with eosinophilic phenotype based on a blood eosinophil level of $\geq 150/\text{mcL}$ OR ◦ Oral corticosteroid dependent asthma AND • Member's asthma has been refractory to recommended evidence-based, guideline-supported pharmacologic therapies AND • Medication is being prescribed as add-on therapy to existing asthma regimen. <p>Quantity Limit: 2 syringes every 28 days after initial 14 days of therapy (first dose is twice the regular scheduled dose)</p> <p>FASENRA (benralizumab):</p> <ul style="list-style-type: none"> • Member is ≥ 6 years of age AND • Member has an FDA-labeled indicated use for treating severe asthma with an eosinophilic phenotype based on a blood eosinophil level of $\geq 150/\text{mcL}$ AND • Member's asthma has been refractory to recommended evidence-based, guideline-supported pharmacologic therapies AND • The requested medication is being prescribed as add-on therapy to existing asthma regimen. |

Quantity Limit: One 30 mg unit dose pack every 28 days for the first 3 doses and then every 8 weeks thereafter

TEZSPIRE (tezepelumab-ekko):

- Member is \geq 12 years of age **AND**
- Member has a diagnosis of severe asthma **AND**
- Member's asthma has been refractory to recommended evidence-based, guideline-supported pharmacologic therapies **AND**
- The requested medication is being prescribed as add-on therapy to existing asthma regimen.

Quantity Limit: Four 210 mg unit dose packs every 28 days

XOLAIR (omalizumab) may receive approval if meeting the following based on prescribed indication:

- Member is \geq 6 years of age **AND**
- Member has an FDA-labeled indicated use for treating asthma **AND**
- Member has a positive skin test or in vitro reactivity to a perennial inhaled allergen or has a pre-treatment IgE serum concentration \geq 30 IU/mL **AND**
- Member's asthma has been refractory to recommended evidence-based, guideline-supported pharmacologic therapies **AND**
- The requested medication is being prescribed as add-on therapy to existing asthma regimen.

Non-Preferred Agents:

Non-preferred FDA-indicated biologic agents for asthma may receive approval if meeting the following:

- The requested medication is being prescribed for treating asthma in alignment with indicated use outlined in FDA-approved product labeling (including asthma type and severity) **AND**
- If prescribed for use for asthma with eosinophilic phenotype, member has a blood eosinophil count \geq 150 cells/mcL **AND**
- The requested medication meets FDA-labeled indicated age for prescribed use **AND**
- Member's asthma has been refractory to recommended evidence-based, guideline-supported pharmacologic therapies **AND**
- The requested medication is being prescribed as add-on therapy to existing asthma regimen **AND**
- Member has trialed and failed‡ two preferred agents.

Quantity Limits:

Non-preferred medications will be subject to quantity limitations in alignment with FDA-approved dosing per product package labeling.

Nucala (mepolizumab) is limited to 100mg every 4 weeks (members \geq 12 years of age) or 40mg every 4 weeks (members 6-11 years of age).

| | | |
|--|--|---|
| | | <p>Failure is defined as a lack of efficacy, allergy, intolerable side effects, contraindication to, or significant drug-drug interactions.</p> <p><u>Continuation of therapy:</u> Members currently taking a preferred agent may receive approval to continue therapy with that agent. Members with current prior authorization approval on file for a non-preferred agent that does not have a preferred biosimilar may receive approval for continuation of therapy with the prescribed agent.</p> |
| Atopic Dermatitis | | |
| Preferred (*Must meet eligibility criteria) <p>*ADBRY (tralokinumab-ldrm) syringe, autoinjector *DUPIXENT (dupilumab) pen, syringe</p> | Non-Preferred PA Required <p>CIBINQO (abrocitinib) tablet RINVOQ (upadacitinib) tablet</p> <p><i>Note: Product formulations in the physician administered drug (PAD) category are located on Appendix P</i></p> | <p>*Preferred products (Adbry and Dupixent) may receive approval if meeting the following:</p> <p>ADBRY (tralokinumab-ldrm):</p> <ul style="list-style-type: none"> • The requested drug is being prescribed for moderate-to-severe atopic dermatitis AND • Member has trialed and failed[‡] the following agents: <ul style="list-style-type: none"> ○ One medium potency to very-high potency topical corticosteroid (such as mometasone furoate, betamethasone dipropionate) AND ○ One topical calcineurin inhibitor (such as pimecrolimus or tacrolimus) <p><u>Maximum Dose:</u> 600 mg/2 weeks</p> <p><u>Quantity Limit:</u> Four 150 mg/mL prefilled syringes/2 weeks</p> <p>DUPIXENT (dupilumab):</p> <ul style="list-style-type: none"> • Member has a diagnosis of moderate to severe atopic dermatitis AND • Member has trialed and failed[‡] the following agents: <ul style="list-style-type: none"> ○ One medium potency to very-high potency topical corticosteroid [such as mometasone furoate, betamethasone dipropionate, or fluocinonide (see PDL for list of preferred products)] AND ○ One topical calcineurin inhibitor (such as pimecrolimus or tacrolimus) <p><u>Quantity Limit:</u> 2 syringes every 28 days after initial 14 days of therapy (first dose is twice the regular scheduled dose)</p> <p>Non-Preferred Agents:</p> <p>Non-preferred agents indicated for the treatment of atopic dermatitis may receive approval if meeting the following:</p> <ul style="list-style-type: none"> • Member has a diagnosis of moderate to severe chronic atopic dermatitis AND • Member has trialed and failed[‡] all of the following agents: <ul style="list-style-type: none"> ○ One medium potency to very-high potency topical corticosteroid (such as mometasone furoate, betamethasone dipropionate, or fluocinonide) AND ○ One topical calcineurin inhibitor (such as pimecrolimus and tacrolimus) AND ○ Opzelura (ruxolitinib) topical cream |

| | | |
|--|--|--|
| | | <ul style="list-style-type: none"> • Member has trialed and failed[‡] therapy with two preferred agents (ADBRY and DUPIXENT) for the prescribed indication • The medication is being prescribed by or in consultation with a dermatologist, allergist, immunologist, or rheumatologist <p><u>Approval:</u> One year</p> <p>[‡]Failure is defined as a lack of efficacy, allergy, intolerable side effects, contraindication, or significant drug-drug interaction.</p> <p><u>Continuation of therapy:</u> Members currently taking a preferred agent may receive approval to continue therapy with that agent. Members with current prior authorization approval on file for a non-preferred agent that does not have a preferred biosimilar may receive approval for continuation of therapy with the prescribed agent.</p> |
|--|--|--|

| Other indications | | |
|---|---|---|
| Preferred (If diagnosis met, No PA required) (Must meet eligibility criteria*) | Non-Preferred PA Required | Preferred Agents: |
| CYLTEZO (adalimumab-adbm) pen, syringe | ACTEMRA (tocilizumab) syringe, Actpen | *DUPIXENT (dupilumab) may receive approval if meeting the following based on prescribed indication: |
| *DUPIXENT (dupilumab) pen, syringe | ARCALYST (rilonacept) injection | Bullous Pemphigoid |
| ENBREL (etanercept) | CIMZIA (certolizumab pegol) syringe | <ul style="list-style-type: none"> • Member is 18 years of age or older AND • Member is diagnosed with bullous pemphigoid AND • Member has trialed and failed[‡] one of the following therapies: <ul style="list-style-type: none"> ○ High-potency topical corticosteroid ○ Oral prednisone ○ Doxycycline |
| *FASENRA (benralizumab) pen, syringe | COSENTYX (secukinumab) syringe, pen-injector | Chronic Spontaneous Urticaria |
| HUMIRA (adalimumab) | ILARIS (canakinumab) vial | <ul style="list-style-type: none"> • Member is 12 years of age or older AND • Member is diagnosed with chronic spontaneous urticaria AND • Member is symptomatic despite H1 antihistamine treatment AND • Member has tried and failed[‡] at least three of the following <ul style="list-style-type: none"> ○ High-dose second generation H1 antihistamine ○ H2 antihistamine ○ First-generation antihistamine ○ Leukotriene receptor antagonist ○ Hydroxyzine or doxepin |
| *KEVZARA (sarilumab) | KINERET (anakinra) syringe | |
| *OTEZLA (apremilast) tablet | NUCALA (mepolizumab) auto-injector, syringe | |
| *TYENNE (tocilizumab-aazg) | OLUMIANT (baricitinib) tablet | |
| XELJANZ IR (tofacitinib) tablet | <i>Note: Product formulations in the physician administered drug (PAD) category are located on Appendix P</i> | |
| XELJANZ XR (tofacitinib ER) tablet | | |
| *XOLAIR (omalizumab) syringe, autoinjector | | |
| YUFLYMA (adalimumab-aaty) auto-injector | | |
| | | |
| | | |

- Member's COPD is an eosinophilic phenotype based on a blood eosinophil level of ≥ 150 cells/mcL **AND**
- Member is receiving, and will continue, standard maintenance triple therapy for COPD (inhaled corticosteroid, long-acting muscarinic agent, long-acting beta agonist) as recommended by the current Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines **AND**
- Member has experienced at least 2 moderate OR 1 severe COPD exacerbation during the past 12 months

Chronic Rhinosinusitis with Nasal Polyposis

- Member is ≥ 12 years of age **AND**
- Medication is being prescribed as an add-on maintenance treatment for inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP) **AND**
- Member has trialed and failed[‡] therapy with at least two intranasal corticosteroid regimens

Eosinophilic Esophagitis (EoE):

- Member is ≥ 1 year of age **AND**
- Member weighs at least 15 kg **AND**
- Member has a diagnosis of eosinophilic esophagitis (EoE) with ≥ 15 intraepithelial eosinophils per high-power field (eos/hpf), with or without a history of esophageal dilations **AND**
- Member is following appropriate dietary therapy interventions **AND**
- Medication is being prescribed by or in consultation with a gastroenterologist, allergist or immunologist **AND**
- Member has trialed and failed[‡] one of the following treatment options for EoE:
 - Proton pump inhibitor trial of at least eight weeks in duration if reflux is a contributing factor **OR**
 - Minimum four-week trial of local therapy with a corticosteroid medication

Prurigo Nodularis:

- Member is ≥ 18 years of age **AND**
- Medication is being prescribed as treatment for prurigo nodularis **AND**
- Member has trialed and failed[‡] therapy with at least two corticosteroid regimens (topical or intralesional injection).

***FASENRA (benralizumab)** may be approved for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).

***KEVZARA (sarilumab)** treatment of adult patients with polymyalgia rheumatica who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.

***OTEZLA (apremilast)** treatment of adult patients with oral ulcers associated with Behçet's Disease.

***TYENNE (tocilizumab-aazg)** may receive approval for use for FDA-label indications

following trial and failure‡ of a preferred adalimumab product or ENBREL

***XOLAIR (omalizumab)** may receive approval if meeting the following based on prescribed indication:

Chronic Rhinosinusitis with Nasal Polyps:

- Member is 18 years of age or older **AND**
- Medication is being prescribed as add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients 18 years of age and older with inadequate response to nasal corticosteroids **AND**
- Member has tried and failed‡ therapy with at least two intranasal corticosteroid regimens

Chronic Spontaneous Urticaria:

- Member is 12 years of age or older **AND**
- Member is diagnosed with chronic idiopathic urticaria **AND**
- Member is symptomatic despite H1 antihistamine treatment **AND**
- Member has tried and failed‡ at least three of the following:
 - High-dose second generation H1 antihistamine
 - H2 antihistamine
 - First-generation antihistamine
 - Leukotriene receptor antagonist
 - Hydroxyzine or doxepin (must include)**AND**
- Prescriber attests that the need for continued therapy will be periodically reassessed (as the appropriate duration of Xolair therapy for CIU has currently not been evaluated).

IgE-Mediated Food Allergy:

- Medication is being prescribed for reduction of allergic reactions (Type I), including anaphylaxis, that may occur with accidental exposure to one or more foods in adult and pediatric patients aged 1 year and older with IgE-mediated food allergy.

All other preferred agents may receive approval for use for FDA-labeled indications.

Non-Preferred Agents:

ARCALYST (rilonacept) may receive approval if meeting the following:

- Medication is being prescribed for one of the following autoinflammatory periodic fever syndromes (approval for all other indications is subject to meeting non-preferred criteria listed below):
 - Cryopyrin-associated Autoinflammatory Syndrome (CAPS), including:
 - Familial Cold Autoinflammatory Syndrome (FCAS)
 - Muckle-Wells Syndrome (MWS)

- Maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing at least 10 kg
- Treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children \geq 12 years of age

AND

- Member has trialed and failed[‡] colchicine **AND**
- Initial approval will be given for 12 weeks and authorization approval for continuation will be provided based on clinical response.

ILARIS (canakinumab) may receive approval if meeting the following:

- Medication is being prescribed for one of the following (approval for all other indications is subject to meeting non-preferred criteria listed below):
 - Familial Mediterranean Fever (FMF)
 - Hyperimmunoglobulinemia D syndrome (HIDS)
 - Mevalonate Kinase Deficiency (MKD)
 - Neonatal onset multisystem inflammatory disease (NOMID)
 - TNF Receptor Associated Periodic Syndrome (TRAPS)
 - Cryopyrin-associated Autoinflammatory Syndrome (including Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome)
 - Symptomatic treatment of adult patients with gout flares in whom NSAIDs and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate (limited to four 150mg doses per one year approval)

AND

- Member has trialed and failed[‡] colchicine.
- Quantity Limits:
 - Cryopyrin-associated periodic syndrome: 600mg (4mL) every 8 weeks
 - All other indications: 300mg (2mL) every 4 weeks

KINERET (anakinra) may receive approval if meeting the following:

- Medication is being prescribed for one of the following indications (approval for all other indications is subject to meeting non-preferred criteria below):
 - Neonatal onset multisystem inflammatory disease (NOMID).
 - Familial Mediterranean Fever (FMF)

AND

- Member has trialed and failed[‡] colchicine.

NUCALA (mepolizumab) may receive approval if meeting the following based on prescribed indication (for any FDA-labeled indications in this subclass category that are not listed, approval is subject to meeting non-preferred criteria listed below):

Maintenance Treatment of COPD:

- Member is 18 years of age or older **AND**
- Requested medication is being prescribed as an add-on maintenance treatment for inadequately controlled chronic obstructive pulmonary disease (COPD) **AND**
- Member's COPD is an eosinophilic phenotype based on a blood eosinophil level of ≥ 300 cells/ mcL **AND**
- Medication is being prescribed by or in consultation with a pulmonologist or allergist **AND**
- Member is receiving, and will continue, standard maintenance triple therapy for COPD (long-acting beta agonist, long-acting muscarinic agent, inhaled corticosteroid) **AND**
- Member has experienced at least 2 moderate COPD exacerbations OR 1 severe exacerbation during the past 12 months **AND**
- Member has trialed and failed[‡] therapy with Dupixent (dupilumab).

Chronic Rhinosinusitis with Nasal Polyps:

- Member is 18 years of age or older **AND**
- Medication is being prescribed as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP) **AND**
- Member has a baseline bilateral endoscopic nasal polyps score (NPS; scale 0-8) **AND** nasal congestion/obstruction score (NC; scale 0-3) averaged over 28-day period **AND**
- Member has trialed and failed[‡] therapy with three intranasal corticosteroids (see PDL Class) **AND**
- Medication is being prescribed by or in consultation with a rheumatologist, allergist, ear/nose/throat specialist or pulmonologist **AND**
- Initial authorization will be for 24 weeks, for additional 12-month approval member must meet the following criteria:
 - NC and NPS scores are provided and show a 20% reduction in symptoms from baseline **AND**
 - Member continues to use primary therapies such as intranasal corticosteroids.

Eosinophilic Granulomatosis with polyangiitis (EGPA):

- Member is 18 years of age or older **AND**
- Member has been diagnosed with relapsing or refractory EGPA at least 6 months prior to request as demonstrated by ALL the following:
 - Member has a diagnosis of asthma **AND**
 - Member has a blood eosinophil count of greater than or equal to 1000 cells/ mcL or a blood eosinophil level of 10%**AND**
- Member has the presence of two of the following EGPA characteristics:
 - Histopathological evidence of eosinophilic vasculitis, perivascular eosinophilic infiltration, or eosinophil-rich granulomatous inflammation
 - Neuropathy
 - Pulmonary infiltrates
 - Sinonasal abnormality

- Cardiomyopathy
- Glomerulonephritis
- Alveolar hemorrhage
- Palpable purpura
- Antineutrophil cytoplasmic antibody (ANCA) positive

AND

- Member has trialed and failed[‡] Fasenra (benralizumab) **AND**
- Dose of NUCALA (mepolizumab) 300 mg once every 4 weeks is being prescribed.

Hypereosinophilic Syndrome (HES):

- Member is 12 years of age or older **AND**
- Member has a diagnosis for HES for at least 6 months that is nonhematologic secondary HES **AND**
- Member has a blood eosinophil count of greater than or equal to 1000 cells/mcL **AND**
- Member has a history of two or more HES flares (defined as worsening clinical symptoms or blood eosinophil counts requiring an increase in therapy) **AND**
- Member has been on stable dose of HES therapy for at least 4 weeks, at time of request, including at least one of the following:
 - Oral corticosteroids
 - Immunosuppressive therapy
 - Cytotoxic therapy**AND**
- Dose of 300 mg once every 4 weeks is being prescribed.

All other non-preferred agent indications may receive approval for FDA-labeled use following trial and failure[‡] of all preferred agents that are FDA-indicated or have strong evidence supporting use for the prescribed indication from clinically recognized guideline compendia (only one preferred adalimumab product trial required).

[‡]Failure is defined as lack of efficacy, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interaction.

Continuation of therapy: Members currently taking a preferred agent may receive approval to continue therapy with that agent. Members with current prior authorization approval on file for a non-preferred agent that does not have a preferred biosimilar will be subject to meeting reauthorization criteria above when listed for the prescribed indication, or if reauthorization criteria are not listed for the prescribed indication, may receive approval for continuation of therapy.

Note: Prior authorization requests for agents prescribed solely for treating alopecia areata will not be approved.

X. Miscellaneous

Therapeutic Drug Class: EPINEPHRINE PRODUCTS – Effective 1/1/2026

| No PA Required | PA Required | |
|--|---|--|
| AUVI-Q (epinephrine) auto-injector | SYMJEPI 0.15mg/0.3ml, 0.3mg/0.3ml (epinephrine) syringe | Non-preferred products may be approved if the member has failed treatment with one of the preferred products. Failure is defined as allergy to ingredients in product or intolerable side effects. |
| Epinephrine 0.15mg/0.15ml, 0.3mg/0.3ml auto-injector | | Quantity limit: 4 singe-dose units per year unless used / damaged / lost |
| EPIPEN 0.3 mg/0.3 ml (epinephrine) auto-injector | | |
| EPIPEN JR 0.15 mg/0.15 ml, (epinephrine) auto-injector | | |
| NEFFY Spray | | |

Therapeutic Drug Class: NEWER HEREDITARY ANGIOEDEMA PRODUCTS – Effective 1/1/2026

| PA Required for all agents in this class | | Medications Indicated for Routine Prophylaxis: |
|--|---|--|
| Preferred | Non-Preferred | |
| <u>Prophylaxis:</u> | <u>Prophylaxis:</u> | Members are restricted to coverage of one medication for <u>routine prophylaxis</u> at one time. Prior authorization approval will be for one year. |
| HAEGARDA (C1 esterase inhibitor) vial | ANDEMBRY (garadacimab-gxii) autoinjector | Preferred products for routine prophylaxis (Haegarda, Orladeyo, Takhzyro) may be approved if the following criteria are met: |
| ORLADEYO (berotralstat) oral capsule | CINRYZE (C1 esterase inhibitor) kit | <ul style="list-style-type: none"> • Member has one of the following diagnoses: <ul style="list-style-type: none"> ○ Type I HAE (Hereditary Angioedema with deficient C1-inhibitor) OR ○ Type II HAE (Hereditary Angioedema with dysfunctional C1-inhibitor) confirmed by laboratory tests obtained on two separate instances at least one month apart (C4 level, C1-INH level) OR ○ Diagnosis of HAE with normal C1-inhibitor and based on clinical presentation |
| TAKHZYRO (lanadelumab-flyo) syringe, vial | <u>Treatment:</u> | <p>AND</p> <ul style="list-style-type: none"> • Member has a documented history of at least one symptom of a moderate to severe HAE attack (moderate to severe abdominal pain, facial swelling, airway swelling) in the absence of hives or a medication known to cause angioedema AND • The request meets one of the following: <ul style="list-style-type: none"> ○ The requested product is being used for short-term prophylaxis to undergo a surgical procedure or major dental work OR ○ The requested product is being used for long-term prophylaxis and member meets one of the following: <ul style="list-style-type: none"> ▪ History of ≥ 1 attack per month resulting in documented ED admission or hospitalization OR ▪ History of laryngeal attacks OR ▪ History of ≥ 2 attacks per month involving the face, throat, or abdomen |
| <u>Treatment:</u> | | |
| BERINERT (C1 esterase inhibitor) kit, vial | FIRAZYR (icatibant acetate) syringe | |
| Icatibant syringe (generic FIRAZYR) | RUCONEST (C1 esterase inhibitor, recomb) vial | |

AND

- Member is not taking medications that may exacerbate HAE including ACE inhibitors and estrogen-containing medications **AND**
- The request meets minimum age and maximum dose limits listed in Table 1 **AND**
- The following criteria are met when listed for the requested medication:
 - For Haegarda (C1 esterase inhibitor), prescriber acknowledges that the member will receive information and/or counseling regarding the information from the FDA-labeled package insert outlining transmission of infectious agents with a medication made from human blood.
 - For Orladeyo (berotralstat): Appropriate drug interaction interventions will be made for members using concomitant medications that may require dose adjustments (such as cyclosporine, fentanyl, pimozide, digoxin)
 - For Takhzyro (lanadelumab-flyo), prescriber acknowledges that though the recommended starting dose is 300 mg every 2 weeks, a dosing interval of 300 mg every 4 weeks is also effective and may be considered if the patient is well-controlled (attack free) for more than 6 months.

Non-preferred products for routine prophylaxis may be approved if the following criteria are met:

- The request meets all criteria listed for preferred products above **AND**
- The member has trialed and failed at least two preferred agents indicated for routine prophylaxis. Failure is defined as lack of efficacy, allergy, intolerable side effect, or a significant drug-drug interaction.

Table 1: FDA-approved Minimum Age and Maximum Dose

| Product Name | Minimum Age | Maximum Dose |
|--|-------------|----------------------------------|
| CINRYZE (C1 esterase inhibitor-human) | 6 years | 2,000 units IV every 3 or 4 days |
| HAEGARDA (C1 esterase inhibitor-human) | 6 years | 60 units/kg twice weekly |
| ORLADEYO (berotralstat) | 2 years | 150 mg once daily |
| TAKHZYRO (lanadelumab-flyo) | 2 years | 300 mg every 2 weeks |

Medications Indicated for Treatment of Acute Attacks:

Members are restricted to coverage of one medication for treatment of acute attacks at one time. Prior authorization approval will be for one year.

Preferred products for treatment of acute attacks (Berinert, Icatibant) may be approved if the following criteria are met:

- Member has one of the following diagnoses:
 - Type I HAE (Hereditary Angioedema with deficient C1-inhibitor) OR
 - Type II HAE (Hereditary Angioedema with dysfunctional C1-inhibitor) confirmed by laboratory tests obtained on two separate instances at least one month apart (C4 level, C1-INH level) OR
 - A diagnosis of HAE with normal C1-inhibitor based on clinical presentation

AND

- Member has a documented history of at least one symptom of a moderate to severe HAE attack (moderate to severe abdominal pain, facial swelling, airway swelling) in the absence of hives or a medication known to cause angioedema **AND**
- Member is not taking medications that may exacerbate HAE including ACE inhibitors and estrogen-containing medications **AND**
- The request meets minimum age and maximum dose limits listed in Table 2 **AND**
- For Berinert (C1 esterase inhibitor): Prescriber acknowledges that the member will receive information and/or counseling regarding the information from the FDA-labeled package insert outlining transmission of infectious agents with a medication made from human blood.

Non-preferred products for treatment of acute attacks may be approved if the following criteria are met:

- The request meets all criteria listed for preferred products above **AND**
- The member has trialed and failed at least two preferred agents indicated for treatment of acute attacks. Failure is defined as lack of efficacy, allergy, intolerable side effect, or a significant drug-drug interaction.

Quantity limit: EKTERLY (sebetalstat) limited to four 300 mg tablets (1,200 mg) per 30 days unless used, damaged, or lost.

Continuation of therapy: Members with previous PA approval on file for Ruconest (C1 esterase inhibitor recombinant) may receive approval for continuation of therapy.

| Table 2: FDA-approved Minimum Age and Maximum Dose | | |
|--|-------------|-------------------|
| Product Name | Minimum Age | Maximum Dose |
| BERINERT (C1 esterase inhibitor) | 5 years | 20 units/kg |
| EKTERLY (sebetalstat) | 12 years | 1,200 mg/24 hours |
| FIRAZYR (icatibant acetate) | 18 years | 30 mg |
| RUCONEST (C1 esterase inhibitor recombinant) | 13 years | 4,200 Units |

All other non-preferred agents may be approved if the member has trialed and failed at least two preferred agents with the same indicated role in therapy as the prescribed medication (prophylaxis or treatment). Failure is defined as lack of efficacy, allergy, intolerable side effects, or a significant drug-drug interaction.

Therapeutic Drug Class: **PHOSPHATE BINDERS** – Effective 10/1/2025

| No PA Required | PA Required | <p>Prior authorization for non-preferred products in this class may be approved if member meets all the following criteria:</p> <ul style="list-style-type: none"> • Member has diagnosis of end stage renal disease AND • Member has elevated serum phosphorus [$> 4.5 \text{ mg/dL}$ or $> 1.46 \text{ mmol/L}$] AND • Provider attests to member avoidance of high phosphate containing foods from diet AND • Member has trialed and failed[‡] one preferred agent (lanthanum products require trial and failure[‡] of a preferred sevelamer product). <p>Auryxia (ferric citrate) may be approved if the member meets all the following criteria:</p> <ul style="list-style-type: none"> • Member is diagnosed with end-stage renal disease, receiving dialysis, and has elevated serum phosphate ($> 4.5 \text{ mg/dL}$ or $> 1.46 \text{ mmol/L}$). AND • Provider attests to counseling member regarding avoiding high phosphate containing foods from diet AND • Member has trialed and failed[‡] three preferred agents with different mechanisms of action prescribed for hyperphosphatemia in end stage renal disease <p>OR</p> <ul style="list-style-type: none"> • Member is diagnosed with chronic kidney disease with iron deficiency anemia and is not receiving dialysis AND • Member has tried and failed[‡] at least two different iron supplement product formulations (OTC or RX) <p>Velphoro (sucroferric oxyhydroxide tablet, chewable) may be approved if the member meets all of the following criteria:</p> <ul style="list-style-type: none"> • Member is diagnosed with chronic kidney disease and receiving dialysis and has elevated serum phosphate ($> 4.5 \text{ mg/dL}$ or $> 1.46 \text{ mmol/L}$). AND • Provider attests to counseling member regarding avoiding high phosphate containing foods from diet AND • Member has trialed and failed[‡] two preferred agents, one of which must be a preferred sevelamer product <p>Maximum Dose: Velphoro 3000mg daily</p> <p>Members currently stabilized on a non-preferred lanthanum product may receive approval to continue therapy with that product.</p> <p>[‡]Failure is defined as lack of efficacy with 6-week trial, allergy, intolerable side effects, or significant drug-drug interaction.</p> <p><i>Note: Medications administered in a dialysis unit or clinic are billed through the Health First Colorado medical benefit or Medicare with members with dual eligibility.</i></p> |
|---|---|--|
| Calcium acetate capsule | AURYXIA (ferric citrate) tablet | |
| PHOSLYRA (calcium acetate) solution | Calcium acetate tablet | |
| Sevelamer carbonate tablet, powder pack | CALPHRON (calcium acetate) tablet | |
| | Ferric citrate tablet | |
| | FOSRENOL (lanthanum carbonate) chewable tablet, powder pack | |
| | Lanthanum carbonate chewable tablet | |
| | RENELA (sevelamer carbonate) powder pack, tablet | |
| | Sevelamer HCl tablet | |
| | VELPHORO (sucroferric oxide) chewable tablet | |
| | XPHOZAH (tenapanor) tablet | |

Therapeutic Drug Class: **PRENATAL VITAMINS / MINERALS** – Effective 10/1/2025

| Preferred *Must meet eligibility criteria | Non-Preferred PA Required | <p>*Preferred and non-preferred prenatal vitamin products are a benefit for members from 11-60 years of age who are pregnant, lactating, or trying to become pregnant.</p> <p>Prior authorization for non-preferred agents may be approved if member fails 7-day trial with four preferred agents. Failure is defined as allergy, intolerable side effects, or significant drug-drug interaction.</p> |
|---|--|---|
| COMPLETE NATAL DHA pack | All other rebateable prescription products are non-preferred | |
| M-NATAL PLUS tablet | | |
| NESTABS tablets | | |
| PRENATAL VITAMIN PLUS LOW IRON tablet (<i>Patrin Pharma only</i>) | | |
| SE-NATAL 19 chewable tablet ^{BNR} | | |
| TARON-C DHA capsule | | |
| THRIVITE RX tablet | | |
| TRINATAL RX 1 tablet | | |
| VITAFOL gummies | | |
| WESNATAL DHA COMPLETE tablet | | |
| WESTAB PLUS tablet | | |

XI. Ophthalmic

Therapeutic Drug Class: **OPHTHALMIC, ALLERGY – Effective 4/1/2025**

| No PA Required | PA Required | Non-preferred products may be approved following trial and failure of therapy with two preferred products (failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions). |
|---|---------------------------------|--|
| ALREX ^{BNR} (loteprednol) 0.2% | ALAWAY (ketotifen) 0.025% (OTC) | |
| Azelastine 0.05% | ALOCRIL (nedocromil) 2% | |
| Cromolyn 4% | ALOMIDE (lodoxamide) 0.1% | |
| Ketotifen 0.025% (OTC) | Bepotastine 1.5% | |

| | | |
|---|--|--|
| LASTACAF (alcaftadine) 0.25% (OTC) | BEPREVE (bepotastine) 1.5% | |
| Olopatadine 0.1%, 0.2% (OTC) (generic Pataday Once/Twice Daily) | Epinastine 0.05% | |
| | Loteprednol 0.2% | |
| | Olopatadine 0.1%, 0.2% (RX) | |
| | PATADAY ONCE DAILY (olopatadine) 0.2% (OTC) | |
| | PATADAY TWICE DAILY (olopatadine) 0.1% (OTC) | |
| | PATADAY XS ONCE DAILY (olopatadine) 0.7% (OTC) | |
| | ZADITOR (ketotifen) 0.025% (OTC) | |
| | ZERVIATE (cetirizine) 0.24% | |

Therapeutic Drug Class: **OPHTHALMIC, IMMUNOMODULATORS – Effective 4/1/2025**

| No PA Required | PA Required | |
|--|--|--|
| RESTASIS ^{BNR} (cyclosporine 0.05%) vials | CEQUA (cyclosporine) 0.09% solution Cyclosporine 0.05% vials MIEBO (Perfluorohexyloctane/PF) RESTASIS MULTIDOSE (cyclosporine) 0.05% TYRVAYA (varenicline) nasal spray VERKAZIA (cyclosporin emulsion) VEVYE (cyclosporine) 0.1% XIIDRA (lifitegrast) 5% solution | <p>Non-preferred products may be approved for members meeting all of the following criteria:</p> <ul style="list-style-type: none"> • Member is 18 years and older AND • Member has a diagnosis of chronic dry eye AND • Member has failed a 3-month trial of one preferred product. Failure is defined as a lack of efficacy, allergy, intolerable side effects, contraindication to, or significant drug-drug interactions AND • Prescriber is an ophthalmologist, optometrist or rheumatologist <p><u>Maximum Dose/Quantity:</u> 60 single use containers for 30 days 5.5 mL/20 days for Restasis Multi-Dose and Vevye 3mL/30 days for Miebo</p> <p>Verkazia (cyclosporine ophthalmic emulsion) may be approved if the following criteria are met:</p> <ul style="list-style-type: none"> • Member is \geq 4 years of age AND • Verkazia is being used for the treatment of vernal keratoconjunctivitis (VKC) AND • Member has trialed and failed therapy with three agents from the following pharmacologic categories: preferred dual-acting mast cell stabilizer/antihistamine from the Ophthalmics-Allergy PDL class, oral antihistamine, preferred topical ophthalmic corticosteroid from the Ophthalmics-Anti-inflammatories PDL class. Failure is defined as lack of efficacy with 2-week trial, allergy, contraindication to therapy, intolerable side effects, or significant drug-drug interaction • <u>Quantity limit:</u> 120 single-dose 0.3 mL vials/15 days |

| | | |
|--|---|---|
| Therapeutic Drug Class: OPHTHALMIC, ANTI-INFLAMMATORIES – Effective 12/2/2025 | | |
| NSAIDs | | |
| No PA Required | PA Required | |
| Diclofenac 0.1% | ACULAR (ketorolac) 0.5%, LS 0.4% | Durezol (difluprednate) may be approved if meeting the following criteria: |
| Flurbiprofen 0.03% | ACUVAIL (ketorolac/PF) 0.45% | <ul style="list-style-type: none"> Member has a diagnosis of severe intermediate uveitis, severe panuveitis, or severe uveitis with the complication of uveitic macular edema AND has trialed and failed prednisolone acetate 1% (failure is defined as lack of efficacy, allergy, contraindication to therapy, intolerable side effects, or significant drug-drug interaction) OR |
| Ketorolac 0.5%, Ketorolac LS 0.4% | Bromfenac 0.07%, 0.075%, 0.09% | <ul style="list-style-type: none"> Members with a diagnosis other than those listed above require trial and failure of three preferred agents (failure is defined as lack of efficacy, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interaction). |
| NEVANAC (nepafenac) 0.1% | BROMSITE (bromfenac) 0.075% | |
| | ILEVRO (nepafenac) 0.03% | Eysuvis (loteprednol etabonate) may be approved if meeting all of the following: |
| | PROLENSA (bromfenac) 0.07% | <ul style="list-style-type: none"> Member is \geq 18 years of age AND Eysuvis (loteprednol etabonate) is being used for short-term treatment (up to two weeks) of the signs and symptoms of dry eye disease AND Member has failed treatment with one preferred product in the Ophthalmic Immunomodulator therapeutic class. Failure is defined as lack of efficacy with a 3-month trial, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interaction) AND Member does not have any of the following conditions: Viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella OR Mycobacterial infection of the eye and fungal diseases of ocular structures <u>Quantity limit:</u> one bottle/15 days |
| Corticosteroids | | |
| No PA Required | PA Required | |
| FLAREX (fluorometholone) 0.1% | Dexamethasone 0.1% | Lotemax SM (loteprednol etabonate) or Inveltys (loteprednol etabonate) may be approved if meeting all of the following: |
| Fluorometholone 0.1% drops | Difluprednate 0.05% | <ul style="list-style-type: none"> Member is \geq 18 years of age AND Lotemax SM or Inveltys (loteprednol etabonate) is being used for the treatment of post-operative inflammation and pain following ocular surgery AND Member has trialed and failed therapy with two preferred loteprednol formulations (failure is defined as lack of efficacy with 2-week trial, allergy, contraindication to therapy, intolerable side effects, or significant drug-drug interaction) AND Member has trialed and failed therapy with two preferred agents that do not contain loteprednol (failure is defined as lack of efficacy with 2-week trial, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interaction) AND Member does not have any of the following conditions: |
| FML FORTE (fluorometholone) 0.25% drops | DUREZOL (difluprednate) 0.05% | |
| LOTEMAX (loteprednol) 0.5% drops, gel | EYSUVIS (loteprednol) 0.25% | |
| LOTEMAX (loteprednol) 0.5% ointment | FML LIQUIFILM (fluorometholone) 0.1% drop | |
| Loteprednol 0.5% drops, 0.5% gel | FML S.O.P (fluorometholone) 0.1% ointment | |
| MAXIDEX (dexamethasone) 0.1% | INVELTYS (loteprednol) 1% | |
| PRED MILD (prednisolone) 0.12% | LOTEMAX SM (loteprednol) 0.38% gel | |
| Prednisolone acetate 1% | PRED FORTE (prednisolone) 1% | |
| | Prednisolone sodium phosphate 1% | |

| | | |
|--|--|---|
| | | <ul style="list-style-type: none"> ○ Viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella OR ○ Mycobacterial infection of the eye and fungal diseases of ocular structures <p>All other non-preferred products may be approved with trial and failure of three preferred agents (failure is defined as lack of efficacy with 2-week trial, allergy, contraindication, intolerable side effects, or significant drug-drug interaction).</p> |
|--|--|---|

Therapeutic Drug Class: **OPHTHALMIC, GLAUCOMA** – Effective 4/1/2025

| Beta-blockers | | |
|--|---|---|
| No PA Required | PA Required | |
| Carteolol 1% | Betaxolol 0.5% | Non-preferred products may be approved following trial and failure of therapy with three preferred products, including one trial with a preferred product having the same general mechanism (such as prostaglandin analogue, alpha2-adrenergic agonist, beta-blocking agent, or carbonic anhydrase inhibitor). Failure is defined as lack of efficacy with 4-week trial, allergy, intolerable side effects or significant drug-drug interactions. |
| Levobunolol 0.5% | BETIMOL (timolol) 0.25%, 0.5% | Non-preferred combination products may be approved following trial and failure of therapy with one preferred combination product AND trial and failure of individual products with the same active ingredients as the combination product being requested (if available) to establish tolerance. Failure is defined as lack of efficacy with 4-week trial, allergy, intolerable side effects or significant drug-drug interactions. |
| Timolol (generic Timoptic) 0.25%, 0.5% | BETOPIC-S (betaxolol) 0.25% | Preservative free products may be approved with provider documentation of adverse effect to preservative-containing product. |
| | ISTALOL (timolol) 0.5% | |
| | Timolol (generic Istalol) 0.5% drops | |
| | Timolol GFS 0.25%, 0.5% | |
| | Timolol/PF (generic Timoptic Ocudose) 0.25%, 0.5% | |
| | TIMOPTIC, TIMOPTIC OCUDOSE (timolol) 0.25%, 0.5% | |
| | TIMOPTIC-XE (timolol GFS) 0.25%, 0.5% | |
| Carbonic anhydrase inhibitors | | |
| No PA Required | PA Required | |
| Brinzolamide 1% | AZOPT (brinzolamide) 1% | |
| Dorzolamide 2% | | |
| Prostaglandin analogue | | |
| No PA Required | PA Required | |

| | | |
|--|---|--|
| Latanoprost 0.005% LUMIGAN ^{BNR} (bimatoprost) 0.01% TRAVATAN Z ^{BNR} (travoprost) 0.004% | Bimatoprost 0.03% IYUZEH (latanoprost/PF) 0.005% Tafluprost 0.0015% Tafluprost PF 0.0015% Travoprost 0.004% VYZULTA (latanoprostene) 0.024% XALATAN (latanoprost) 0.005% XELPROS (latanoprost) 0.005% ZIOPTAN (tafluprost PF) 0.0015% | |
| Alpha-2 adrenergic agonists | | |
| No PA Required ALPHAGAN P ^{BNR} 0.1%, 0.15% (brimonidine) Brimonidine 0.2% | PA Required Apraclonidine 0.5% Brimonidine 0.1%, 0.15% IOPIDINE (apraclonidine) 0.5%, 1% | |
| Other ophthalmic, glaucoma and combinations | | |
| No PA Required COMBIGAN ^{BNR} 0.2%-0.5% (brimonidine/timolol) Dorzolamide/Timolol 2%-0.5% RHOPRESSA (netarsudil) 0.02% ROCKLATAN (netarsudil/latanoprost) 0.02%-0.005% | PA Required Brimonidine/Timolol 0.2%-0.5% COSOPT/COSOPT PF (dorzolamide/timolol) 2%-0.5% Dorzolamide/Timolol PF 2%-0.5% PHOSPHOLINE IODIDE (echothiophate) 0.125% Pilocarpine 1%, 1.25%, 2%, 4% SIMBRINZA (brinzolamide/brimonidine) 1%-0.2% | |

| | | |
|--|----------------------------|--|
| | VURITY (pilocarpine) 1.25% | |
|--|----------------------------|--|

XII. Renal/Genitourinary

Therapeutic Drug Class: BENIGN PROSTATIC HYPERPLASIA (BPH) AGENTS – Effective 10/1/2025

| No PA Required | PA Required | <p>*CIALIS (tadalafil) may be approved if meeting the following criteria:</p> <ul style="list-style-type: none"> Member has a documented diagnosis of BPH AND Member has trialed and failed each of the following: Finasteride. Failure is defined as lack of efficacy with a 3-month trial, allergy, intolerable side effects, contraindication, or significant drug-drug interaction AND Either a nonselective alpha blocker or tamsulosin. Failure is defined as lack of efficacy, allergy, intolerable side effects, contraindication, or significant drug-drug interaction AND Documentation of BPH diagnosis will require BOTH of the following: <ul style="list-style-type: none"> AUA Prostate Symptom Score \geq 8 AND Results of a digital rectal exam AND Cialis (tadalafil) is not being prescribed for use for continuing alpha blocker therapy, as use of tadalafil in this population is not recommended due to the potential for hypotension. <p>Maximum Dose: Doses exceeding Cialis (tadalafil) 5mg per day will not be approved.</p> <p>Prior authorization for all other non-preferred products may be approved if meeting the following criteria:</p> <ul style="list-style-type: none"> Member has tried and failed[‡] three preferred agents AND For combinations agents, member has tried and failed[‡] each of the individual agents within the combination agent and one other preferred agent. <p>[‡]Failure is defined as lack of efficacy with 8-week trial, allergy, intolerable side effects, contraindication, or significant drug-drug interaction.</p> |
|---------------------|---|---|
| Alfuzosin ER tablet | AVODART (dutasteride) softgel | |
| Doxazosin tablet | CARDURA (doxazosin) tablet | |
| Dutasteride capsule | CARDURA XL (doxazosin ER) tablet | |
| Finasteride tablet | *CIALIS (tadalafil) 2.5 mg, 5 mg tablet | |
| Tamsulosin capsule | Dutasteride/tamsulosin capsule | |
| Terazosin capsule | Finasteride/tadalafil capsule | |
| | FLOMAX (tamsulosin) capsule | |
| | PROSCAR (finasteride) tablet | |
| | RAPAFLO (silodosin) capsule | |
| | Silodosin capsule | |
| | *Tadalafil 2.5 mg, 5 mg tablet | |
| | Tezruly (terazosin) solution | |

Therapeutic Drug Class: ANTI-HYPERURICEMICS – Effective 10/1/2025

| No PA Required | PA Required | <p>Non-preferred xanthine oxidase inhibitor products (allopurinol or febuxostat formulations) may be approved following trial and failure of preferred allopurinol. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction. If member has tested positive for the HLA-B*58:01 allele, it is not recommended that they trial allopurinol. A positive result on this genetic test will count as a failure of allopurinol.</p> <p>Prior authorization for all other non-preferred agents (non-xanthine oxidase inhibitors) may be approved after trial and failure of two preferred products. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction.</p> |
|------------------------------------|-----------------------------|--|
| Allopurinol 100 mg, 300 mg tablets | Allopurinol 200 mg tablets | |
| Colchicine tablet | Colchicine capsule | |
| Febuxostat tablet | COLCRYS (colchicine) tablet | |

| | | |
|------------------------------|-------------------------------------|---|
| Probenecid tablet | GLOPERBA (colchicine) oral solution | GLOPERBA (colchicine) oral solution may be approved for members who require individual doses <0.6 mg OR for members who are unable to use a solid oral dosage form. Colchicine tablet quantity limits: <ul style="list-style-type: none"> • Chronic hyperuricemia/gout prophylaxis: 60 tablets per 30 days • Familial Mediterranean Fever: 120 tablets per 30 days |
| Probenecid/Colchicine tablet | MITIGARE (colchicine) capsule | |
| | ULORIC (febuxostat) tablet | |

Therapeutic Drug Class: **OVERACTIVE BLADDER AGENTS** – *Effective 10/1/2025*

| No PA Required | PA Required | |
|--|------------------------------------|---|
| Fesoterodine ER tablet | Darifenacin ER tablet | Non-preferred products may be approved for members who have failed treatment with two preferred products. Failure is defined as: lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction. |
| MYRBETRIQ (mirabegron) tablet ^{BNR} | DETROL (tolterodine) tablet | |
| Oxybutynin IR, ER tablets, syrup | DETROL LA (tolterodine) ER capsule | |
| Solifenacin tablet | Flavoxate tablet | |
| Tolterodine tablet, ER capsule | GEMTESA (vibegron) tablet | |
| Trospium ER tablet | Mirabegron tablet | |
| | MYRBETRIQ (mirabegron) suspension | |
| | Oxybutynin 2.5 mg tablet | |
| | OXYTROL (oxybutynin patch) | |
| | TOVIAZ (Fesoterodine ER) tablet | |

XIII. RESPIRATORY

Therapeutic Drug Class: **RESPIRATORY AGENTS** – *Effective 1/1/2026*

Inhaled Anticholinergics

| Preferred No PA Required (Unless indicated*) | Non-Preferred PA Required | <p>*SPIRIVA RESPIMAT (tiotropium) 1.25 mcg may be approved for members \geq 6 years of age with a diagnosis of asthma (qualifying diagnosis verified by AutoPA). SPIRIVA RESPIMAT is intended to be used by members whose asthma is not controlled with regular use of a combination medium-dose inhaled corticosteroid and long-acting beta agonist (LABA).</p> <p>*SPIRIVA RESPIMAT (tiotropium) 2.5 mcg may be approved for members with a diagnosis of COPD who have trialed and failed SPIRIVA HANDIHALER. Failure is defined as intolerable side effects or inability to use dry powder inhaler (DPI) formulation.</p> <p>LONHALA MAGNAIR (glycopyrrolate) may be approved for members \geq 18 years of age with a diagnosis of COPD including chronic bronchitis and emphysema who have trialed and failed[‡] treatment with two preferred anticholinergic agents.</p> <p>Non-preferred single agent anticholinergic agents may be approved for members with a diagnosis of COPD including chronic bronchitis and/or emphysema who have trialed and failed[‡] treatment with two preferred agents, one of which must be SPIRIVA HANDIHALER.</p> <p>[‡]Failure is defined as lack of efficacy with 6-week trial, allergy, intolerable side effects, or significant drug-drug interaction.</p> |
|--|--|---|
| Solutions Ipratropium solution | Solutions YUPELRI (revefenacin) solution | |
| Short-Acting Inhalation Devices ATROVENT HFA (ipratropium) | Short-Acting Inhalation Devices | |
| Long-Acting Inhalation Devices | Long-Acting Inhalation Devices | |
| SPIRIVA Handihaler ^{BNR} (tiotropium) | INCRUSE ELLIPTA (umeclidinium) | |
| *SPIRIVA RESPIMAT (tiotropium) | Tiotropium DPI | |
| | TUDORZA PRESSAIR (aclidinium) | |

Inhaled Anticholinergic Combinations

| No PA Required | PA Required | |
|---|--|--|
| Solutions Ipratropium/Albuterol solution | Solutions | BREZTRI AEROSPHERE (budesonide/glycopyrrolate/formoterol) may be approved for members \geq 18 years of age with a diagnosis of COPD who have trialed and failed [‡] treatment with two preferred anticholinergic-containing agents. |
| Short-Acting Inhalation Devices COMBIVENT RESPIMAT (albuterol/ipratropium) | Short-Acting Inhalation Devices | DUAKLIR PRESSAIR (aclidinium/formoterol) may be approved for members \geq 18 years of age with a diagnosis of COPD who have trialed and failed [‡] treatment with two preferred anticholinergic-containing agents. |
| Long-Acting Inhalation Devices ANORO ELLIPTA (umeclidinium/vilanterol) ^{BNR} | Long-Acting Inhalation Devices BEVESPI AEROSPHERE (glycopyrrolate /formoterol fumarate) BREZTRI AEROSPHERE (budesonide/glycopyrrolate/ formoterol) DUAKLIR PRESSAIR (aclidinium/formoterol) STIOLTO RESPIMAT (tiotropium/olodaterol) Umeclidinium/Vilanterol | All other non-preferred inhaled anticholinergic combination agents may be approved for members with a diagnosis of COPD including chronic bronchitis and/or emphysema who have trialed and failed [‡] treatment with two preferred inhaled anticholinergic combination agents OR three preferred inhaled anticholinergic-containing agents (single ingredient or combination). Members who are currently stabilized on Bevespi AerospHERE may receive approval to continue therapy with that product. [‡] Failure is defined as lack of efficacy with 6-week trial, allergy, intolerable side effects, or significant drug-drug interaction. |

Inhaled Beta2 Agonists (short acting)

| No PA Required | PA Required |
|----------------|-------------|
|----------------|-------------|

| | | |
|---|--|--|
| <p>Solutions Albuterol solution, for nebulizer</p> <p>Inhalers VENTOLIN^{BNR} HFA (albuterol)</p> | <p>Solutions Levalbuterol solution</p> <p>Inhalers AIRSUPRA (budesonide/albuterol)</p> <p>Albuterol HFA</p> <p>Levalbuterol HFA</p> <p>PROAIR RESPICLICK (albuterol)</p> <p>XOPENEX (levalbuterol) Inhaler</p> | <p>Non-preferred short acting beta-2 agonists may be approved for members who have failed treatment with one preferred agent. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction.</p> <p>MDI formulation quantity limits: 2 inhalers / 30 days</p> <p><u>Airsupra minimum age:</u> 18 years old</p> |
|---|--|--|

Inhaled Beta2 Agonists (long acting)

| Preferred | Non-Preferred PA Required | |
|---|---|--|
| <p>Solutions</p> <p>Inhalers SEREVENT DISKUS (salmeterol) inhaler</p> | <p>Solutions Arformoterol solution</p> <p>BROVANA (arformoterol) solution</p> <p>Formoterol solution</p> <p>PERFOROMIST (formoterol) solution</p> <p>Inhalers STRIVERDI RESPIMAT (olodaterol)</p> | <p>Non-preferred agents may be approved for members with moderate to severe COPD, AND members must have failed a trial of Serevent. Failure is defined as lack of efficacy with a 6-week trial, allergy, intolerable side effects, or significant drug-drug interaction.</p> <p>For treatment of members with diagnosis of asthma needing add-on therapy, please refer to preferred agents in combination Long-Acting Beta Agonist/Inhaled Corticosteroid therapeutic class.</p> |
| | | |

Inhaled Corticosteroids

| No PA Required | PA Required | |
|---|---|--|
| <p>Solutions Budesonide nebulus</p> <p>Inhalers ARNUITY ELLIPTA^{BNR} (fluticasone furoate)</p> <p>ASMANEX HFA (mometasone furoate) inhaler</p> <p>ASMANEX Twisthaler (mometasone)</p> <p>PULMICORT FLEXHALER (budesonide)</p> <p>QVAR REDIHALER (beclomethasone)</p> | <p>Solutions PULMICORT (budesonide) respules</p> <p>Inhalers ALVESCO (ciclesonide) inhaler</p> <p>Fluticasone Ellipta</p> <p>Fluticasone propionate diskus</p> <p>*Fluticasone propionate HFA</p> | <p>Non-preferred inhaled corticosteroids may be approved in members with asthma who have failed an adequate trial of two preferred agents. An adequate trial is defined as at least 6 weeks. (Failure is defined as: lack of efficacy with a 6-week trial, allergy, contraindication to, intolerable side effects, or significant drug-drug interactions, or dexterity/coordination limitations (per provider notes) that significantly impact appropriate use of a specific dosage form.)</p> <p>*FLUTICASONE PROPIONATE HFA is available to members without prior authorization for:</p> <ul style="list-style-type: none"> • Members with a diagnosis of eosinophilic esophagitis (EoE) OR • Members \leq 12 years of age. <p><u>Maximum Dose:</u> Pulmicort (budesonide) nebulizer suspension: 2mg/day</p> <p><u>Quantity Limits:</u></p> |
| | | |

| | | |
|--|--|--|
| | | Pulmicort flexhaler: 2 inhalers / 30 days |
| Inhaled Corticosteroid Combinations | | |
| No PA Required (*Must meet eligibility criteria) | PA Required | |
| ADVAIR DISKUS ^{BNR} (fluticasone/salmeterol) | BREO ELLIPTA (vilanterol/fluticasone furoate) | * TRELEGY ELLIPTA (fluticasone furoate/umeclidinium/vilanterol) may be approved if meeting the following: <ul style="list-style-type: none"> • The member has trialed and failed‡ 6 weeks of continuous therapy with a long-acting beta agonist (LABA) used in combination with a long-acting muscarinic antagonist (LAMA) OR • The member has documented eosinophils ≥ 300 cells/μL and has trialed and failed‡ 6 weeks of continuous therapy with one of the following: <ul style="list-style-type: none"> ○ A product containing a long-acting beta agonist (LABA) OR ○ A product containing a long-acting muscarinic antagonist (LAMA). |
| ADVAIR HFA ^{BNR} (fluticasone/salmeterol) | Budesonide/formoterol (generic Symbicort) | |
| AIRDUO RESPICLICK ^{BNR} (fluticasone/salmeterol) | Fluticasone/salmeterol (generic Airello/Advair Diskus) | |
| DULERA (mometasone/formoterol) | Fluticasone/salmeterol HFA (generic Advair HFA) | |
| SYMBICORT ^{BNR} (budesonide/formoterol) inhaler | Fluticasone/vilanterol (generic Breo Ellipta) | |
| * TRELEGY ELLIPTA (fluticasone furoate/umeclidinium/vilanterol) | WIXELA INHUB (fluticasone/salmeterol) | |
| | | Non-preferred inhaled corticosteroid combinations may be approved for members meeting both of the following criteria: <ul style="list-style-type: none"> • Member has a qualifying diagnosis of asthma or severe COPD AND • Member has trialed and failed‡ two preferred agents |
| | | ‡Failure is defined as lack of efficacy with a 6-week trial, allergy, intolerable side effects, significant drug-drug interactions, or dexterity/coordination limitations (per provider notes) that significantly impact appropriate use of a specific dosage form. |
| Phosphodiesterase Inhibitors (PDEIs) | | |
| No PA Required | PA Required | |
| Roflumilast tablet | DALIRESP (roflumilast) tablet | Requests for use of the non-preferred brand product formulation may be approved if meeting criteria outlined in the Appendix P "Generic Mandate" section. |
| | OHTUVAYRE (ensifentrine) suspension | |